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Abstract
Hyperglycemia is prevalent in critical care, as patients experience stress-
induced hyperglycemia, even with no history of diabetes. Hyperglycemia
has a significant impact on patient mortality and other negative clinical out-
comes such as severe infection, sepsis and septic shock. Tight glycemic control
can significantly reduce these negative outcomes by reducing hyperglycemic
episode, but achieving it remains clinically elusive, particularly with regard
to what constitutes tight control and what protocols are optimal in terms of
results and clinical effort.
The model used in this thesis is validated using an independent data
and readily be used for different clinical interventions. Moreover, this model
also able to accurately predict clinical intervention outcomes given that the
model prediction error is very small, which is better than any other reported
model. In particular, model-based glycemic control methods is used to capture
patient-specific physiological dynamics, such as insulin sensitivity, SI .
To date, sepsis diagnosis has been a great challenge despite advance-
ment in technologies and medical research. Critically, septic patients are of-
ten classified by practitioners according to their experience before standard
test results can be assessed, as to avoid delay in treatment. Moreover, several
scoring systems have also been widely used to represent sepsis condition and
better standardization of sepsis definition across different centers.
In this thesis, insulin sensitivity, SI , a model-based metric is used to
identify sepsis condition based on the finding that SI represents metabolic
xxvi ABSTRACT
condition of a patient. Additionally, several clinical and physiological vari-
ables obtained during patient’s stay in critical care are also investigated using
mathematical computation and statistical analysis to identify relevant metric
which can be accurately use for sepsis interventions. Even though informa-
tion on SI , clinical and physiological variables of a patient are insufficient to
determine the sepsis status, these informations have brought to a different
perspective of diagnosing sepsis.
Microcirculation dysfunction is very common in sepsis. Tracking of mi-
crocirculation state among septic patient enable better tracking of patient
state particularly sepsis status. The tracking can potentially be done by us-
ing a pulse oximeter that can extract additional information related to oxygen
extraction level. The processed signals are therefore represent relative absorp-
tion of oxyhemoglobin and reduced hemoglobin that can be used to assess
microcirculation status.
In addition, this thesis focus on the real challenge of early treatment
of sepsis and sepsis diagnosis where several potential metabolic markers are
investigated. Microcirculation conditions are assessed using a non-invasive
method that is generally used in typical ICU settings. In particular, the
concept and method used to assess microcirculation and metabolic conditions
are developed in this thesis.
Finally, the work presented in this thesis can act as a starting point for
many other glycemic control problems in other environments. These areas
include cardiac critical care and neonatal critical care that share most sim-
ilarities to the environment studied in this thesis, to general diabetes where
the population is growing exponentially world wide. Eventually, this added
ABSTRACT xxvii
knowledge can lead clinical developments from protocol simulations to better
clinical decision making.

Chapter 1
Introduction
Clinically, hyperglycemia can be a marker of severity of illness and is directly
associated with mortality [Krinsley, 2003; Egi et al., 2006; Laird et al., 2004;
Jeremitsky et al., 2005]. Hyperglycemia is thus a very serious clinical illness
and it is also associated with increases in other negative clinical outcomes,
including severe infection [Bistrian, 2001], sepsis and septic shock [Branco
et al., 2005; Das, 2003; Oddo et al., 2004], myocardial infarction [Capes et al.,
2000], and polyneuropathy and multiple organ failure [Langouche et al., 2005;
Van den Berghe et al., 2001].
Landmark studies by Van den Berghe et al [Van den Berghe et al., 2001,
2003] and Krinsley [Krinsley, 2004] focused significant attention and research
on managing hyperglycemia and its effects. These studies formed a basis for
several additional clinical and model-based studies [Van den Berghe et al.,
2006a; Wong et al., 2006b; Chase et al., 2006; Doran et al., 2004b; Goldberg
et al., 2004; Laver et al., 2004; Finfer and Heritier, 2009; Brunkhorst et al.,
2008; Griesdale et al., 2009; Preiser et al., 2009]. As a result, it has become a
significant research area in its own right, and has been recently reviewed by
Chase et al [Chase et al., 2007, 2008a, 2010b, 2011b].
The incidence of hyperglycemia is very high globally and great improve-
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ment has been documented in recent years with the use of tight glycemic con-
trol (TGC) in terms of reducing mortality and morbidity [Chase et al., 2008b;
Krinsley, 2004; Van den Berghe et al., 2001, 2006a]. Despite differences in
TGC protocol across different centers and studies, many positive outcomes
have been documented from some trials. However, several others have found
these results difficult to reproduce [Finfer and Heritier, 2009; Brunkhorst et al.,
2008; Griesdale et al., 2009; Preiser et al., 2009]. More specifically, different
target range of TGC management has been used in clinical trials ranging from
4.4-6.1 mmol/L [Chase et al., 2008b; Pachler et al., 2008; Dortch et al., 2008;
Shulman et al., 2007; Juneja et al., 2009; Van den Berghe et al., 2001] and sev-
eral others with wider or higher target ranges [Krinsley, 2004; Thomas et al.,
2005; Preiser et al., 2009; Meynaar et al., 2007; Davidson et al., 2005].
Model-based glycemic control is an emerging treatment approach for
managing hyperglycemia in critical illness. In particular, model-based
glycemic control methods are able to directly capture the patient-specific phys-
iological dynamics of the human metabolism. The benefits of using model-
based glycemic control with TGC are better and adaptive control [Evans et al.,
2011] through direct management of patient-specific variability [Lin et al.,
2008; Chase et al., 2011b] that thus significantly reduces the risk of hypo-
glycemia seen using some TGC protocols [Brunkhorst et al., 2008; Preiser
et al., 2009; Van den Berghe et al., 2006b; Preiser and Devos, 2007; Vanhore-
beek et al., 2007a,b].
This chapter introduces and describes the relation between hyper-
glycemia, multiple organ failure and sepsis, which are some of the most com-
mand and critical problems faced in the ICU. All these issues have resisted
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significant improvement despite advances in technology and medicine, and
extensive clinical studies. The used of model-based glucose-insulin system
models in critical illness enables the real-time identification of patient-specific
model parameters that can be used to indicate patient condition. The ability
to capture patient-specific model parameters in clinical settings, particularly
in real-time, yields significant insight into the physiological condition of criti-
cally ill patients. Hence, model-based glycemic control methods offer signifi-
cant potential to provide further tools to diagnose or guide treatment of other
diseases.
1.1 Hyperglycemia in Critical Care
Hyperglycemia is common in acutely and critically ill patients [Capes et al.,
2000; McCowen et al., 2001], including those who have not previously had
diabetes [Capes et al., 2000; Krinsley, 2003; Van den Berghe et al., 2001]. It
is defined as blood glucose concentration higher than a basal level of 4.4-5.5
mmol/L [Mizock, 2001]. For blood glucose concentrations consistently higher
than 7 mmol/L, therapy should be initiated as recommended by the American
Diabetes Association.
Hyperglycemia is highly associated with insulin resistance in critically
ill patients [Wolfe et al., 1979, 1987; Shangraw et al., 1989; Capes et al., 2000]
and known to stimulate glucose metabolism [Vander and Luciano, 2001]. In-
creased counter-regulatory hormone secretion stimulates endogenous glucose
production and increases insulin resistance [McCowen et al., 2001; Mizock,
2001], elevating equilibrium glucose levels and reducing the amount of glucose
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the body can utilize. Additionally, high glucose content nutritional support
regimes can cause an excess of blood glucose that cannot be utilized [Patino
et al., 1999; Weissman, 1999; Elia et al., 2005].
Hyperglycemia worsens outcomes, increasing myocardial infarction
[Capes et al., 2000], severe risk of infection [Bistrian, 2001], sepsis and septic
shock [Das, 2003; Branco et al., 2005; Oddo et al., 2004; Marik and Raghavan,
2004], and other critical illness such as axonal dysfunction and degeneration
[Sidenius, 1982], polyneuropathy, and multiple organ failure [Van den Berghe
et al., 2001; Langouche et al., 2005; Chase et al., 2010a]. Hyperglycemia also
decreases immune function response [Marik and Raghavan, 2004; Weekers
et al., 2003; Turina et al., 2005]. According to Weekers et al [Weekers et al.,
2003], the immune response is essentially completely ineffective at 10 mmol/L
and only ⇠33% effective at 8 mmol/L. An ineffective immune response can
have obvious significant consequences in terms of fighting off bacterial or viral
infections, in addition to other complications noted. Finally, hyperglycaemia
can also induce damage at a cellular level including immunosupression, in-
flammation, thrombosis and increased oxidative stress [Sarikabadayi et al.,
2011; Hirsch and Brownlee, 2005; Lelkes et al., 2001; Xi et al., 2011].
Increasing hyperglycemia also correlates with increasing risk of death
and increasing length of stay in ICU [Vlasselaers et al., 2009; Jeremitsky
et al., 2005]. In addition, hyperglycemia, particularly severe hyperglycemia,
is highly associated with increased morbidity and mortality [Krinsley, 2009,
2003; Laird et al., 2004]. Equally importantly, glycemic variability and poor
control are independently associated with increased mortality [Krinsley, 2008;
Ali et al., 2008; Egi et al., 2006].
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Finally, the use of a certain drugs have been recognized to exacerbate
hyperglycemia and thus mortality. For example, some steroid-based therapies
antagonise insulin action and production, further exacerbating the problem
[Pretty et al., 2011; Dimitriadis et al., 1997; Qi and Rodrigues, 2007]. Hence,
glycemic level and variability are also at least partly a function treatment and
thus, potentially, of patient diagnosis or disease.
From the nutritional input aspect, several studies [Dickerson, 2005; Kr-
ishnan et al., 2003; Dickerson et al., 2002; Iyer, 2002] have found that moderate
nutrition reductions may reduce mortality. Krishnan and colleagues [Krish-
nan et al., 2003] showed that feeding over 66% of ACCP recommended rates
increased the ICU mortality, as did feeding less than 33%. Reduced enteral
nutrition [Elia et al., 2005; Ahrens et al., 2005; Kim et al., 2003] or its car-
bohydrate content [Patino et al., 1999] and reducing dextrose as a diluent in
intravenous medication [Krajicek et al., 2005] can also result in reductions in
glycemic levels.
Hence, a number of studies have investigated the effect on patient out-
comes when blood glucose levels are controlled with insulin. Several have
shown some measurable positive results showing the clear potential of this
approach [Lewis et al., 2004; Mowery et al., 2011; Shan et al., 2011; Hasegawa
et al., 2011; Arabi et al., 2011; Chase et al., 2008b; Krinsley, 2004; Malmberg,
1997; Van den Berghe et al., 2001, 2003; Finney et al., 2003; Laver et al.,
2004]. These studies primarily examined the effectiveness of intensive insulin
therapy on mortality, and/or the risk of hypoglycemia and other clinical out-
comes. Hence, the use of intensive insulin therapy governed by frequent blood
glucose monitoring are useful in improving blood glucose level in critically ill
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patients. There is also evidence of significant reductions in the need for dial-
ysis, bacteremia testing and the number of blood transfusions with aggressive
blood glucose control using intensive insulin therapy [Van den Berghe et al.,
2001, 2003; Krinsley, 2004; Malmberg et al., 1999]. All of these results point
towards the conclusion that the control of blood glucose levels in critical care
have a significant clinical impact.
In counterpoint, it must also be noted that several studies have not
shown benefit [Finfer and Heritier, 2009; Brunkhorst et al., 2008; Preiser et al.,
2009], as surveyed by Griesdale et al [Griesdale et al., 2009]. However, several
of these studies failed to achieve good control [Chase et al., 2011b] primarily
or potentially due to poor protocols and patient metabolic variability. Thus,
while there is good evidence, clear and effective protocols are lacking to provide
conclusive proof in the field.
1.2 Organ Failure
Infection is one of the worst outcomes of hyperglycemia and if not successfully
controlled, it can lead to multiple organ failure (MOF) [Fry et al., 1980].
In MOF, patient may suffers acute respiratory failure, acute renal failure,
cardiovascular failure and/or other organ dysfunctions. MOF is the leading
cause of ICU mortality, regardless of etiology and cause.
The severity of organ dysfunction and illness on human have lead to
the development of therapeutic interventions with the aim of reducing its
incidence. However, the therapeutic intervention begins with the definition
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for quantifying the degree of organ failure to assess therapies and treatments.
Vincent and colleagues [Vincent et al., 1996] describe organ dysfunction as a
process, rather than an event, since the process can be seen as a continuum.
Table 1.1 lists the variables to describe organ dysfunction.
Table 1.1: Ideal variables for describing organ dysfunction [Vincent et al.,
1996].
Objective
Simple, easily, available, but reliable
Obtained routinely and regularly in every institution
Specific for the function of the organ considered
Continuous variable
Independent of the type of patients
Independent of the therapeutic interventions
Several scoring system of organ failure/dysfunction have been developed
to better describe the progression of complications such as SOFA (Sepsis-
related Organ Failure Assessment), MODS (Multiple Organ Dysfunction
Score), the Brussels Score, and MSOF (Multiple System Organ Failure). Most
of the scoring systems were developed at a round table conference on clinical
trials in sepsis [Sibbald and Vincent, 1995]. The objectives of these scoring
systems is to represent and evaluate the increased complexity of disease and
its continuum in patients. Specifically, patient risks and level of severity of
their condition [Knaus et al., 1991] are the main objectives and to better as-
sess treatment needs. Table 1.2 describes the similarities and differences of
these scoring systems.
To date, these scoring systems only define the occurrence of organ fail-
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ure and are incapable of prediction. Even though MSOF was designed for
prediction, the outcome of clinical trials showed a lack of accuracy in this ca-
pability [Hebert et al., 1993]. Overall, SOFA is the most commonly used score
in most ICU studies because of its simplicity and effectiveness in describing
organ dysfunction [Vincent et al., 1998].
Despite of the various scoring systems used in ICU, the invention of new
scoring systems is still taking place. In particular, clinicians and researchers
are still looking to find a better system to represent the occurrence of organ
failure and disease. Therefore, new scoring systems have been developed in an
attempt to meet this challenge. However, the use of a scoring system depends
on both its application and its level of complexity. As the system becomes
more complex, it may not be effective at the ICU bedside or practicable, even
if its predictive performance improves.
1.3 Sepsis
Sepsis is an increasingly common clinical condition defined by the presence
of both infection and a systemic inflammatory response. Increasingly severe
sepsis is defined by increasing organ failure, linking this condition with organ
failure. Overall, sepsis is thus one of the most common and serious medical
problems faced in ICU, with a 30-60% mortality rate with 11-15% of all cases
defined as severe sepsis events [Angus et al., 2001] from the more than 751
000 cases of severe sepsis reported annually [Li et al., 2011]. In addition, the
number of patients with sepsis increases significantly each year and the number
of sepsis-related deaths is also increasing [Martin et al., 2003; Parrillo et al.,
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Table 1.2: Similarities and differences between SOFA, MODS, Brussels and
MOSF Scores.
SOFA Score Description.
Simple and easily calculated.
Evaluate morbidity.
Individualize degree of dysfunction of each organ.
Developed in 1994 at ESICM meeting [Vincent et al., 1996].
MODS Score Description.
Complex.
Evaluate morbidity.
Individualize degree of dysfunction of each organ.
Developed by J. Marshall et al [Marshall et al., 1995].
Brussels Score Description.
Complex.
Evaluate morbidity and risk of mortality.
Does not individualize degree of dysfunction of each organ.
Developed by G. Bernard et al.
MSOF Score Description.
Simple
Evaluate morbidity and risk of mortality
Individualize degree of dysfunction of each organ
Developed by P. Hebert et al [Hebert et al., 1993].
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1990; Walkey et al., 2011] despite significant research to better understand
the occurrence of this disease.
Sepsis has been classified into several stages according to definitions
created by the Society of Critical Care Medicine (SCCM) in 1992 [Levy et al.,
2003]. These stages are used for better representation for the occurrence
of sepsis and to aid standardization of definitions between different centers.
Detailed descriptions of these classifications are discussed in Chapter 5. To
date, blood bacteria culture is considered as the only standard method for
absolutely confirming an infection. However, this test requires incubation and
standard procedures that result in a delayed outcome of 2-3 days preventing
real-time monitoring. The delayed outcome consequently delays treatment
and can thus worsen patient condition and risk if clinician wait for this result.
Equally, ⇠50% of all sepsis that is clinically defined is "culture negative"
[Carrigan et al., 2004]. Hence, there are no ideal definitions nor any real-time
definitions.
Several clinical trials [Walkey et al., 2011; Wagner et al., 2011; Cronshaw
et al., 2011; Cardoso et al., 2010; Patel et al., 2010; Takahashi et al., 2011;
Hirasawa et al., 2009] have examined the risk of death among sepsis patients.
The Surviving Sepsis Campaign (SSC) is one of the collaborative initiatives
to reduce mortality from severe sepsis and septic shock [Marshall et al., 2010].
This campaign has been supported by professional organizations around the
world despite controversial issues around of the protocol used. The SSC pro-
vides standard care management guidelines. However, outcomes are varied
across different centers [Machado and Mazza, 2010; Cronshaw et al., 2011;
Tromp et al., 2011; Cardoso et al., 2010
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Nevertheless, clinical trials on septic patients remains a challenge. Many
factors contribute to the difficulties in treating septic patients and designing
clinical trials and protocols for effective diagnosis and treatment. However,
one significant success has been the reduction in the incidence of sepsis has
been observed by implementing a blood glucose control protocol [Van den
Berghe et al., 2001; Takahashi et al., 2011; Hirasawa et al., 2009]. There are
also some studies suggested different methods such as early administration of
antibiotics [Kumar et al., 2006; Micek et al., 2011], fluid resuscitation [Khan
et al., 2011; Nguyen et al., 2011], administration of activated protein C [Wag-
ner et al., 2011; Cohen et al., 2011] and early goal-directed therapy [Rivers
et al., 2001; Sivayoham et al., 2011; Burney et al., 2011; Turi and Von Ah,
2011; Colin et al., 2011].
However, most current research on sepsis focuses more on finding a bet-
ter test or method that can confirm the existence of infection, one of the
cornerstones of sepsis, as early as possible. Early diagnosis is critical because
early interventions have been documented to reduce mortality from 46.5% to
30.5% [Rivers et al., 2001] and thus show significant potential. Moreover,
early goal-directed resuscitation is recommended for the septic patient, par-
ticularly during the first 6 hours after infection recognition [Dellinger et al.,
2004]. Hence, the ability to recognize infection and diagnose sepsis as early as
possible will consequently improve mortality outcome and patient condition.
In this thesis in particular, the link between one effective therapeutic
approach, glycemic control, and sepsis diagnosis is investigated directly. More
specifically, is there a link between model-based metabolic markers and sepsis?
Such a link would have potential given the success of model-based glycemic
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control [Chase et al., 2007, 2008a, 2010b, 2006].
1.4 The Glucose-Insulin Regulatory System
Immediately after a high carbohydrate meal, nutrients enter the blood and
lymph from the gastrointestinal tract as monosaccharides, triglycerides, and
amino acids. The glucose absorbed into blood from carbohydrate causes rapid
secretion of insulin and consequently increases blood glucose levels. The in-
sulin leads to glucose uptake and storage for later use by almost all the tissues
in the body [Guyton, 1991]. Most of the glucose absorbed is stored in the
liver in the form of glycogen. When food is not consumed, blood glucose
concentration falls and glycogen is transformed to glucose for energy and to
prevent low or hypo- glycemia. However, if the amount of glucose absorbed
is too high and exceeds the limit the liver can store as glycogen, the excess
glucose will be transformed into fatty acids. Figure 1.1 illustrates the overall
glucose-insulin regulatory system in which insulin and glucagon play critical
functions in glucose homeostasis and serve as acute regulators of blood glucose
concentration.
1.4.1 Glucose
Glucose is a simple form of sugar that plays an important role in providing
energy to the human body. Glucose is stored mainly in the liver and muscle
cells as glycogen. Typically, the blood glucose concentration for normal indi-
vidual is in a range between 4.4 and 5.0 mmol/L before breakfast and 6.7 to
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Figure 1.1: Diabetes insulin glucose model system. The schematic shows
effect of high and low blood glucose levels on the body. Adapted from
health.howstuffworks.com.
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7.8 mmol/L after a meal. However, a high glucose intake from carbohydrate
of all forms results in high blood glucose levels or extracellular hyperglycemia.
When the blood glucose concentration falls, glucagon is secreted by the alpha
cells of the pancreas to increase blood glucose concentration. Glucagon is a
large polypeptide hormone and composed of a chain of 29 amino acids that
stimulates EGP or endogenous glucose production from the liver [Guyton,
1991].
1.4.2 Insulin
Insulin is a hormone produced by the beta cells in the pancreas [Guyton,
1991]. Insulin can be conceptualized as glucose-regulatory and glucose-
counterregulatory hormone [Jefferson et al., 2001]. In particular, insulin se-
cretion increases to lower plasma glucose at high levels of blood glucose. In
contrast, insulin secretion decreases to raise plasma glucose at low level blood
glucose. Thus, insulin is secreted in response to blood glucose concentrations
and has a very important rule in maintaining blood glucose levels.
1.5 Insulin Therapy and Glucose Control
Hyperglycemia, organ dysfunction and sepsis are highly correlated dysfunc-
tions. One of the category in defining sepsis is the presence of organ failure
indicating sepsis is severe enough to lead to organ dysfunction [Levy et al.,
2003; Bone et al., 1992]. As discussed earlier, organ dysfunction is one of
the worst outcomes of hyperglycemia and a leading cause of ICU death. Fur-
1.5. INSULIN THERAPY AND GLUCOSE CONTROL 15
thermore, hyperglycemia potentiates the pro-inflammatory response, which
is common in sepsis and thus may be partly causal. Therefore, treatment
of hyperglycemia consequently reduces the patient’s risk of developing organ
dysfunction and sepsis, as seen in several studies.
The positive effects of insulin therapy and glucose control observed in
studies that achieved good, low variability control suggest that intensive in-
sulin therapy and tight glycemic control (TGC) are necessary to be imple-
mented in critical illness. In addition, intensive insulin therapy and glycemic
management reduced mortality in patients with MOF and sepsis, regardless
of hyperglycemia [Capes et al., 2000]. Insulin therapy and glucose control can
also protect the cardiovascular system, reduce secondary infections, attenuate
inflammatory response [Vlasselaers et al., 2009; Hasegawa et al., 2011], and
reduce the risk of cholestasis [Van den Berghe et al., 2001].
Relevant to this research, reduces episodes of sepsis can be seen with
the implementation of blood glucose control [Hirasawa et al., 2009; Taka-
hashi et al., 2011; Van den Berghe et al., 2001; Marik and Raghavan, 2004].
Similarly, the reduced incidence of sepsis leads to reduced negative clinical
outcomes, such as fibrinolytic impairment [Savioli et al., 2009] and the need
for mechanical ventilation [Van den Berghe et al., 2001]. Other beneficial ef-
fects of insulin therapy and TGC on critical illness that have been previously
documented include the prevention of catabolism, acidosis, excessive inflam-
mation, and impaired innate immune function [Weekers et al., 2003; Li et al.,
2011; Toft and Tonnesen, 2011].
TGC has thus emerged as a major research focus in critical care due
to its potential to simultaneously reduce both mortality and costs [Krinsley,
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2004, 2003; Van den Berghe et al., 2001, 2003]. Additionally, TGC reduced the
use of resources in intensive care and complications among patients including
septicemia and prolonged antibiotic therapy needs. In a randomised controlled
study by Vlasselaers and colleagues [Vlasselaers et al., 2009], intensive insulin
therapy reduced the duration of stay and need for extended stay in paediatric
cohort.
Despite the emerging evidence of TGC on the outcome of septic pa-
tients and patients with organ failure, it is still a challenge to reproduce these
beneficial effects in the clinical setting. Therefore, treatments for sepsis are
more directed and focus on the systemic inflammatory response and infection,
rather than controlling blood glucose levels. The recommended protocols used
in the Surviving Sepsis Campaign have also created much debate under in-
creasing scrutiny [Barochia et al., 2010; Eichacker et al., 2006; Hicks et al.,
2008; Marik and Varon, 2010; Perel, 2008]. However, recent studies still sug-
gest the implementation of early goal-directed therapy for septic patients and
clearer operational guidelines in achieving optimal outcomes [Burney et al.,
2011; Rivers et al., 2001; Turi and Von Ah, 2011; Colin et al., 2011; Sivayoham
et al., 2011; O’Neill et al., 2011].
1.5.1 Model-Based Glycemic Control
To date, most typical practice of glycemic management in the ICU is com-
prised of ad-hoc protocols based primarily on experience, where relatively
large amounts of intravenous insulin, up to 50 U/h, are titrated against glu-
cose measurements variably taken every 1-4 hours. In reality, there are several
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circumstances that may exacerbate these situations on a patient by patient,
or patient-specific base. For example, unpredictable and sudden metabolic
changes, changes in nutritional support administration, and non-standard or
non-robust insulin protocols can result in highly variable and poorly controlled
blood glucose levels [Chase et al., 2011b].
A physiological model that captures the glucose-insulin system dynamics
is thus the basis for more optimally addressing the glycemic control problem
[Chase et al., 2011a]. Metabolic modelling of the glucose-insulin system has a
very deep history in the published literature. The vast majority of these mod-
els have their roots in basic compartment modelling with differential equations
[Carson and Cobelli, 2001]. To date, the primary use of metabolic models has
been the development of model-based measures to assess metabolic parame-
ters, with a particular focus on measuring insulin sensitivity [Bergman et al.,
1981, 1979, 1985; Pacini and Bergman, 1986; Yang et al., 1987; Mari et al.,
2001; Mari, 1998; Lotz et al., 2006; Toffolo et al., 1999, 2006].
Implementing TGC includes the increased risk of severe hypoglycemia
and difficulty in achieving normoglycemia in critically ill patients [Griesdale
et al., 2009]. Because of this issue and uncertainty about the balance of risks
and benefits, TGC is used infrequently by some clinicians. Hence, a model for
glycemic control needs to be applicable for real-time clinical control, as well as
addressing the needs and limitations typical of most ICUs. More specifically,
models for glycemic control in the ICU need to satisfy the following basic
criteria:
• Accurately capture insulin and glucose pharmacokinetics, and glucose-
18 CHAPTER 1. INTRODUCTION
insulin pharmacodynamics typical of critically ill patients.
• Feature a simple structure preferably requiring only blood glucose levels
as physiological feedback to identify a patient-specific model.
• Address inter- and intra- patient variability over time.
• Have rapidly identifiable patient-specific model parameters.
• Have good accuracy in predicting glycemic outcomes of interventions
over 1-3 hour time intervals, to accurately and safely guide therapy.
Given an accurate model satisfying these criteria, model-based glycemic
control can offer individualized control adaptable to the critically ill patient’s
highly dynamic physiological condition. It can also be used as a tool to diag-
nose a disease in real-time by capturing patient-specific parameters associated
with that disease state. Furthermore, such a physiological model may also be
used as a patient simulator for protocol development incorporating individual
patient-specific parameters [Hann et al., 2005; Wong et al., 2006a; Lonergan
et al., 2006; Evans et al., 2011]. Additional knowledge of critically ill popula-
tion’s variable dynamics can further enhance model-based control with more
accurate or safer predictive performance [Lin et al., 2008].
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1.6 Preface
In summary, sepsis and organ failure are highly associated with hyperglycemia
and represent a very serious clinical problem as reflected by their increasing
rate of incidence, mortality, and other negative clinical outcomes. Therefore,
hyperglycemia can be a marker to represent the severity of illness. Hyper-
glycemia and sepsis events have been documented to reduce with the imple-
mentation of safe, effective TGC in critical illness. However, in few TGC stud-
ies [Brunkhorst et al., 2008; Preiser et al., 2009; Vanhorebeek et al., 2007a],
septic patients were put at an increased risk due to excessive hypoglycaemia.
As a result, some practitioners are reluctant to implement TGC for the critical
illness at their centers.
The aim of this research is to investigate the potential of a metabolic
model-based parameter to represent the severity of illness of a patient, and
to capture sepsis in particular. The model used can capture patient-specific
parameters that capture patient-specific physiological condition. The ability
of model-based parameters to represent the severity of illness will be helpful
for monitoring, controlling and diagnosing patient condition.
Critically, the issue of sepsis is not only limited to the definitions and
systems typically used to identify this disease. There are many factors that
contribute to the challenge in sepsis diagnosis despite advancements in tech-
nologies and medical research. Hence, septic patients are often classified by
practitioners according to their experience before standard test results can be
obtained or assessed to avoid delay in treatment. Therefore, the ability to
treat a septic patient as early as possible has become a real challenge.
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Hence, the more specific goal of this research is to develop and examine a
model-based bio-marker that can be used to diagnose a disease or condition in
critically ill patients. The potential bio-markers need to be clinically practical,
incorporate patient-specific parameter(s) that represent dynamic metabolic
condition and physiology of a patient, and, importantly, can be identified in
real-time for real-time diagnosis. The thesis is organized as follows:
Chapter 2 reviews previous glucose-insulin models that have been exten-
sively applied for controlling glycemia. This chapter also presents an
updated glucose-insulin control model that is currently used for real-
time glycemic control.
Chapter 3 presents the analysis of two TGC trials for root causes of the dif-
ferences achieved in control. In this chapter, insulin sensitivity profiles,
SI(t), and stochastic models, are used to assess metabolic condition and
variability. Model-based insulin sensitivity, SI , is therefore defined as a
real-time, hour-to-hour patient-specific parameter representing patient
metabolic condition.
Chapter 4 presents the overall validation of the glucose-insulin system model
and model-based metric, SI introduced in Chapter 2. Model validation
was assessed by using a virtual trials method and simulations run on
independent data sets. The end result validates the efficacy of SI as an
independent marker of real-time patient-specific condition.
Chapter 5 reviews current methods used to diagnose sepsis state by an-
alyzing current scoring systems in terms of the definitions and score
representation in real-time diagnosis. A different scoring system is also
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developed to better classify patients and determine prognosis.
Chapter 6 discusses the use of model-based insulin sensitivity, SI , as a
patient-specific parameter to aid sepsis diagnosis. The relation of SI
and the suggested sepsis score is observed for over hourly intervals for
real-time diagnosis using a 30 patient sepsis cohort.
Chapter 7 presents the analyses of potential sepsis predictors by looking at
available clinical variables typically gathered for sepsis patients. Ar-
tificial neural network (ANN) is used to compute predictive values of
sepsis state on hourly basis. Sensitivity and specificity of the tests are
compared and examined using mathematical computations to obtain
variables that may potentially become a sepsis bio-marker.
Chapter 8 presents the study of sepsis as a disease of the microcirculation.
Principles and operation of pulse oximeters are developed as a medium
to diagnose microcirculation function.
Chapter 9 validates the concept and operation of pulse oximeters that has
been discussed in Chapter 8. In this chapter, pulse oximeters are used
to investigate oxygen extraction to the tissues as a potential sensor for
diagnosing microcirculation failure in sepsis.
Chapter 10 summarizes the key aspects of the thesis.
Chapter 11 presents the possible future improvements and applications for
this research.

Chapter 2
Model Background and
Development
This chapter examines several forms of existing metabolic control models that
have been used for controlling glycemia in humans. Depending on the type
of application, different models have been developed with distinct levels of
complexity based on the application and outcome goal. The majority of these
models use basic compartmental modelling with differential equations [Co-
belli et al., 1984; Carson and Cobelli, 2001]. These approaches vary from
second [Ackerman et al., 1965; Lehmann and Deutsch, 1992] to 19th [Parker
et al., 1999] order, showing the wide range of possibilities. As the complexity
of the models grows, more variables tend to be identified, and more clinical
and computational effort are needed. Importantly, a model should be able
to accurately describe the physiologically relevant responses, and, for control
applications, be clinically applicable, while minimizing mathematical com-
plexity.
Metabolic models have been developed to assess a number of metabolic
phenomena. These investigations focused on understanding rather than inter-
vention or control, and center around glucose, insulin, and insulin sensitivity
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[Bergman et al., 1981, 1979; Yang et al., 1987; Pacini and Bergman, 1986; Mari
et al., 2001; Mari, 1998]. Critically, a physiological model that captures the
glucose-insulin dynamics is also the basis of any glycemic control problem. In
recent years, metabolic modelling of insulin and glucose has been developed
due to a high demand for model predictive control (MPC) [Hovorka et al.,
2004] and automated or semi- automated glycemic control [Chase et al., 2007,
2008b; Parker et al., 1999, 2001; Plank et al., 2006; Hovorka et al., 2004].
These are all models for clinical intervention.
2.1 Physiology of a Glucose-Insulin System
Model
Early modeling studies [Ackerman et al., 1965; Bolie, 1961] in diabetic in-
dividuals have become a basis for analysing glucose-insulin system models
in terms of mathematical and physiological identification. Later studies ex-
tended to more complicated and nonlinear models, such as the well known
Minimal Model [Bergman et al., 1981]. The Minimal Model became popular
and forms a basis in most of the models developed despite numerous param-
eter identifiability issues [Pillonetto et al., 2002, 2003; Caumo et al., 1999;
Docherty et al., 2011]. Additionally, other physiological systems have been in-
corporated in some of the model structure [Cobelli and Mari, 1983] for better
representation of human physiology.
Several forms of metabolic system model have been developed, and some
have been applied clinically, where various mathematical control algorithms
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have been implemented. Some of these models have been used in examining
critical care patients and glycemic control [Hovorka et al., 2004; Chee et al.,
2003b,a; Parker et al., 1999; Chase et al., 2007]. Besides capturing physiolog-
ical and metabolic condition, these model must also be designed for clinical
applicability and performance. Thus, different models have been developed
with different criteria to suit particular applications. In particular, a con-
trol model should focus on the ability to predict outcomes of interventions,
although many do not [Chase et al., 2011a].
The following sections present a broad cross-section of models to illus-
trate the range of possibilities. The first model discussed is that of Chee and
colleagues [Chee et al., 2003b,a] who introduced a model using an optimised
PID form of control. The integral control (Equation 2.1) is implemented when
sliding tables do not provide adequate glycemic reduction and the amount of
additional insulin is calculated using Equation 2.2, a normalized weighted av-
erage of the blood glucose zones using a 2-hour triangular window. Derivative
control is implemented using Equations 2.3 - 2.6. Expert control is imple-
mented by keeping an active sliding table and offsetting the recommended
sliding table input according to several conditions, based on Equations 2.3 -
2.6. In Equation 2.6, xmax and xmin represent the maximum and minimum
time value in the 30-min window respectively, whereas ymax and ymin represent
maximum and minimum BG value in the 30-min window.
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Insulin increment =
8>>>>>>><>>>>>>>:
4 U/hr, if kW zonek > 4.5
2 U/hr, if 3.6  kW zonek  4.5
1 U/hr, if 2.7  kW zonek  3.6
0 U/hr, if kW zonek < 2.7
(2.1)
where:
kW zonek = 1P24
i=1 i
✓ 24X
n=1
n.Wzone[n]
◆
(2.2)
Bolus =
8>>>><>>>>:
6 U/hr, if  yproj   2 mmol/L
4 U/hr, if 1   yproj < 2 mmol/L
0 U/hr, if  yproj < 1 mmol/L
(2.3)
 yproj =
✓P6
i=1XiYiP6
i=1Xi
2
◆
 x (2.4)
Xi = xi   x˜ and Yi = yi   y˜ (2.5)
x˜ =
xmax + xmin
2
and y˜ =
ymax + ymin
2
(2.6)
The use of sliding tables and normalized weighted average in this model
are incapable of capturing the physiology of glucose-insulin model. Moreover,
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expert control is part of the implementation, where keeping and offsetting
the recommended sliding input is based on clinical judgement. Hence, any
physiology is implicit in this clinical input. It also does not take account for
patient variability, as each individual patient has different metabolic condition
that can vary with time. Therefore, this model is designed from a control point
of view without incorporating the physiological point of view.
The second model is adapted by Hovorka et al from type 1 diabetes
control applications. This model is used in critically ill patients, although
designed for controlling blood glucose in Type 1 diabetes [Hovorka et al.,
2004]. The structure of the model is shown in Figure 2.1 and the model
equations are shown in Equations 2.7 - 2.19.
Figure 2.1: Compartment model of glucose-insulin system (Adapted from
Hovorka et al. [2002]).
28 CHAPTER 2. MODEL BACKGROUND AND DEVELOPMENT
Q˙1(t) =  

F c01
VGG(t)
+ x1(t)
 
Q1(t) + k12Q2(t)  FR + UG(t) +EGP0[1  x3(t)]
(2.7)
Q˙2(t) = x1(t)Q1(t)  [k12 + x2(t)]Q2(t) (2.8)
y(t) = G(t) = Q1(t)/VG (2.9)
F c01 =
8><>: F01 if G   4.5 mmol/LF01G/4.5 otherwise (2.10)
FR =
8><>: 0.003(G  9)VG if G   9.0 mmol/L0 otherwise (2.11)
UG(t) =
DGAGte t/tmax,G
t2
(2.12)
S˙1(t) = u(t)  S1(t)
tmax,I
(2.13)
S˙2(t) =
S1(t)
tmax,I
  S2(t)
tmax,I
(2.14)
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I˙(t) =
UI(t)
VI
  keI(t) (2.15)
where:
UI(t) =
S2(t)
tmax,I
(2.16)
x˙1(t) =  ka1x1(t) + kb1I(t) (2.17)
x˙2(t) =  ka2x2(t) + kb2I(t) (2.18)
x˙3(t) =  ka3x3(t) + kb3I(t) (2.19)
where Q1 and Q2 in Equations 2.7 and 2.8 represent masses of glucose in the
accessible and inaccessible compartments. k12 represents the transfer rate be-
tween the inaccessible and accessible compartments. The distribution volume
of the accessible compartment is VG, the measurable glucose concentration is
y and G, and EGP0 is the endogenous glucose production extrapolated to
the zero insulin concentration. FC01 is the total non-insulin-dependent glucose
flux corrected for the ambient glucose concentration and FR is the renal glu-
cose clearance above the glucose threshold of 9 mmol/L. UG(t) is the gut ab-
sorption rate, dependent upon the carbohydrates digested, DG, carbohydrate
bioavailability, AG, and the time of maximum appearance rate of glucose in
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the accessible compartment, tmax,G. The insulin subsystem is described by
Equations 2.13 - 2.19. S1 and S2 are a two-compartment chain for absorption
of subcutaneously administered rapid-acting insulin, u(t) the insulin input
(bolus/infusion), and tmax,I the time-to-maximum insulin absorption. I(t) is
the plasma insulin concentration, ke is the fractional elimination rate and VI
the distribution volume. The insulin action subsystem consists of three com-
ponents, endogenous glucose production, transport/distribution and disposal
(x1, x2 and x3). Finally, kai and kbi (i =1, ..., 3) represent the activation and
deactivation rate constant of insulin action, respectively.
Overall, the model uses 9 population values or generic constants, and
requires a further 6 patient-specific parameters to be identified. Nonlin-
earity comes from insulin action on parameters of glucose production, glu-
cose distribution/transport and glucose disposal, and difference in the acti-
vation/deactivation profile of the three insulin actions. Consequently, several
additional measurements are required to identify patient-specific parameters.
However, this model has been used in critical care for glycemic management
and achieved promising results [Plank et al., 2006].
Another model used to estimate insulin sensitivity and glucose effec-
tiveness is the Minimal Model [Bergman et al., 1981, 1979]. This classical
model of glucose disposal has been constructed by using an iterative numeri-
cal algorithms. The minimal model was developed to characterize Intravenous
Glucose Tolerance Test (IVGTT) responses. The IVGTT is an insulin sensi-
tivity test that measures the glucose and insulin responses to an intravenous
glucose injection. Glucose and insulin kinetics are described by two compart-
ments where parameters have been estimated separately within each compo-
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nent. The glucose-insulin system is illustrated by the compartmental model in
Figure 2.2 and can be described mathematically, in its most commonly used
form, by Equations 2.20 - 2.22.
Figure 2.2: Bergman’s minimal model describing the glucose and insulin ki-
netics in an IVGTT study [Bergman et al., 1981].
G˙(t) =  p1(G(t) Gb) X(t)G(t) (2.20)
X˙(t) =  p2X(t) + p3(I(t)  Ib) (2.21)
where:
G(0) = Go ; X(0) = 0 ; I(0) = Io (2.22)
SI = p3/p2 (2.23)
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where G(t) is the plasma glucose concentration at time t, I(t) is the plasma
insulin concentration and X(t) is the interstitial insulin. Gb is the basal
plasma glucose concentration and Ib is the basal plasma insulin concentra-
tion. p1, p2, p3 and Go are four unknown parameters and SI represents insulin
sensitivity.
This simple model illustrates the basic dynamic of insulin pharmacoki-
netics, glucose pharmacokinetics and glucose-insulin pharmacodynamics ac-
counting for the removal of glucose that should be captured for any glycemic
control problem. It is physiological, but still has too many parameters requir-
ing patient-specific identification. Equally, its predictive accuracy has been
called into question [Chase et al., 2006].
2.2 Critical Care Glucose-Insulin Model
Any model used in critical care must effectively account for the fundamental
dynamics of the glucose-insulin system, while maintaining clinical applica-
bility. This requirement exists because patients in intensive care units are
highly monitored, and insulin and glucose must be carefully administered to
achieve homeostasis. Model-based decision support can improve the preci-
sion of glycemic control [Wong et al., 2006a; Chase et al., 2006]. However,
the model complexity has to be reasonable and, critically, must also account
for observed physiological response, dynamics, and inter- and intra- patient
variability [Chase et al., 2011a].
There have been several metabolic models used to examine critical care
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patients. Chase and colleagues used a model derived from the Minimal Model
with additional, physiologically relevant non-linear terms, and a grouped term
for insulin sensitivity [Chase et al., 2007; Wong et al., 2006b]. These changes
were made because the Minimal Model has significant limitations where it
does not accurately capture the dynamics observed in glycemic control [Doran
et al., 2004a,b], particularly saturation of glucose removal by insulin [Prigeon
et al., 1996; Rizza et al., 1981; Natali et al., 2000; Docherty et al., 2011],
saturation of insulin transport [Prigeon et al., 1996; Ellemann et al., 1987],
dynamics of insulin receptors and measurable and unmeasurable glucose com-
partments [Cobelli et al., 1999, 1992]. As a result, a more descriptive model
was developed by Chase et al [Chase et al., 2007, 2005].
Figure 2.3 illustrates the schematic of the critical care glucose-insulin
model developed by Chase et al. This model has been employed in several
critical care glycemic control trials using different control methods, as well
as in retrospective analyses [Wong et al., 2006b; Chase et al., 2005, 2007;
Lin et al., 2004]. Additional non-linear terms have been introduced to this
model that include patient endogenous glucose clearance and insulin sensitiv-
ity. The mathematical equations are shown in Equations 2.24 - 2.26, where
these equations are the result of several small evolutions as described.
G˙ =  pGG  SIG Q
1 + ↵GQ
+
P (t) + EGPmax   CNS
VG(t)
(2.24)
Q˙ =  kQ+ kI (2.25)
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Figure 2.3: Schematic of Critical Care Glucose-Insulin Model adapted from
Chase et al.
I˙ =   nI
1 + ↵II
+
Uex(t)
VI
+ e kIUex(t)IB (2.26)
where t [min] is time, the symbols G(t) [mmol/L] denotes the total blood
glucose concentration, and I(t) [mU/L] is the plasma insulin resulting from
exogenous insulin input, uex(t) [mU/min]. Q(t) [mU/L] represents the effect
of previously infused insulin being utilised over time, with k [1/min] account-
ing for the effective life of insulin in the system. Patient endogenous glucose
clearance and insulin sensitivity are pG [1/min] and SI [L/mU/min], respec-
tively. VI [L] and VG [L] are the insulin distribution volume and glucose
distribution volume, respectively. n [1/min] is the constant first order de-
cay rate for insulin from plasma and external nutrition is P (t) [mmol/min].
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Michaelis-Menten functions are used to model saturation, with ↵I [L/mU]
used for the saturation of plasma insulin disappearance and ↵G [L/mU] for
the saturation of insulin-dependent glucose clearance. IB [mU/L/min] and kI
[min/mU] are endogenous insulin secretion, CNS [mmol/min] is central ner-
vous system glucose uptake and EGPmax [mmol/min] represents maximum
endogenous glucose production at zero insulin.
Patient-specific insulin mediated glucose removal is captured with in-
sulin sensitivity, SI , which is identified hourly from clinical data as a time-
dependent variable that reflects evolving patient condition. Exogenous inputs
are glucose appearance P (t) from the carbohydrate content of nutrition in-
fusion via a two compartment model, and intravenous insulin administration
uex(t). The remaining parameters are physiologically defined population con-
stants for transport rates (n, k), saturation parameters (↵G, ↵I), endogenous
insulin secretion (IB, kI) or volumes (VG, VI). This model was developed
and validated in critical care glycemic control studies [Suhaimi et al., 2010;
Le Compte et al., 2009]. All the compartmental transport and utilisation rates
are assumed to be constant population values except insulin sensitivity, SI .
2.3 Intensive Control Insulin Nutrition Glucose
Model (ICING)
Finally, another more advanced model used in this study is the ICING Model.
This model is the improved version of the model used in critical care, and was
recently developed at the University of Canterbury [Lin et al., 2011b]. This
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model extensively described the glucose appearance in a patients. Figure 2.4
illustrates the ICING model system. The mathematical formulations used in
this model are described in Equations 2.27 - 2.33.
G˙ =  pGG  SIG Q
1 + ↵GQ
+
P (t) + EGPb   CNS
VG
(2.27)
Q˙ = nI(I  Q)  nC Q
1 + ↵GQ
(2.28)
I˙ =  nKI   nLI
1 + ↵II
  nI(I  Q) + uex(t)
VI
+ (1  xL)uen
VI
(2.29)
P˙1 =  d1P1 +D(t) (2.30)
P˙2 =  min(d2P2, Pmax) + d1P1 (2.31)
P (t) = min(d2P2, Pmax) (2.32)
uen(t) = k1e
I(t)k2
k3 (2.33)
where G [mmol/L] is the total blood glucose concentration, Q [mU/L] rep-
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resents the effect of previously infused insulin being utilised over time and
I [mU/L] is the plasma insulin. Patient endogenous glucose clearance and
insulin sensitivity are pG [1/min] and SI [L/mU/min], respectively. VI [L] is
the insulin distribution volume and VG [L] is the glucose distribution volume.
External nutrition is P (t) [mmol/min], EGPb [mmol/min] is basal endogenous
glucose production and CNS [mmol/min] is central nervous system glucose
uptake. ↵I [L/mU] is the saturation of plasma insulin disappearance and ↵G
[L/mU] is the saturation of insulin-dependent glucose clearance. nI [L/min] is
the diffusion constant of insulin between compartments and nC [1/min] is the
cellular insulin clearance rate from interstitium. nK [1/min] and nL[1/min]
represent plasma insulin clearance rate at kidney and liver, respectively. xL
is the fraction of extraction. uex [mU/min] and uen [mU/min] are exogenous
insulin infusion and endogenous insulin production, respectively.
Equations 2.30 - 2.32 present the gastric absorption of glucose, where P1
[mmol] represents the glucose in the stomach and P2 [mmol] is for the gut.
Transport rates between the compartments are d1 [1/min] and d2 [1/min].
Amount of dextrose from enteral feeding is D(t) [mmol/min]. Glucose ap-
pearance, P (t) [mmol/min] from enteral food intake D(t), is the glucose flux
out of the gut P2. Pmax [mmol/min] represents maximum enteral feeding.
The EGPb term in Equation 2.27 is a constant and represent the theoret-
ical endogenous glucose production for a patient with no exogenous glucose
or insulin. Equation 2.33 is a generic representation of endogenous insulin
production when C-peptide data is not available from the patient for specific
identification of its production. Endogenous insulin production, with the base
rate being k1 [mU/min], is suppressed with elevated plasma insulin levels. The
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exponential suppression is described by generic constants k2 and k3.
2.4 Summary
This chapter discusses the basis of glucose-insulin system models and reviews
several forms of model that have been developed and used for glycemic un-
derstanding, control and management. These different models have been used
clinically for various studies for understanding or intervention. The use for
understanding versus intervention require differences in model capability and
complexity that may not translate directly from one use to another. However,
not all of these models were physiologically complete and some failed to cap-
ture inter- and intra- patient variability. The final models presented in this
chapter provide an overall measure of a patient’s insulin sensitivity, particu-
larly to exogenous insulin and nutrition inputs that guide and determine the
metabolic balance in ICU patients. The glucose-insulin models presented are
already proven to be suitable for clinical control applicability while accurately
accounting for all relevant physiological behavior.

Chapter 3
Successful TGC and Model-Based
Metabolic Markers
Tight glycemic control (TGC) can reduce intensive care unit (ICU) patient
mortality up to 45%, with glycemic targets from 6.1 to 7.75 mmol/L [Van den
Berghe et al., 2006b; Chase et al., 2008b; Krinsley, 2004]. Despite the poten-
tial, many ICUs have issues in safely and effectively delivering TGC, particu-
larly in using a fixed protocols (NICE, VISEP, Glucontrol).
This chapter analyses data from two TGC trials for root causes of the
differences achieved in control and thus, potentially, in glycemic and mortality
outcomes. The two different control trials are Glucontrol [Preiser et al., 2009]
and SPRINT protocol [Lonergan et al., 2006]. Specifically, these two protocols
vary in terms of clinical practice and nutritional standards, in particular,
which both play a major role in BG outcome. Insulin sensitivity profiles
SI(t) of the cohort are generated to assess metabolic condition and stochastic
models are used to assess metabolic variability. From the analysis of metabolic
condition and TGC interventions, aspects of successful TGC are delineated.
Therefore, this chapter provides insight and clearer guidance into the design
and implementation of clinical TGC protocols based on metabolic condition.
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3.1 SPRINT Protocol
Specialized Relative Insulin Nutrition Titration (SPRINT) is a model-derived
protocol [Lonergan et al., 2006; Wong et al., 2006b; Chase et al., 2007] that
controls both insulin and (carbohydrate) nutrition inputs. It was implemented
at the Christchurch Hospital Department of Intensive Care on August 2005
[Chase et al., 2008b] and has now been used on over 1,000 patients. In
SPRINT, the interventions consider current and previous blood glucose mea-
surements, current nutrition rate relative to a patient specific goal rate, and
the prior hourly insulin dose to determine a new nutrition and insulin inter-
vention for the coming 1-2 hour measurement interval defined in the protocol
[Chase et al., 2008b].
The SPRINT protocol consists of two wheels dedicated to insulin bolus
administration and enteral nutrition optimization, as shown in Figures 3.1-
3.4. In SPRINT, blood glucose measurements are taken 1-2 hourly at bedside
based on the protocol. The approach is patient-specific in nutrition rate and
its titration of inputs in response to the patient-specific metabolic condition.
More specifically, SPRINT titrates its insulin and nutrition inputs to
achieve a target range of 4-6 mmol/L based on the patient’s current insulin
sensitivity, which is effectively determined by the response to the insulin and
nutrition interventions. More resistant patients receive more insulin and less
nutrition (relative to their 100% goal feed rate). Stability and stopping crite-
ria were also based on patient-specific insulin sensitivity. Hence, the protocol
explicitly considers glycemic response in the context of both insulin and car-
bohydrate intake and is thus not blind to carbohydrate intake, which is unique
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Figure 3.1: The SPRINT insulin wheel with dial [Lonergan et al., 2006].
Figure 3.2: The SPRINT insulin wheel without dial [Lonergan et al., 2006].
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Figure 3.3: The SPRINT feed wheel with dial [Lonergan et al., 2006].
Figure 3.4: The SPRINT feed wheel without dial [Lonergan et al., 2006].
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[Chase et al., 2011b]. Virtually all other studies leave nutritional intake to lo-
cal clinical standards and are thus blind to this critical parameter that directly
affects glycemic levels.
A low carbohydrate enteral nutrition formula was also specified for all
SPRINT patients, reducing the percentage of carbohydrate calories as a per-
centage of the total caloric intake. Minimum and maximum nutrition rates
are 7.5 and 25 kcal/kg/day respectively, with 2.7 to 9 kcal/kg/day (35-40%)
from carbohydrates, which matches ACCP guidelines at the maximum level
[Cerra et al., 1997].
Finally, SPRINT uses insulin boluses, limited to 6U per hour to mini-
mize insulin saturation [Chase et al., 2005; Natali et al., 2000; Prigeon et al.,
1996]. Boluses also avoid high rates of insulin infusion being left running when
clinical staff are occupied, increasing potential safety, which is an important
aspect in situations where high insulin infusion rates combined with infre-
quent measurement can lead to significantly increased hypoglycemic events
and variability resulting from acute changes in patient condition and metabolic
response. This latter point is critical because, like hyperglycaemia, low BG
or hypoglycaemia is also linked to increased mortality [Griesdale et al., 2009].
Overall, SPRINT is a unique TGC protocol among all those published.
It was the only TGC protocol to reduce both mortality and hypoglycaemia,
where many attempts fail at both [Brunkhorst et al., 2008; Preiser and Devos,
2007; De La Rosa et al., 2008; Van den Berghe et al., 2006b]. Its uniqueness
stems from its direct management of insulin and nutrition based on patient-
specific, time varying insulin sensitivity. It thus manage inter- and intra-
patient variability, and thus glycaemia and hypoglycaemia risk, better than
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others [Griesdale et al., 2009].
3.2 Glucontrol Protocol
The Glucontrol protocol is a glycemic control protocol that controls only the
amount of insulin given to a patient to change [Preiser et al., 2009]. Hourly
measurement was used when the glycemic level was not within the target
range. Otherwise, 2-hourly measurement was used in the case of limited vari-
ation of glycaemia, defined as less than a, rather large, 50% change from the
previous BG in 2-hour range. Finally, 4-hourly measurement was used when
the glycemic level was less than 50% of the highest glycaemia of the four last
hours. Insulin was administered as a continuous IV infusion. However, nutri-
tional input was left to local and/or clinician standards, and was not explicitly
considered in the design or implementation of the protocol.
In the randomised clinical trial of Glucontrol, there were two different
insulin targets used, which are defined as intensive insulin therapy and con-
ventional insulin therapy. Patients treated with intensive insulin therapy are
known as Group A, whereas patients treated with conventional insulin therapy
are known as Group B. Both groups, intensive and conventional, were targeted
for different blood glucose levels of 4.4-6.1 mmol/L and 7.8-10.0 mmol/L, re-
spectively. The insulin infusion rates defined by each target protocol are shown
in Tables 3.1-3.2 for the Intensive and Conventional protocols.
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Table 3.1: Glucontrol protocol for intensive insulin therapy (Group A). (a)
Starting insulin infusion rate. (b) Maintenance insulin infusion rates and
increments.
a)
Glycemia Insulin infusion rate
< 110 mg/dl On hold
110 - 140 mg/dl 1 U/H
140 - 180 mg/dl 2 U/H
> 180 mg/dl 4 U/H
b)
Glycemia Incremental insulin infusion rate
> 300 mg/dl + 3 U/H
180 - 300 mg/dl + 2 U/H
140 - 180 mg/dl + 1 U/H
110 - 140 mg/dl + 0.5 U/H
80 - 110 mg/dl + 0 U/H (target range)
40 - 80 mg/dl Stop insulin,
Hourly measurement of glycemia
until > 80mg/dl
< 40 mg/dl Stop insulin, 10gr glucose IVD,
Call physician immediately,
Hourly measurement of glycemia
until > 80 mg/dl
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Table 3.2: Glucontrol protocol for intensive insulin therapy (Group B). (a)
Starting insulin infusion rate. (b) Maintenance insulin infusion rates and
increments.
a)
Glycemia Insulin infusion rate
< 180 mg/dl On hold
180 - 250 mg/dl 1 U/H
250 - 300 mg/dl 2 U/H
> 300 mg/dl 4 U/H
b)
Glycemia Incremental insulin infusion rate
> 300 mg/dl + 3 U/H
250 - 300 mg/dl + 2 U/H
180 - 250 mg/dl + 1 U/H
140 - 180 mg/dl + 0 U/H (target range)
80 - 140 mg/dl Decrease 50% rate insulin
40 - 80 mg/dl Stop insulin,
Hourly measurement of glycemia
until > 80mg/dl
< 40 mg/dl Stop insulin, 10gr glucose IVD,
Call physician immediately,
Hourly measurement of glycemia
until > 80 mg/dl
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3.3 Patient Data
In this study, data was used from 350 patients treated using the Glucontrol
protocol at CHU de Liege, Belgium, between March 2004 and April 2005.
Thus, the Glucontrol data is from only one centre out of the full study [Preiser
et al., 2009]. For the purpose of analysis, patients were selected following
several considerations.
Figure 3.5 shows the selection of patients used in this model-based anal-
ysis, which requires good data density. For the Glucontrol cohort, patients
were eliminated from the analysis if they received no insulin for their entire
stay, had less than 5 blood glucose measurements over their time in the study
or received little or no recorded carbohydrate administration in any form for
more than 48 hours of their stay. Out of 350 patients, 211 patients met these
criteria. Moreover, all 393 SPRINT patients study met these criteria.
The selection process is crucial in analysing this data as it eliminates
biases in comparison to retrospective data that has been obtained from
Christchurch Hospital, and to generate virtual patients with sufficient data
density. At the end of the selection process, there were 142 patients treated in
Group A (Glucontrol) , 69 patients in Group B (Glucontrol) and 393 SPRINT
patients.
Table 3.3 compares the SPRINT and Glucontrol patients characteristics,
where the latter are separated by tight glycemic control therapy (Groups A
and B). Severity of illness over all Glucontrol (A+B) patients, via APACHE II
and percentage of male patients were similar (p > 0.35). The total Glucontrol
cohort (A+B) was slightly older (p = 0.011). The distribution of APACHE II
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Figure 3.5: Cohort selection for SPRINT and Glucontrol A (Intensive) and B
(Conventional) insulin therapy groups.
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score among Glucontrol cohort, Group A and Group B, are shown in Figures
3.6 and 3.7. Overall, SPRINT had more hours of control with a total of 49,008
compared to 16,831 and 12,946 for Glucontrol A and B, respectively. SPRINT
also had a higher measurement frequency given that total BG measurements
were 29,919 for a total of 49,008 hours of control.
Table 3.3: Comparison of Glucontrol and SPRINT cohort characteristics.
The P -values are for comparing the Glucontrol A+B cohorts together ver-
sus SPRINT.
SPRINT Glucontrol A Glucontrol B P value
Number of patients 393 142 69
Percentage of males (%) 62.8 64.8 56.5 0.8531
Age median [IQR] 65 [50 - 74] 71 [61 - 80] 69 [53 - 77] 0.0011
APACHE II score
median [IQR] 18[14 - 24] 17 [14 - 22] 17 [14 - 21] 0.3894
Hours of control 49,008 16,831 12,946
Total blood glucose
measurements 29,919 4,571 2,820
3.4 Insulin Sensitivity as a Model-Based Metric
3.4.1 Model-Based Insulin Sensitivity
The essential model parameter that drives the observed patient-specific
glycemic response to insulin and nutrition inputs is insulin sensitivity, SI .
Using the glucose-insulin system model, patient-specific profiles can be gen-
erated for time-varying SI and its hour-to-hour variation as patient condition
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Figure 3.6: APACHE II score distribution for Group A (Glucontrol).
Figure 3.7: APACHE II score distribution for Group B (Glucontrol).
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evolves. This task is achieved by fitting the model to retrospective clinical
data for blood glucose measurements, insulin and carbohydrate administra-
tion input data from the protocols. The resulting insulin sensitivity profile
has been validated in correlation to gold standard euglycemic clamp and in-
travenous glucose tolerance test data [Lotz et al., 2006, 2008], as well as in in
silico virtual trials [Lonergan et al., 2006; Chase et al., 2007; Lin et al., 2008;
Le Compte et al., 2009].
Figures 3.8 and 3.9 show empirical per-patient CDFs of model-based in-
sulin sensitivity, SI , for each protocol. The shaded areas show the 90% confi-
dence interval (CI) range and IQR, with the median patient noted by a dashed
line. It is clear that the Glucontrol cohort has higher insulin sensitivity at all
likelihoods (y-axis) and for all observed percentile patients compared to the
SPRINT cohort. It is also clear that the spread or range of insulin sensitivity
across the cohort is almost two times wider for Glucontrol, indicating a cohort
with far greater inter-patient variability in insulin sensitivity or resistance, and
thus one potential reason for its greater outcome glycemic variability given the
relatively fixed non-patient-specific structure of the Glucontrol protocol.
3.4.2 Stochastic Model
Insulin sensitivity can evolve both gradually and acutely over time in ICU
patients. Stochastic models based on the hour-to-hour variation of this model
variable yield distribution of the potential change in insulin sensitivity over
1-4 hours [Lin et al., 2008, 2006]. These distributions then allow the creation
of outcome blood glucose confidence bands for a given insulin and nutrition in-
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Figure 3.8: Empirical CDFs per-patient of insulin sensitivity on SPRINT.
Figure 3.9: Empirical CDFs per-patient of insulin sensitivity on Glucontrol.
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tervention [Evans et al., 2011]. Thus, these models also quantify the potential
affect on glycemic control of both minor and acute evolutions in patient con-
dition, as a function of current metabolic state and the clinical interventions.
As a result, a model-based or adaptive TGC system can optimise interven-
tions to minimise the risk of unexpected glycemic excursion and provide better
decision making [Lin et al., 2008; Le Compte et al., 2009].
Knowledge of these dynamic changes provides further metrics of how
metabolically dynamic and insulin resistant a given cohort may be. Therefore,
they provide another physiologically relevant means of comparing cohorts for
similarities and differences relevant to the quality of glycemic control achieved.
While details are left to the references, a more dynamic and insulin resistant
cohort would expect to have different bounds on this variability, and thus, all
else equal, more variable glycemic control. Similarly, a more insulin resistant
cohort would be expected to require more insulin to achieve equal glycemic
outcomes. Thus, this model based-based parameter and its variation can be
used to quantify inter-patient and intra-patient variability for different co-
horts, also enabling comparison of metabolic variability (over time and across
patients) between cohorts.
This metric is thus a unique, but physiologically and clinically relevant
metric not only for glycemic control but also for assessing overall patient-
specific stress response to illness. In particular, since the counter-regulatory
and acute immune responses of critically ill patients are primary drives of
insulin resistance, this metric thus captures their net effect. Hence, SI is a
direct, metabolic-based biomarker of the level of critical illness.
Figure 3.10 shows the distribution and hour-to-hour variation of fitted
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SI over time for all Glucontrol protocol patients, where measurements were
1-2 h apart, enabling the use of the stochastic model of Lin and colleagues
[Lin et al., 2008, 2006]. The x-axis shows the SI value at hour t, and a vertical
line shows the distribution of possible SI values in the next hour, t+ 1 based
on the entire cohort’s data. The median, IQR and 90% CI lines provide
context and indicate the potential variability and the shape of its distribution
over the next hour. This plot thus shows the hour-to-hour distribution and
likelihood of metabolic intra-patient glycemic variability in response to insulin
for the Glucontrol cohorts. Hence, it might be hypothesized that the greater
the intra-patient variability in response to insulin interventions, the greater
the resulting glycemic variability in response, if not directly managed by the
protocol.
Figure 3.10: Fitted hourly SI variation and probability distribution function
of Glucontrol (1-2 h interval).
Figure 3.11 provides the same data for SPRINT. Figure 3.12 shows the
combination of IQR, median and 90% CI from figures 3.10 and 3.11 for both
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protocols. Figure 3.12 clearly shows very similar trends of median, IQR and
90% CI, indicating very similar metabolic intra-patient variability, as assessed
by this clinically validated parameter.
Figure 3.11: Fitted hourly SI variation and probability distribution function
of SPRINT.
Referring to Figures 3.8 and 3.9, its clearly shown that the Glucontrol
cohorts span a wider range of insulin sensitivity than the SPRINT cohort
with more inter-patient variability. However, their hour-to-hour variation can
significantly affect the level of glycemic control, especially in cases with less
frequent measurement, where small evolutions over several hours can result
in large changes in metabolic status and glycemic outcome for a constant
infusion of insulin and nutrition.
Hourly changes are the same for both Glucontrol and SPRINT given the
similar plots in Figure 3.12, where one hour variations may be considered sig-
nificant with respect to glycemic control and interventions when outside a 15%
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change from the prior hour [Lin et al., 2008; Chase et al., 2011b]. Thus, de-
spite the different inter-patient variation between SPRINT and Glucontrol in
Figures 3.8 and 3.9, the hour-to-hour intra-patient variation between cohorts
is, perhaps surprisingly, very similar.
Figure 3.12: Fitted hourly SI variation and probability distribution function
of SPRINT and Glucontrol with a 1-2 h measurement interval.
3.5 Glucose Control Analysis
3.5.1 Glycemic Outcome
Table 3.4 summarizes the control results of SPRINT and Glucontrol. Median
blood glucose for groups A and B were 6.3 and 8.2 mmol/L, respectively, as
expected, and SPRINT was 5.7 mmol/L, which is close to the Group A value
due to their similar glycemic targets. However, variability is much different
across these protocols. Median interquartile range (IQR) spread (75th -25th
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percentile) was 1.6 mmol/L for SPRINT, but 2.3 mmol/L for Group A and
2.5 mmol/L for Group B over the entire cohorts.
To achieve these results, SPRINT used approximately two times as much
insulin as Group A, since the median insulin rate for SPRINT is 2.8 U/h and
1.5 U/h for Group A, noting that both of these groups had similar glycemic
target. However, SPRINT used four times more than Group B with 0.7 U/h
due, in part, to its higher glycemic target. Since patients who did not receive
insulin were eliminated from the Glucontrol cohort examined, the comparison
shown is per-protocol patients treated at some point with insulin.
Median nutrition, reported as appearance rate of carbohydrate in the
nutritional formulas used, was broadly similar with median rates of 0.3, 0.6 and
0.42 mmol/min for Group A, Group B and SPRINT respectively. However,
it is also clear in Table 3.4 that the spread of carbohydrate administration
rates is much more tightly controlled by SPRINT with an IQR range of 0.27
mmol/min for SPRINT versus 0.9 mmol/min for Glucontrol groups A and B.
Hence, even where there are similar targets, interventions were significantly
different.
With respect to variability and safety from hypoglycaemia, SPRINT
had increasingly lower percentages of measurements below 4.0, 3.0 and 2.2
mmol/L compared to the similarly targeted Group A. Surprisingly, it also had
lower percentages of measurements below 3.0 and 2.2 mmol/L than Group
B, which had a much higher glycemic target, indicating that this protocol
had significant variability in glycemic response. As a percentage of patients,
SPRINT thus had a much lower rate of hypoglycaemia below 2.2 mmol/L
with 2% compared to Group A with 7.7% and the higher-targeted Group B
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with 2.9%.
Regarding tightness of control, SPRINT had 48.2% of measurements in
its target range, which is higher than that for the similarly targeted Group
A with 35.8%. In addition, Group B had 40.6% total blood glucose measure-
ment in its target range of 7.8 - 10.0 mmol/L. The results for hyperglycemic
measurements (percentage > 8.0 mmol/L) follow similar trends with expected
differences for the higher-targeted Group B. Hence, SPRINT was more effec-
tive and tighter in its target range indicating better management of inter- and
intra-patient variability.
On a per-patient basis, the median patient’s median blood glucose was
6.4 mmol/L for Group A, 8.3 mmol/L for Group B, and 5.8 mmol/L for
SPRINT, similar to those results for each overall cohort. However, the spread
of median glucose levels across patients in each cohort was comparable for
SPRINT, with 1.1 mmol/L separating the 25th and 75th percentile patient’s
median blood glucose value, and Glucontrol, with 1.0 and 1.2 mmol/L spreads
for groups A and B, respectively.
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All these results indicate that SPRINT maintained far tighter control on
a cohort-wide basis, but was comparable for intra-patient glycemic variability
when analyzing on a per-patient basis. Figure 3.13 provides cumulative distri-
bution functions (CDFs) for each protocol’s entire cohort, where the steeper
SPRINT CDF clearly shows the lower variability compared to Glucontrol. The
Glucontrol CDFs are similar in slope, but shifted, indicating similar behavior
around each glycemic target for each cohort.The crossover of the Group A and
SPRINT CDFs at 0.1 y-axis likelihood value shows the higher hypoglycaemia
risk in the similarly targeted Group A cohort.
Figure 3.13: Cumulative distribution function of measured blood glucose on
cohort basis for SPRINT, Group A and Group B (Glucontrol).
Figure 3.14 shows the same cohort CDFs for insulin delivered and Figure
3.15 for nutritional carbohydrate (all sources) delivery rate. It is clear in Fig-
ures 3.14 and 3.15 that SPRINT provides insulin and nutrition far more con-
sistently across the cohort (steeper and less zero-valued CDFS). Thus SPRINT
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Figure 3.14: Cumulative distribution function for hourly insulin infusion rate
on cohort basis for SPRINT, Group A and Group B (Glucontrol).
Figure 3.15: Cumulative distribution function of nutrition rate on cohort basis
for SPRINT, Group A and Group B (Glucontrol).
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provided a more constant nutrition rate in terms of carbohydrate appearance
from all sources to balance the insulin given with far less variation in glycemic
outcome. Importantly, nutrition rate was not a controlled variable and spec-
ified only to local standards in the Glucontrol study, which likely resulted in
the greater variability in this input, and thus the greater resulting glycemic
variability and greater hypoglycaemia.
Figure 3.16: Empirical cumulative distribution function of measured blood
glucose on SPRINT.
Figures 3.16 - 3.18 illustrate the inter-patient variability in the resulting
glycemic outcomes. The curves show the 5th, 25th, 50th (median), 75th and
95th percentile patient responses, and shaded areas show the resulting IQR
and 90% confidence interval range, where the x-axes and y-axes show the
blood glucose level and proportion of measurements, respectively.
In Figure 3.16, the per-patient CDFs shown reveal a tighter result across
patients, particularly over the 25th to 75th percentile IQR patients, for the
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Figure 3.17: Empirical cumulative distribution function of measured blood
glucose on Group A of Glucontrol.
Figure 3.18: Empirical cumulative distribution function of measured blood
glucose on Group B of Glucontrol.
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SPRINT protocol, despite the differences of variability noted in prior results.
The same lower variability seen for SPRINT over the cohort (steeper CDF in
Figure 3.13) is also evident for all percentile patients in Figures 3.17 - 3.18,
in comparison to the Glucontrol cohorts shown in Figure 3.13.
SPRINT achieved tighter control compared to Glucontrol A or B (for
the one center examined) around their respective target glycemic levels, as
clearly seen in Figure 3.13. The steeper CDFs indicate the lower, by cohort,
glycemic variability. Importantly, the Glucontrol CDFs are very similar, but
primarily shifted to their respective target glucose levels, resulting in higher
hypoglycaemia for the Group A cohort with the lower target. This result is
reinforced by the steeper and less variable per-patient CDFs for the middle
50% of patients (IQR) in each cohort shown in Figures 3.16 - 3.18, which
thus indicates the ability of each protocol to manage the inter-patient and
intra-patient variability. Notably, intra-patient variability, which determine
the per-patient CDF slope, was similar between Glucontrol and SPRINT in
Figure 3.12 but resulted in less steep slopes for Glucontrol in Figures 3.16 -
3.18, indicating a protocol failure in managing variability.
The higher incidence of hypoglycaemia for lower percentile patients is
clear in Figure 3.17. In particular, Figure 3.17 indicates that the intensive
Glucontrol A protocol could not effectively account for the inter-patient and
intra-patient variability in metabolic behavior seen in Figures 3.8 - 3.11, de-
spite the wider range of insulin and nutrition inputs used. Hence, some Glu-
control A patients were simply controlled by the protocol to too low glycemic
level, resulting in increased risk of hypoglycaemia, which has been commonly
reported in other studies [Griesdale et al., 2009
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This outcome clearly indicates that the Group A Glucontrol protocol was
not able to fully account for differences between patients or/and intra-patient
variability. This outcome was reinforced by the cohort and per-patient results
in Table 3.4, which show cohort IQR ranges for glycemic outcomes are much
wider in this group than in the similarly targeted SPRINT case. As a result,
SPRINT also had far less hypoglycaemia, and thus a significantly decreased
risk of death [Bagshaw et al., 2009; Egi et al., 2008; Egi and Bellomo, 2009].
In terms of providing nutrition and insulin, SPRINT has a higher pro-
portion of patients receiving, on average, more insulin than Group A and more
consistently as well for Group B (less zero values on the CDF in Figure 3.14).
In current thinking, this increased insulin usage should have resulted in simi-
lar or greater hypoglycaemia, which was not the case here. However, SPRINT
patients also received a more consistent input of carbohydrate administration
from all sources compared to Glucontrol Groups A and B , as seen in the
relatively very steep CDFs for SPRINT in Figure 3.15 with virtually no zero
values.
Considering the carbohydrate intake, note that all sources of carbohy-
drate includes enteral and parenteral nutrition and intravenous dextrose. This
difference in CDFs is critical given that the median and average values are sim-
ilar across all three cohorts. However, per-patient results for all three cohorts
show that the spread of carbohydrate administration rates was much tighter
for SPRINT than for either Group A or Group B by a factor of almost 4x for
median rates across patients, as seen in Table 3.4.
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3.5.2 Insulin and Nutritional Input in Glycemic Control
Figure 3.19: Cumulative distribution function of nutrition rate on cohort basis
for SPRINT, Group A and Group B (Glucontrol).
Figure 3.19 summarizes the control and metabolic balance delivered by
the protocols between carbohydrate administration, insulin administration
and resulting glucose levels. It uses three-dimensional plots of median blood
glucose, median insulin dose and median carbohydrate administration rates
for every patient in all three cohorts. Importantly, these inputs operate on
the insulin-glucose balance mediated by SI and its variability to determine
the resulting outcome glycaemia.
For clarity, Figures 3.20 - 3.22 show the decomposition of this three-
dimensional plot into two of the dimensions for each parameter. It is clear in
Figures 3.20 - 3.22 that the SPRINT data and glycemic outcomes are far less
variable and/or more tightly controlled. This result is particularly valid with
respect to the median nutrition rate and carbohydrate content versus outcome
median blood glucose. In Figure 3.20, both groups had zero feed rates at some
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Figure 3.20: Cumulative distribution function of nutrition rate on cohort basis
for SPRINT, Group A and Group B (Glucontrol).
Figure 3.21: Cumulative distribution function of nutrition rate on cohort basis
for SPRINT, Group A and Group B (Glucontrol).
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Figure 3.22: Cumulative distribution function of nutrition rate on cohort basis
for SPRINT, Group A and Group B (Glucontrol).
portions for very short staying patients. In SPRINT, some patients were not
fed, which corresponds to 1-2% of hours with no feed as shown in Figure 3.15.
Overall, these plots show the metabolic balance achieved for each patient
between insulin and carbohydrate inputs and the resulting glycemic outcome.
They also clearly show the outlying patients with unbalanced and/or extreme
insulin and nutrition inputs resulting in poor glycemic control to the desired
target.
Krishnan and associates [Krishnan et al., 2003] shows that 33-66% of
the ACCP guidelines of 25 kcal/kg/day [Cerra et al., 1997] are the optimal
rates of carbohydrate administration with respect to mortality outcome. The
SPRINT data are thus clustered almost entirely in this range. In contrast,
the greater spread in Glucontrol data is due to not controlling this variable,
and leaving carbohydrate administration to local clinical practice for that
patient cohort. Hence, it may not be unexpected that there was no correla-
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tion between mortality and median per-patient carbohydrate administration
in SPRINT, but that it was significant considering all Glucontrol patients.
Moreover, in Glucontrol study [Preiser et al., 2009], the nutritional inputs
were left to local standards of care, which can be quite variable, both between
centers and between clinicians in a center. Hence, the failure of Glucontrol to
achieve a mortality difference, as well as its increased hypoglycaemia may not
be surprising.
These results indicate that the higher insulin usage combined with co
nsistent, tightly managed carbohydrate input was balanced in the SPRINT
protocol, resulting in less glycemic variation and, for similar target glucose,
less hypoglycaemia. More specifically, the SPRINT protocol interventions
were both more consistent and within their tighter range, better able to man-
age the inter and intra-patient variation in their cohort. Overall, hypogly-
caemia and tight control are explicit functions of the nutrition and insulin
dosing ,leading to the conclusion that explicit knowledge of carbohydrate in-
take must be accounted for in successful TGC. In particular, without this
information, it will be far more difficult, if not impossible, to strike a safe,
long term, consistently achieved glycemic balance for such highly variable and
dynamic patients.
More importantly, it can be evaluated that clear guidelines for nutrition
intake of carbohydrate are essential in TGC protocol design, regardless of the
nutritional standards and practices across different countries. In addition,
considering frequent and convenient measurement, future protocols should
also consider bedside glucose monitoring system for reduced clinical effort and
better control. Finally, these recommendations arise from the recognition of
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insulin sensitivity and model-based SI (as defined) as being significant markers
of patient metabolic and overall condition.
3.6 Summary
From this analysis, two conclusions may be drawn. Firstly, any protocol must
be able to adapt to a given patient’s specific level of insulin resistance and
its changes with time, thus accounting for inter- and intra-patient variability.
It is clear that Glucontrol was potentially unable to manage one or both
of these aspects, as per-patient glycemic outcomes were similarly shaped in
CDFs across Group A and Group B, with a simple shift due to different
glycemic targets. Secondly, to control glycemic levels better, carbohydrate
administration must be explicitly accounted for in the protocol design and
implementation, which enables assessment or estimation of effective insulin
sensitivity in real time in response to interventions. In particular, this data
would allow protocols to adapt their inputs to match gradual or acute changes
in a patient’s metabolic status (insulin resistance or insulin sensitivity, SI),
which is what SPRINT effectively does [Chase et al., 2008b; Lonergan et al.,
2006], and thus provide potentially tighter control and more consistent care.
In a nutshell, successful TGC protocols must be able to account for
the significant inter-patient and intra-patient variability in insulin resistance
(sensitivity) that can be observed in critically ill cohorts. In addition, ex-
plicit knowledge of potential control of carbohydrate administration within
reasonable limits appears to be a mandatory component in reducing outcome
glycemic variability and thus, potentially, in achieving all the benefits of TGC
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with minimal risk. It is a factor that is missing from many of the published
protocols to date. While inter-patient variability in insulin sensitivity can be
quite different between cohorts that are otherwise similar in severity of illness,
the evolution and dynamic change or intra-patient variability of this param-
eter appears to be very similar across the cohorts studied here, which is a
unique and potentially valuable insight.
Finally, this chapter highlights the key aspects of TGC trials and data
that can be used in developing improved protocols, as well as used for retro-
spective analysis and comparisons that may have been previously overlooked.
It does by identifying a patient-specific marker of patient condition in insulin
sensitivity or SI . As the balance or mediator between insulin and carbohy-
drate appearance, it thus determines the success or failure of specific TGC
protocols. Hence, the main outcome of this chapter is that model-based SI
is a validated means of assessing both patient condition as reflected by the
analysis of different TGC protocols on metabolically similar cohorts.

Chapter 4
Model Validation
This chapter presents the overall validation of the glucose-insulin system
model on Glucontrol data, a cohort from Belgium Hospital. Model validation
was assessed by looking at the ability of producing patient dynamic through
a fitting process. Virtual trials method was introduced for better understand-
ing of developing virtual patients process. Simulations are run to capture the
behavior of the cohort and protocol, which was different from the data used
to replicate the model. Hence, the ability of the model to fit clinical data and
physiological parameters validates the dynamics of the model. The overall
validation of the model and methods serve to validate the use of model-based
metrics in later chapters as representative of patient condition independent of
other factors.
4.1 Glucontrol Study
A retrospective analysis using records from a 211 patients subset of the Glu-
control trial taken in Leige, Belgium was used in the Glucontrol study. In
the Glucontrol trial [Preiser et al., 2009], patients were randomised into two
groups, intensive (Group A) and conventional (Group B) insulin therapy. Both
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Group A and Group B were targeted for different levels of BG, which were
4.4-6.1 mmol/L and 7.8-10.0 mmol/L, respectively. They are thus very dif-
ferent treatment regimes, particularly in potential physiological outcome at
these different BG level [Chase et al., 2006, 2010a].
In the Glucontrol trial, insulin was administered as a continuous IV
infusion [Preiser et al., 2009]. The protocol used hourly, 2-hourly and 4-
hourly measurement intervals in obtaining the BG level and determining the
resulting insulin treatment. Details of the protocols are shown and discussed
in Section 3.2. However, nutritional input was left to local and/or clinician
standards, and was not explicitly considered in the design or implementation
of the protocol.
Clinical details of the resulting cohorts are shown in Table 4.1. This table
provides the baseline variables and results from glucose control on Groups A
and B. There were 64.8% of males patient in Group A whereas 56.5% in Group
B. Patients in Group A were slightly older than Group B with median age
of 71 and 69, respectively. However, there were no significant differences in
severity of illness as measured by APACHE II score, weight or BMI. Patients
in Group B had a slightly higher initial BG compared to Group A.
The total hours of control for Groups A and B were 16831 and 12946,
respectively. There were 7391 total BG measurements, where 4571 measure-
ments were from Group A and 2820 measurements from Group B. Even though
more hours of control were required for Group A, a relatively high frequency
of BG measurement was also observed for Group B.
Figure 4.1 shows the 5th - 95th percentile range, IQR and median prob-
4.1. GLUCONTROL STUDY 77
Table 4.1: Comparison of Group A and B of Glucontrol cohort. P -values are
computed using chi-squared and Mann-Whitney tests as appropriate.
Glucontrol Cohort A B P value
Baseline Variables
Number of patients 142 69
Percentage of males (%) 64.8 56.5 0.2460
Median age [IQR] 71 [61 - 80] 69 [53 - 77] 0.0352
Median weight [IQR] 72 [62 - 85] 75 [68 - 81] 0.3802
Median BMI [IQR] 25.4 [22.6 - 29.3] 26.0 [23.2 - 29.3] 0.4577
Median APACHE II score [IQR] 17 [14 - 22] 17 [14 - 21] 0.7605
Median initial BG [IQR] 6.56 [5.56 - 8.56] 6.61 [5.65 - 9.36] 0.5845
Glucose Control
Total hours of control 16, 831 12, 946
Total BG measurement 4, 571 2, 820
Median BG [IQR] (mmol/L) 6.3 [5.3 - 7.6] 8.2 [6.9 - 9.4]
Median insulin rate [IQR]
(mU/min) 25.0 [8.3 - 50.0] 11.7 [0.0 - 28.3]
Median carbohydrate
administration rate
(all sources) [IQR] (mmol/min) 0.30 [0.00 - 0.90] 0.60 [0.10 - 1.00]
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ability bounds for stochastic models for Group A and Group B. The distri-
butions indicate the hour to hour metabolic variability in insulin sensitivity
is very similar across the majority of the SI range for both groups, particu-
larly for the middle 50% IQR. Hence, both groups are similar in metabolic
variability, which is critical for this validation.
Figure 4.1: Hourly insulin sensitivity distribution for Group A and Group B
of Glucontrol cohort.
In particular, 89% - 93% of the data for both groups was in the range of
0.01 x 10 3  SI  0.8 x 10 3, which is where there was greatest agreement
between the groups. Above this range sparse data had an effect, particularly
on the 5% and 95% bounds. Hence, the clinically matched cohorts of Table 4.1
are also similar in metabolic variability, which is significant evidence of similar
metabolic response and variability in the context of insulin across patients and
cohorts.
Despite significant differences between the two protocols of Glucontrol
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A and B, the hour-to-hour intra-patient variation between cohorts is very sim-
ilar, indicating hour-to-hour changes in insulin sensitivity are patient-specific
and protocol independent. The cohorts can thus be considered interchange-
able for the purpose of cross-validation. The intra-patient variation helps
independently validate the assumption that this model-based insulin sensitiv-
ity is independent of the clinical inputs used to identify it, which is important
as this assumption is the basis of the virtual trials.
4.2 Virtual Trials Method
Virtual trials are used to simulate a clinical trial using patient-specific data,
such as model-based insulin sensitivity, SI . The insulin sensitivity profile,
SI(t), identified from clinical data captures a patient’s time varying glycemic
response to insulin and nutrition inputs. Later, this profile can be used to
simulate the blood glucose response to other combinations of insulin and dex-
trose inputs specified by a modified tight glycemic control protocol to obtain
a new glycemic response.
The process of developing a virtual patients start by collecting raw clin-
ical data for a set of patients such as blood glucose measurements, insulin
rates and enteral and parenteral dextrose rates. The collection of data is then
fitted to identify a collection of virtual patients defined by their unique SI(t)
profile. From the fitting process, hourly variation of insulin sensitivity, SI ,
can also be assessed.
Figures 4.2 - 4.3 show examples of fitting process output for Patient 186
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and Patient 213 from the Glucontrol cohort. The top panels of Figures 4.2
- 4.3 show the blood glucose data fit and measured blood glucose concentra-
tion, indicated by solid lines and crosses, respectively. The resulting insulin
sensitivity profiles are plotted in the middle panel, and insulin and dextrose
data are shown in the bottom panel.
Figure 4.2: Patient 186 blood glucose data fit (top panel, solid line), measured
BG (top panel, crosses), corresponding insulin sensitivity SI (middle panel),
and insulin and dextrose (bottom panel).
The next part is the in silico virtual patient simulation. In this process,
the collection of virtual patients is simulated using their identified SI(t) profile
with a selected glycemic control protocol. Therefore, simulation results will
be based on the protocol applied. The output of the control simulations are
insulin rates, dextrose rates, blood glucose response and other relevant per-
formance and safety data. Different controllers will generate different blood
glucose responses. Moreover, in silico virtual patient simulation provides the
ability to collate and compare blood glucose response between protocols to
optimise them before clinical use in a fast and safe manner. Figure 4.4 sum-
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Figure 4.3: Patient 213 blood glucose data fit (top panel, solid line), measured
BG (top panel, crosses), corresponding insulin sensitivity SI (middle panel),
and insulin and dextrose (bottom panel).
marizes the method in developing virtual patients and in silico virtual trial
simulation method.
4.3 Virtual Trials Validation
In this analysis, two groups of virtual patients were created from clinical
data from the Group A and B patients. They are defined by whether they
were clinically treated with either the Glucontrol A (intensive) or Glucontrol
B (conventional) protocols. Since the patients are clinically matched and
metabolically similar, it is possible to compare them for validation purposes.
Three major forms of validation using virtual trials was performed in this
study. The first approach is model fit and prediction error where it assesses
overall model dynamics by looking at the simulation results and clinical data.
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The other forms of validation are self- and cross- validation. In self-validation,
Protocol B is simulated on Group B virtual patients and similarly Protocol A is
simulated on Group A virtual patients. These results are compared to clinical
results for each group of patients. In contrast, in cross-validation, Protocol
A is simulated on Group B virtual patients, and Protocol B is simulated on
Group A virtual patients, with results compared to clinical results to see if
matched patients treated by one protocol match results when simulated on
another.
Figure 4.5 represents the virtual trial validation method used in this
analysis. The patient profiles obtained are then used to resimulate the Glu-
control A and Glucontrol B protocols for comparison to the appropriate clin-
ical results. Self-validation assesses the ability of the in silico virtual trials
to repeat the clinical data. On the other hand, cross-validation assesses the
assumption that the SI(t) accurately capture patient dynamics, independent
of the insulin and nutrition inputs used to create them.
Cross-validation is the critical step in assessing methods and models.
Self-validation indicates model errors. Finally, fit and, especially, prediction
errors show overall model quality and ability to capture clinically observed
dynamics.
4.3.1 Model Fit and Prediction Error
Model fit and prediction error are used to show the ability of the model to fit
the data and predict the expected patient state, which is critical for control.
Simulations were performed for Groups A and B using the clinically recorded
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Figure 4.5: Virtual trial validation method.
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insulin and dextrose administration rates as model inputs. The simulated BG
measurements were compared to clinical BG data.
Prediction errors are a function of hour-to-hour patient variability and
ability of the model to accurately capture insulin and glucose dynamics. Pre-
diction results are generated by holding insulin sensitivity, SI constant for
an upcoming hour, for lack of better information, and simulating the blood
glucose one hour into the future using the recorded clinical insulin and dex-
trose inputs. This blood glucose prediction is then compared to the clinically
recorded blood glucose or a linear estimate between 2-hourly measurements.
Prediction errors thus assess the model’s ability to predict the outcome of an
intervention in this population.
Figures 4.6 - 4.7 show the example of model generated blood glucose
response for two of the same patients shown in Section 4.2. Predictions are
generated after each recorded BG measurement assuming a constant SI over
one hour of prediction interval. In Figures 4.6 - 4.7, stars indicate the clinical
BG value (input) and crosses indicate the predicted BG value simulated from
the model. Dotted and solid lines represent the model BG fit for the input
and the simulated BG, respectively. Differences between clinical BG values
and simulated BG profiles indicate the prediction error.
Figure 4.8 shows the model fit and prediction errors for the entire Glu-
control cohort (A + B), and separated into Group A and Group B. Results
are shown on a cohort and a per-patient basis. Model fit error was consistent
across all three groups analysed, with median fit error < 0.25% in all cases.
The model fit errors in Figure 4.8 are relatively very small and almost overlaid
for Group A, B and the entire Glucontrol cohort.
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Group B has the lowest prediction error among these three distributions.
The Glucontrol cohort prediction error median value was 3.5%, whereas Group
A and Group B were 4.3% and 2.8% respectively. All these median errors are
well below sensor errors of 7-12%. Despite the significant differences in clinical
insulin usage for Group A and B, the model prediction errors are similar for
these patients. This outcome is due to the fact that variability of insulin
sensitivity for the cohort is similar, as seen in Figure 4.1.
Furthermore, the model prediction validation results can be seen as an
estimate of the variability of insulin sensitivity in this cohort, as well as a
sign of model fitness. Low prediction errors were found for both groups.
For context, this result suggests the use of model-based targeted BG control
will be effective for these cohorts of critically ill patients, as demonstrated for
Christchurch ICU cohorts upon whom this model was derived and used. Thus,
they also serve as an independent validation of this model using different ICU
cohorts.
4.3.2 Self-Validation
In general, self-validation tests the ability of the in silico virtual patient mod-
elling method to reproduce the clinical data from which a virtual cohort was
derived. For the self-validation on Glucontrol A, the Glucontrol A protocol
defined in Table 3.1 is simulated on Group A virtual patients, and these vir-
tual trial results are compared to the clinical data of Group A. This step was
repeated for self-validation on Glucontrol B. The clinically recorded dextrose
administration profiles were used for the carbohydrate inputs into the model
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in both cases to match the local standard used in the trial, as they were not
specified by the protocol.
Differences between clinical and virtual trial results can be ascribed to
model errors, and/or lack of perfect compliance in the clinical study versus
the perfect compliance and timing in silico. Hence, two self-validation virtual
trials were simulated on each group considering:
• The actual measurement timing used in the clinical trials (actual mea-
surement), and
• Measurement timing from the protocol (per-protocol).
Comparing actual and per-protocol measurement timing allows one to
assess one aspect of compliance error and its impact on results. For self-
validation of actual measurement, the timing used in the virtual trial strictly
follows the measurement timing in the clinical trials where the controller se-
lects the proper intervention in response to the blood glucose values at the
exact time correspond to its clinical time. In contrast, per-protocol self-
validation follows exactly the Glucontrol A and B protocols defined in Tables
3.1 and 3.2 regardless of the measurement timing they had clinically. The
controller will still select the intervention according to the current blood glu-
cose values. However, because the Glucontrol protocols modify insulin by
increments to a prior infusion rate in Tables 3.1 and 3.2, different measure-
ment timing could significantly change dosing, which would thus indicate the
impact of compliance to measurement timing.
Figure 4.9 shows the cumulative distribution function of measured blood
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glucose on a cohort basis. This figure compares the distribution of clinical
blood glucose for Group A and B to the simulated blood glucose distribution
from the virtual trials of the Glucontrol A protocol on virtual patients of
Group A and virtual trials of the Glucontrol B protocol on virtual patients of
Group B.
Figure 4.9: Cumulative distribution function of measured blood glucose on a
cohort basis for clinical data and self-validation.
The breakdown of distributions shows a clear separation between the
protocols for Glucontrol A and Glucontrol B simulations, as expected from
the clinical results and Glucontrol trial design. The three distributions for
the Glucontrol A protocol show particularly close agreement. The Glucontrol
A clinical median blood glucose value of 6.2 mmol/L agrees well with the
6.0 mmol/L and 6.2 mmol/L medians for simulated trials using actual and
per-protocol blood glucose measurement timing, respectively.
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Blood glucose distributions for the Glucontrol B protocol show a slightly
greater spread in results, particularly below the target of 8 mmol/L. However,
the median blood glucose value of 8.1 mmol/L still agrees with the medians
of 8.5 mmol/L and 8.7 mmol/L for Glucontrol B self-validation with actual
and per-protocol measurement frequency, respectively.
Figure 4.10 shows the same results for the cumulative distribution func-
tion of the median patient blood glucose levels across all patients in Group A
and Group B. This per-patient comparison has the same whole cohort trend
in Figure 4.9. Interestingly, and as with the cohort results, the largest gap
is between self-validation and clinical data for Glucontrol B. The wider error
below 8 mmol/L is due to the fact that the Glucontrol B protocol requires
zero exogenous insulin below its target, creating greater reliance on model as-
sumptions and thus creating opportunity for inter-patient variability in these
assumptions to play a rule.
4.3.3 Cross-Validation
Cross-validation uses the matched A and B cohorts to determine the ability
of the modelling method to reproduce the clinical data on a matched, but
independent cohort. For example, protocol A is simulated on virtual patients
derived from Group B clinical data. The results of this test are then compared
to the clinical data of Glucontrol A. Similarly, protocol B is test on virtual
patients of Group A and the results are compared to Group B clinical data. If
patients were perfectly, exactly matched the in silico and clinical data would
also match. Differences using large matched cohorts can thus be ascribed
4.3. VIRTUAL TRIALS VALIDATION 93
Figure 4.10: Cumulative distribution function of measured blood glucose on
a per-patient basis for clinical data and self-validation.
to how well the assumption holds that these virtual patient SI(t) profiles are
independent of the clinical inputs used to derive them, which is critical to
saying SI(t) represents patient condition and not other factors.
Figure 4.11 compares the cumulative distribution function of clinical
blood glucose for Group A and B to the simulated blood glucose distribution
for virtual trials of the Glucontrol A protocol on virtual patients of Group B
and virtual trials of the Glucontrol B protocol on virtual patients of Group A.
The Glucontrol A clinical median blood glucose value of 6.2 mmol/L agrees
well with 6.5 mmol/L for simulated trials of Glucontrol A on Group B virtual
patients. In addition, the median blood glucose values for Glucontrol B clinical
data and simulated trials of Glucontrol B on Group A virtual patients were
8.1 mmol/L and 8.5 mmol/L, which is less than 5% and quite low compared
to sensor errors.
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In comparison to the self-validation results for Protocol A and B, the
cross-validation results lies between the clinical data and self-validation result
indicating it is within the model and/or compliance error. Figure 4.12 shows
the same results for the cumulative distribution function of the median patient
blood glucose levels across all patients in Group A and Group B.
Figure 4.11: Cumulative distribution function of measured blood glucose on
a cohort basis for clinical data and cross-validation.
4.3.4 Virtual Trials Results
Details of self-validation and cross-validation results are discussed in this sec-
tion. Table 4.2 and Table 4.3 show the comparison of clinical trials to the
self-validation and cross-validation on Glucontrol A and Glucontrol B, respec-
tively. Results compare per-patient insulin rate, nutrition rate, blood glucose
and blood glucose measurement rate.
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Figure 4.12: Cumulative distribution function of measured blood glucose on
a per-patient basis for clinical data and cross-validation.
In Table 4.2, per-patient results show a reasonably close agreement be-
tween self-validation per-protocol to the clinical data. However, the insulin
rates are higher given the almost 2x higher measurement rate when using the
protocol specified rules. Using the actual measurement rate, the insulin rates
are similar, indicating the impact on insulin of measurement compliance.
For the cross-validation, the Glucontrol A protocol required almost 3x
higher rates of insulin for Group B, compared to the clinical data. However,
this result may be a function of the interaction of protocol and measurement
frequency where there was a 1.4x difference that results from per-protocol ver-
sus actual measurement self-validation, which is significant non-compliance.
Equally, the Glucontrol B patients received 2.6x greater carbohydrate input to
offset much of this difference in insulin administration showing also a protocol
response. Specifically, the cross-validation in Table 4.2 required 3.2x more
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insulin to offset 2.6x more carbohydrate administration. Adjusting by 2.5/1.8
the per-protocol versus actual measurement increase in insulin administered
yields an estimated 1.4x increase in insulin use to offset this increased carbohy-
drate administration. Hence, the increased insulin in cross-validation in Table
4.2 is assessed as primarily due to the increased carbohydrate administered to
Group B.
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Comparison of clinical trials with self-validation and cross-validation on
Glucontrol B is summarized in Table 4.3. Self-validation results show close
agreement to the clinical result and for cross-validation lower Group A insulin
requirements are reflected by the lower nutrition given that group and the
higher target blood glucose under the Glucontrol B protocol, which is similar
to the difference in insulin in the cross-validation in Table 4.2, but in the
reverse direction. Similarly, virtual trials of Glucontrol B per-protocol have
higher measurement frequency compared to the actual measurement indicat-
ing significant non-compliance. Thus, the actual measurement case indicates
closer agreement with the insulin given and glycemic outcomes, as with the
Glucontrol A results.
Differences in measurement rate and insulin dose can be ascribed to
non-compliance and due to the design of Glucontrol, where the rate of change
of insulin dose is tied to blood glucose measurement frequency. In particu-
lar, the clinical and actual measurements were taken 52.0% of the potential
per-protocol specified times based on in silico glycemic results for Glucontrol
A and 63.5% for Glucontrol B in Table 4.3. Note that Glucontrol B had
a higher compliance rate (% of per-protocol measurement) likely due to its
higher glycemic target, which allowed 4 hour measurements to start sooner
than for Glucontrol A. Thus, it could be construed that Glucontrol A clinical
staff were less compliant to a potentially burdensome protocol in this regard.
Figure 4.13 shows the combination of all the cumulative distribution
function of measured blood glucose in a cohort basis. The distribution com-
pares the clinical data of Group A and B, self-validation using actual mea-
surement and per-protocol and cross-validation. The per-patient results of
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cumulative distribution function of measured blood glucose is illustrated in
Figure 4.14.
The distribution of clinically measured blood glucose values shows a very
clear difference between Glucontrol protocol A and B, as expected. The virtual
trials results are within 5% of the clinical results for both the self-validation
and cross-validation. Referring to Figure 4.13 the obvious separation between
two protocols indicates the inter-protocol differences are, as expected, much
larger than any inter group differences thus supporting the fundamental as-
sumption behind this virtual trials approach. The close correlation of self- and
cross-validation results to clinical data validates the idea that these in silico
virtual trial simulations can accurately predict the expected clinical results of
a tight glycemic control protocol prior to clinical implementation.
Figure 4.13 illustrates some variation between clinical data and virtual
trials. Glucontrol A results are closer to the clinical data compared to Glu-
control B. The major difference is that Protocol B uses much less insulin given
its higher glycemic target. Therefore, the impact of intrinsic and potentially
variable patient-specific dynamics, such as endogenous insulin production IB
and kI and endogenous glucose production EGPmax, are more pronounced
with respect to the far lesser exogenous insulin given to Group B, especially
at blood glucose levels below 8.0 mmol/L. As these metrics are unidentifiable
and thus, by necessity, assumed population constants, some of the Group B
simulation errors may reflect errors in these population values.
Comparing Glucontrol B results, the clinical results for Glucontrol B
have most mismatched line compared to the simulation results. The fact that
the clinical data are lower than the simulations in this region could indicate
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non-compliance in timing or dosing of insulin, or simple overriding of the pro-
tocol recommendations by clinical staff. Computer simulations will always
follow protocols exactly as instructed. Hence, the self-validation error cap-
tures both model and compliance errors, which are clearly evident in Table
4.3 where insulin doses and protocol-specified measurement frequency are very
different from the actual measurement case. Reducing measurements in the
B protocol would not reduce insulin as fast as the per-protocol case, resulting
in lower clinical blood glucose levels. The actual measurement self-validation
simulation for Glucontrol B is much closer to the clinical data, having ac-
counted for this effect.
Overall, the gap between the self-validation using actual measurement
timing and clinical data indicates the possibility of compliance error. In con-
trast, the difference between self-validation simulations using exact protocol-
specified timing and the clinical data shows one possible indication of model
error. However, it may also suggest that the conventional, lower intensity
Group B protocol may not have been followed as strictly with respect to dos-
ing.
For the cross-validation, Protocol A on Group B is a very good match
with errors similar to the self-validation results for Group A. In addition, Pro-
tocol B on Group A virtual patients is within a similar range as the Group B
self-validation and close to the slope and trends of the clinical data. Thus, the
insulin sensitivity independence assumption behind this virtual trials approach
holds, independently validating the concept and the virtual trial method based
on this model.
Differences between self- and cross-validation results are ascribed to re-
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maining differences between patient groups, despite clinical matching. The
main notable difference pointed out in the results and Tables 4.2 - 4.3 is the
difference in nutrition given in each cohort. The virtual trials approach treats
each group as being treated differently, including the carbohydrate and glu-
cose infusions administered. These infusions were patient specific and specified
based on local and individual clinician standards, rather than per a protocol
of any type. Thus, they were kept for each patient. As a result, Glucontrol B
patients with the higher target had 2.6x higher glucose administration, which
in cross-validation was offset by 3.2x more insulin in the virtual trials. Differ-
ences in insulin rates between per-protocol and per actual measurement rates
makes these differences almost equal at 2.6x higher glucose administration
and 2.4x greater insulin required to achieve the almost identical glycemic out-
come. Hence, the patients display similar overall insulin sensitivity, and the
virtual trials took independently treated, matched patients and achieved the
same outcome despite different initial treatments in the clinical data used to
create the virtual patient. More specifically, nutritional treatment differences,
within reason, did not affect or influence the results outside of expectations.
4.4 Summary
The clinical data in this study was independent from the Christchurch Hos-
pital ICU data used in prior development and clinical validation of the model
employed. More importantly, there are two cohorts matched by severity of ill-
ness, weight and sex, as well as metabolic variability which is a key parameter
in this case, which had significantly different glycemic targets and glycemic
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control therapies.
The small model fit errors and low prediction validation results can be
seen as an estimate of the variability of insulin sensitivity in this cohort, as
well as a sign of model fitness. Moreover, self-validation indicated a clinically
insignificant error in these virtual patient methods due to the model and/or
clinical compliance. They also showed the impact of some none-compliance
independent of model error. In contrast, cross-validation clearly showed that
the virtual patient methods and models enabled by patient-specific SI(t) pro-
files are effective and the assumption that the SI(t) profiles are independent
of the clinical inputs used to generate them holds.
Therefore, virtual patients and in silico virtual trial methods are vali-
dated in their ability to accurately simulate, in advance, the clinical results of
an independent tight glycemic control protocol, directly enabling rapid design
and optimisation of safe and effective tight glycemic control protocols with
high confidence of clinical success. In conclusion, model-based data driven in
silico methods has the potential and capable to aid protocol design, as well as
providing accurate, safe and effective real time tight glycemic control.
Importantly, as a result, model-based metric, SI , is effectively validated
as an independent metric indicating patient-specific response to condition.
Therefore, it can be used as a marker to represent metabolic condition as a
response to patient-specific counter-regulatory and immune system (inflam-
matory) responses that are major parts of the etiology of sepsis in ICU cohorts.

Chapter 5
Sepsis and Sepsis Diagnosis
Treating sepsis as early as possible may reduce mortality in intensive care
[Rivers et al., 2001; Bone et al., 1989]. Currently, it is almost impossible to
diagnose a patient at the onset of sepsis due to the lack of real-time metrics
with high sensitivity and specificity. Patient condition is mostly determined
by clinician experience and observation of patient reaction to treatment. In
addition, the ability to compare protocols or evaluate different therapeutic
interventions is difficult since there are few guidelines in investigating and
diagnosing sepsis.
This chapter discusses and analyzes current methods used to determine
sepsis condition. Typically, a sepsis score is calculated according to several
criteria to determine the level of sepsis to differentiate between severe sepsis,
septic shock and refractory septic shock. The different scores are created with
the aim of helping clinicians with treatment decisions, and to better classify
patients and determine prognosis.
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5.1 Sepsis Definition
Severe sepsis and septic shock are common and highly associated with sub-
stantial mortality. Sepsis is an increasingly common cause of morbidity and
mortality, particularly in elderly, immunocompromised, and critically ill pa-
tients [Balk and Bone, 1989; Ayres, 1985; Wheeler and Bernard, 1999]. The
incidence of sepsis or septic shock and the related mortality rates are sub-
stantially higher in elderly persons than those in younger persons. By the
year 2020, the projected growth of the elderly population in the United States
will contribute to an increase of 1.5 percent of incidence per year, yielding an
estimated of 1,110,000 cases [Angus et al., 2001]. In addition, sepsis has been
reported to be the most common cause of death in the noncoronary intensive
care unit [Parrillo et al., 1990].
Sepsis is a clinical syndrome defined by the presence of both infection
and a systemic inflammatory response (SIRS). In 2001, infection was defined
as a pathologic process caused by the invasion of normally sterile tissue or
fluid or body cavity by pathogenic or potentially pathogenic microorganisms
[Levy et al., 2003]. This definition was created by the 2001 International
Sepsis Definitions Conference. However, frequently, infection is strongly sus-
pected without being able to be microbiologically confirmed for several reasons
creating so-called "culture negative" sepsis [Carrigan et al., 2004].
Systemic Inflammatory Response Syndrome (SIRS) is an inflammatory
state affecting a person’s body. It is frequently associated to a response of the
immune system to infection, but that is not necessarily always the case. SIRS
is also related to organ dysfunction and organ failure [Bone et al., 1992; Levy
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et al., 2003], which also occur frequently with and without sepsis. According to
the American College of Chest Physicians/Society of Critical Care Medicine,
SIRS is considered to be present when patients have more than one of the
following clinical conditions [Bone et al., 1992]:
• Body temperature less than 36  C or greater than 38  C,
• Heart rate greater than 90 beats per minute,
• Hyperventilation evidenced by a respiratory rate of greater than 20
breaths per minute or an arterial partial pressure of carbon dioxide less
than 32 mmHg,
• White blood cell count greater than 12 x 109 cells/L or less than 4 x 109
cells/L or the presence of greater than 10% immature granulocytes.
The SIRS criteria are summarized in Table 5.1. However, the presence
of SIRS may, or may not, represent the presence of sepsis. The SIRS concept
is valid to the extent that a systemic inflammatory response can be triggered
by a variety of infectious and noninfectious conditions, because, signs of sys-
temic inflammation occur in the absence of infection among patients with
burns, pancreatitis and other disease states. Hence, alone, SIRS has limited
diagnostic potential for sepsis.
Figure 5.1 shows the interrelationship between SIRS, sepsis and infec-
tion. The figure implies that a similar or even identical SIRS response can
arise in the absence of infection. For example, a frequent complication of SIRS
is the development of organ system dysfunction, including acute lung injury,
shock, renal failure and multiple organ dysfunction syndrome. These effects
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Table 5.1: SIRS criteria.
Score Criteria
+1 Temperature  36  C,   38  C
+1 Heart rate   90/min
+1 Respiratory rate or PaCO2   20/min,  32 mmHg
+1 White blood cell count  4 x 10
9/L or   12 x 109/L
or presence of > 10% immature granulocytes
too occur with or without infection. Hence, the diagnosis of sepsis and SIRS
are inter-related, but not exclusive.
Figure 5.1: The interrelationship between systemic inflammatory response
syndrome (SIRS), sepsis and infection.
The occurrence of sepsis can be classified into several stages. Sepsis is
a condition where the systemic response to infection is manifested by two or
more SIRS criteria as a result of infection. Severe sepsis is a sepsis condition
that is also associated with organ dysfunction, hypoperfusion or hypotension.
Septic shock is defined as severe sepsis with arterial hypotension, despite ad-
equate fluid resuscitation.
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Despite the definition for sepsis, severe sepsis and septic shock, these
terms do not precisely characterize patient’s stage and condition and may be
confounded by a number of issue. More specifically, sepsis, in all levels, is
a syndrome or collection of conditions. Grouped together as "sepsis" they
categorize patients with a significantly increased risk of death. Hence, un-
fortunately perhaps, sepsis is a much of a patient category as it is a specific
physiological condition. This issue makes sepsis diagnosis quite difficult.
5.1.1 Scoring System
The most accepted sepsis score is calculated following criteria classified
by American College of Chest Physicians (ACCP)/Society of Critical Care
Medicine (SCCM) definitions of 1992 and 2001 [Levy et al., 2003]. The crite-
ria calculate a sepsis score including Systemic Inflammatory Response Score
(SIRS) and Sepsis-related Organ Failure (SOFA) score [Bone et al., 1992]. De-
tails of the criteria are shown in Tables 5.1 - 5.3. Table 5.2 shows the criteria
in determining the organ failure score as a component in calculating the sepsis
score.
The rationale for using a scoring system is to ensure that the increased
complexity of disease in patients currently being treated is consistently rep-
resented in evaluations and descriptions. Therefore, clinicians can more ac-
curately monitor patient condition and therapy can be more precisely deter-
mined. However, it is apparent that if one waits for the emergence of SIRS
or organ failure then clinicians are thus treating more severely ill patients at
a later stage of illness.
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Referring to Table 5.3, the level of sepsis score is a hierarchical process,
where a tick indicates a necessary criterion that must be present to achieve
the sepsis score labeled. For example, if a patient had SIRS > 2, an infection
during stay without an organ failure, and received fluid and inotropes, the
patient is classified as having sepsis, where the sepsis score is 1 instead of
septic shock, where the sepsis score is equal to 3. This apparently contrasting
outcome occurs because the patient does not meet the criteria for organ failure.
Each criteria in defining a sepsis level must be met before classifying the
patient’s condition.
5.2 Retrospective Cohort Analysis
A collection of clinical data was obtained from the Intensive Care Unit (ICU)
of Christchurch Hospital, Christchurch, New Zealand. There were a total of
30 patients that had sepsis during their hospital stay and were selected in this
study. They were identified by having positive blood culture results and by
the judgement of experienced senior intensive care clinicians. This study was
approved by the Upper South Regional Ethics Committee, New Zealand.
Initially, there were 104 patients admitted to the ICU. SIRS is recorded
every hour for all of the patients. Patients with SIRS > 2 or suspected to have
sepsis were selected to participate in this study. The background information
of the retrospective cohorts is shown in Table 5.4.
Table 5.5 summarize the demographics, where 60% of the cohort is male
with a median age of 63 years. The severity of illness was defined by calculating
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Table 5.4: Retrospective patient cohort background information.
Patient Medical APACHE II Age Sex Mortality
ID Subgroup Score
BSL002 Septic shock 19 49 F
BSL010 Septic shock 17 55 F
BSL012 Pneumonia 18 60 F
BSL013 Otitis 18 43 F
BSL017 Pneumonia 15 64 M Y
BSL022 CAP 17 61 F
BSL027 CAP 22 74 M
BSL030 Multiple trauma 19 63 F
BSL031 CAP 23 52 F
BSL032 Pneumonia 20 64 M Y
BSL033 CAP 23 75 M
BSL035 Pneumonia 21 75 M
BSL038 Pneumonia 27 70 F
BSL039 GBS 8 43 M
BSL044 CAP 24 80 M
BSL047 Pneumonia 25 71 M
BSL051 Pneumonia 10 30 F
BSL052 ARDS 11 63 M
BSL055 Respiratory failure 17 76 M Y
BSL056 Type 1 DM 29 46 M Y
BSL063 Type 2 DM 19 78 F
BSL069 COPD 17 54 M
BSL078 CAP 24 88 M Y
BSL079 Sepsis 19 64 F
BSL080 Gastrectomy 12 49 M
BSL083 Pneumonia 18 56 M
BSL095 Sepsis 16 67 F
BSL100 COPD 13 55 M
BSL101 Pneumonia 15 78 M
BSL104 Sepsis 29 59 M
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the sepsis score for each patient according to clinical data available. Sepsis
score is then calculated for every hour using the method mentioned in Section
5.1.
Table 5.5: Summary data for Sepsis cohort taken in ICU, Christchurch Hos-
pital.
Baseline characteristics of the patients
Variable
Number of patients 30
Percentage of male 60 %
Age 63 [54 - 74]
Apache II score 19 [16 - 23]
Total hours in ICU 7624
Length of stay (days) 10.5 [6 - 15]
Entry criteria
Temperature ( C) 36.6 [36.0 - 37.6]
Heart rate (beats/min) 97 [87 - 110]
Mean arterial pressure (mm Hg) 73 [67 - 83]
White cell count (per Liter) 11.6 [7.9 - 20.4]
Partial pressure of carbon dioxide (mm Hg) 47.5 [39.0 - 58.0]
Partial pressure of oxygen (mm Hg) 90 [72 - 113]
Baseline laboratory values
Creatinine (µmol/L) 110 [82 - 221]
Bilirubine (mmol/L) 11 [5 - 17]
Figure 5.2 shows the distribution of sepsis scores for the 30 identified
sepsis patients during their entire stay in the ICU. The histogram shows the
distribution of sepsis score for day 1, day 2, day 3 and the final days of their
stay. There were 13 patients with a sepsis score of 1 when they were admitted
to the ICU. Two patients had 0 sepsis score, 8 patients had sepsis score of 2,
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4 patients had sepsis score of 3, and 3 patients had the maximum score of 4.
Note that the sepsis score is not calculated when patients were admitted.
Therefore, a patient may or may not have sepsis on the first day they were
admitted into the ICU. In addition, length of stay varies between patients.
The figure shows an improving pattern of sepsis score from day 1 to the final
day of patient stay in the ICU, as expected in many cases, with more patients
having a lower sepsis score compared to their early stay.
Figure 5.2: Sepsis score distribution for 30 patients during their stay in ICU.
Figures 5.3 - 5.6 show the hourly distribution of sepsis score for the whole
length of stay for four patients randomly selected from the sepsis cohort. These
plots suggest that sepsis scores vary and may change rapidly over an hourly
interval. For example in Figure 5.3, Patient 002 had a sepsis score of 3 at
minute 1680, then it decreased to 0 at 1740 minutes and changed back to 3
at 1800 minutes.
Similarly, in Figure 5.4 Patient 012 had a rapid change from 3 to a score
of 1 and vice versa over a short time interval. Although the plot in Figure
5.5 shows a more stable and less variable sepsis score, there are times when
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the score of Patient 063 changes effectively instantly, with a difference of two
levels of sepsis score, as seen at minutes 1620 to 2160. In Figure 5.6, it is
observed that the sepsis scores highly variable between a score of 0 and 1 for
most of the stay of Patient 079.
Overall, from the whole length of stay for this sepsis cohort, the sepsis
scores are fluctuating even over one hour intervals. Generally, the condition
of a patient may change, either getting better or worse after several hours of
treatment. Similarly, sepsis scores are expected to change by either increasing
or decreasing over time. However, the change should be much more stable than
seen here, with a much more infrequent rate of change over short intervals.
Figure 5.3: Hourly plot of sepsis score for Patient 002.
By definition, sepsis exists by the presence of SIRS and infection. How-
ever, the frequent change and irregular sepsis score pattern shown in Figures
5.3 - 5.6 suggest that these patients may have had an on and off condition. It
is almost impossible to report that a patient had an infection at this hour and
was free from infection at the next hour, especially if the condition oscillates
frequently.
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Figure 5.4: Hourly plot of sepsis score for Patient 012.
Figure 5.5: Hourly plot of sepsis score for Patient 063.
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Figure 5.6: Hourly plot of sepsis score for Patient 079.
In contrast, SIRS does have a higher likelihood of changing rapidly since
it has several components that may change abruptly. Equally, SIRS symptoms
are treated, such as high temperature. Thus, the treatment modifies the SIRS
score, causing an apparent change of state.
From a clinical point of view, the patient condition should be aligned
with the level of a sepsis they have. If a doctor were treating a patient ac-
cording to their sepsis score level, the doctor might want to treat based on a
stable protocol and assessment. However, rapid changes in score would create
a challenge to determining suitable treatments necessary for a patient.
A more stable sepsis representative score are thus required, which is
more suitable for hourly, instead of daily evaluation. In particular, the original
ACCP/SCCM score was designed for daily use, using a worst or average daily
score for each component. Thus, one aspect of the variability seen is simply
this metrics unsuitability for hourly assessment without modification.
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5.3 Scoring System Analysis
To obtain a useful score that can be used by a clinician to guide diagnosis
and treatment, the current score is considered for improvement. The follow-
ing section discusses the effectiveness aspects of the current sepsis score, and
evaluates if any specific component is the cause for the fluctuation and vari-
ability in sepsis score. It then creates a near more realistic score suitable for
hourly use.
Figure 5.7 shows the classification for calculating SS1, a scoring system
that uses the same individual components in determining a current sepsis
score. SS1 is determined by calculating the summation of individual compo-
nent scores used to calculate the current sepsis score. In contrast, the original
sepsis score is determined by following the hierarchy component, as shown in
Table 5.3.
Figure 5.7: Individual components for determining SS1 score.
In Figure 5.7, components A, B, C and D have a value of 1 if they are
true. For example, at time t, if a patient had SIRS   and had an infection,
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the score for A will become 1. If the patient had SIRS   2 but was free from
infection, the score for A is 0. Moreover, if the patient had an organ failure,
defined by SOFA   1 for at least one SOFA score component, at time t, B will
become 1, otherwise it is 0. The same method is applied to the criteria in C
and D. C and D represent fluid resuscitation and inotrope usage, respectively.
Finally, the SS1 value is then calculated by summing the values of A,B,C
and D, as shown in Equation 5.1. The range of SS1 is 0 - 4; and there is no
hierarchy involved.
SS1 = A+B + C +D (5.1)
Figure 5.8 illustrates the population of SS1 for 30 patients during their
whole stay in ICU. Overall, there were a total of 7624 hours of treatment where
patients had SS1 = 2 for the most hours (43%). There were 25.9%, 9.8% and
2.6% of hours where patients had a SS1 score of 1, 3 and 4, respectively. The
remaining 18.7% of the total hours are where patients had SS1 = 0.
Figure 5.8: Distribution of SS1 for 30 patients in sepsis cohort during their
stay in ICU.
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Figures 5.9 - 5.12 show an hourly distribution of sepsis score and SS1
for the entire stay of the same four patients selected from the sepsis cohort.
The right panel of y-axes represents SS1 and left panel of y-axes represents
the original sepsis score. From all the plots, it can be concluded that SS1 add
more noise to the sepsis score given that the occurrence of fluctuation is more.
Figure 5.9: Hourly plot of sepsis score and SS1 for Patient 002.
Figure 5.10: Hourly plot of sepsis score and SS1 for Patient 012.
Referring to Figure 5.9, most of the time during the stay Patient 002
had a higher score for SS1 compared to the original sepsis score. Similarly,
with Patient 012, a higher score of SS1 has been observed in Figure 5.10 with
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a fluctuating score in the second half of the stay. However, Patient 063 had
a similar pattern of SS1 compared to the original sepsis score with a shifted
score seen for SS1. As seen in Figure 5.12, the SS1 of Patient 079 is also more
variable, unlike the plot of the original sepsis score.
Figure 5.11: Hourly plot of sepsis score and SS1 for Patient 063.
Figure 5.12: Hourly plot of sepsis score and SS1 for Patient 079.
The change in SS1 is happen regularly for most of the patients in the
sepsis cohort. In comparison to sepsis score, SS1 adds more noise and changed
inconsistently over time. Since SS1 is calculated based on each component in
determining sepsis score, it can be observed that the plot of SS1 indicates
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the factor contributing to the sepsis score itself. It can be either SIRS, organ
failure, fluid resuscitation, inotrope dosing or combination any of these factors.
Figure 5.13 represents the cumulative data points of A, B, C and D when
SS1 = 1. There were 1976 measurement of SS1 = 1 during the stay for all 30
patients in the cohort. A has the highest frequency followed by B, D and C.
Referring to Figure 5.13, A dominates the total measurement of SS1 at score
1 with a 56% (1086) of total measurements. B is recorded as the second major
factor with a total of 690 measurements, followed by D and C with 104 and
96 measurements respectively.
Figure 5.13: Comparison of A, B, C and D score for SS1 value of 1.
The high frequency for A proved that SIRS is the leading factor in
developing the SS1 score. In addition, looking at the individual patient plots,
it can be observed that the score was on and off between 0 and 1 for most of
the time. Therefore, SIRS is the factor contributing to the fluctuation seen in
the SS1 scoring system.
Therefore, another sepsis score is introduced, called SS2. In SS2, the
SIRS factor is eliminated to obtain a more comprehensive and stable scoring
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for diagnosing sepsis. The equation used is shown in Equation 5.2. Since SS2
eliminates the A value of Figure 5.7, maximum and minimum scores are 3 and
0, respectively.
SS2 = B + C +D (5.2)
Figures 5.14 - 5.17 compare the hourly distribution of SS2 and the origi-
nal sepsis score for the same four different patients in sepsis cohort. Significant
improvement can be seen in Figure 5.14, particularly at minutes 500 to 1000.
Less fluctuation and no drastic change has been observed compared to the
original sepsis score, which is indicated by the dashed line. Figure 5.15 clearly
shows that SS2 improves the scoring system with less oscillation in the first
half of stay and a stable score in the second half.
Figure 5.14: Hourly plot of sepsis score and SS2 for Patient 002.
Similarly, Patient 063 also has a better, more physiological and clinically
relevant pattern indicated by less frequency of on and off changes in SS2.
In Figure 5.16, the original sepsis score changed dramatically from 3 to 1
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Figure 5.15: Hourly plot of sepsis score and SS2 for Patient 012.
Figure 5.16: Hourly plot of sepsis score and SS2 for Patient 063.
at minutes 1020 to 1440. However, SS2 demonstrates a more reliable score
with a single step change at a time. Finally, Figure 5.17 illustrates that SS2
exhibits an improving pattern of sepsis score even though it changes relatively
frequently.
Overall, SS2 plots are more stable and had less non-physiological vari-
ability in comparison to the original sepsis score and SS1. By eliminating the
SIRS component, the resulting sepsis score is more stable and less fluctuation
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Figure 5.17: Hourly plot of sepsis score and SS2 for Patient 079.
occurs during the stay. Although some patients had frequent changes in SS2,
it may suggest that the pattern is caused by the condition of the patient itself.
From the overall plot, it may suggest that SS2 can be used as a marker for
a clinician to determine a suitable treatment given that SS2 varies somewhat
in the level of sepsis, and thus enhance stability for an hourly metric to help
guide diagnosis and treatment.
5.4 Challenges in Diagnosing Sepsis
Currently, diagnosing sepsis in critical care has many challenges. It is almost
impossible for a clinician to determine the best treatment due to the long (1-3
day) process of getting blood culture results. Therefore, the inability to guar-
antee accurate, early diagnosis affects treatment selection, patient condition
and mortality outcome.
According to Rivers and colleagues [Rivers et al., 2001], early goal-
directed treatment of sepsis reduced mortality from 46.5% to 30.5%. More-
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over, severe sepsis and septic shock have high incidence and high mortality
rates in the intensive care unit. Clinical studies by Rivers et al. [Rivers et al.,
2001] observed lower mortality rates in patients with septic shock assigned to
early goal-directed therapy (42.3%) than in those assigned to standard ther-
apy (56.8%). Even survive, sepsis usually reduces quality life for those who
suffer this disease [Chen et al., 2008; Perl et al., 1995; Heyland et al., 2000;
Buysse et al., 2007] and especially if not specifically treated, driven primarily
by the body’s inflammatory response.
Separately, and in addition, the syndrome and condition of sepsis itself
covers a wide range of illness including organ failure, inflammatory response
and infection, which result in a complex diagnostic situation. More often
systemic inflammatory respond syndrome (SIRS) manifest in critically ill pa-
tients and thus reduce the ability to distinguish between SIRS and sepsis. On
the other hand, infection is frequently suspected without being microbiolog-
ically confirmed [Levy et al., 2003] and hence affecting treatment selection
which usually take place beforehand. Thus, sepsis is a condition that requires
timely intervention, but is difficult to diagnose [Vincent et al., 1996; Wheeler
and Bernard, 1999; Wiersinga, 2011].
Additionally, antibiotic therapy has been widely accepted in the course
of an infection due to its effectiveness in reducing morbidity and mortality [Ku-
mar et al., 2006; Micek et al., 2011]. There have been several study [Roberts
et al., 2011; Taccone et al., 2011a; Gonzalez de Molina and Ferrer, 2011; Tex-
toris et al., 2011] that describe and potentially recommend for an effective
dosing of antibiotics therapy. This is due to the high demand in prescribing
an appropriate antibiotic regimen. However, starting an antibiotic therapy to
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a patient may escalate the rates of antibiotic resistance [Taccone et al., 2011b;
Bassetti et al., 2011; Micek et al., 2011; Hemels et al., 2011] especially be-
fore confirming the infection. Pharmacokinetics of antibiotics are commonly
altered in sepsis patients which consequently may result in insufficient drug
concentrations, even when the concentrations used was recommended [Dick-
inson and Kollef, 2011; Taccone et al., 2011b].
What is needed is the means to evaluate sepsis based on clinical variables
that are easily and routinely measured in the ICU. These variables should be
independent of the therapy used since therapeutic management may vary from
one institution to another. Development of sepsis bio-markers is therefore
important to provide an indicator for sepsis intervention and thus improve
patient outcome by enabling effective treatment as early as possible.
5.5 Summary
Sepsis is an increasingly common condition and a leading cause of ICU mor-
tality. It represents a major healthcare problem as affected patients have a
high morbidity and mortality leading to high direct and indirect costs [Angus
et al., 2001]. The mortality rates of 40% to 60% have not changed significantly
in the past 20 years, despite intense research advances in treatment.
Current sepsis scores show a irregular patterns with high oscillation when
applied or evaluated hourly. In reality, the existence of sepsis in a patient
cannot just disappear within an hourly interval and appear again the next
hour. Similarly, patient condition takes some time to improve after being
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treated. Hence, the existing sepsis scores are seen to be ineffective when
evaluated hourly rather than from a daily average or worst case score.
Individual components of the original sepsis score are evaluated to iden-
tify the cause of the observed fluctuations. As a result, a different scoring
system has been introduced. The revised scoring system simplifies the way
the sepsis score is calculated and eliminates the hierarchical concept.
The new scoring system, denoted SS2, shows an improving more physio-
logical and clinically relevant pattern. SS2 eliminates the effect of SIRS score,
which has been found to be the main factor of the fluctuations observed in the
original sepsis score. Overall, SS2 is more stable and changes reasonably in a
clinical and physiological sense with less occurrence of on and off within an
unrealistic short time interval. This stable scoring system will be evaluated
as a tool to more accurately aid in the diagnosis of sepsis in real-time.
Chapter 6
Insulin sensitivity and sepsis
The use of metabolic markers in addition to other clinical variables is emerg-
ing area of study [Lin et al., 2011a; Chase et al., 2008a; Blakemore et al.,
2008]. The main goal is increasing the positive predictive diagnosis of sepsis.
However, like many decisions made in the ICU sepsis diagnosis and treatment
are largely based on clinical experience and broad standard guidelines. De-
velopment of a physiological bio-metric to help diagnose sepsis, particularly
as early as possible, could reduce the high mortality rate of this disease and
likely reduce the cost of treatment.
This chapter discusses the use of model-based insulin sensitivity, SI ,
as a patient-specific parameter to aid sepsis diagnosis. It has the advantage
of being readily available every hour at the bedside. Equally, it reflects the
counter-regulatory and inflammatory status of the patient, which are signif-
icantly augmented in sepsis [Cavaillon and Adib-Conquy, 2007; Marik and
Raghavan, 2004; Andersen et al., 2004]. Hence, it could prove to be an ideal
bio-marker for early, real-time diagnosis.
Several studies [Lin et al., 2011a; Blakemore et al., 2008] have shown
that SI accurately represents the patient’s metabolic condition. SI is very low,
relative to healthy individuals, in patients in critical condition, and decreases
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further as condition worsens [Chase et al., 2008a]. As noted, SI is available
hourly via computer analysis. Therefore, it is possible to be used for real-time
diagnosis where current sepsis scores [Levy et al., 2003; Bone et al., 1992]
are based on daily or 12-hourly assessments. Hence, it is likely to be able to
produce a much earlier diagnosis, if successful. Finally, it has the advantage
that it is noninvasive and no additional testing is required to obtain this value
in real-time.
6.1 Insulin sensitivity
Insulin sensitivity is defined as the dependance of fractional glucose disap-
pearance on plasma insulin. SI represents the effective insulin sensitivity of
a specific patient and it is uniquely independent of insulin transport and sat-
uration. As discussed in Chapter 5, SI is an independent parameter that
represents metabolic condition of a patient, independent of the treatment
given [Chase et al., 2010b].
SI can be determined using parameter compartment models that have
been extensively validated clinically [Chase et al., 2010b, 2007; Lonergan et al.,
2006; Le Compte et al., 2009]. This model has been used to develop blood
glucose protocols for critically ill patients [Chase et al., 2007; Lonergan et al.,
2006]. Hence, the SI value is readily available for most if not all sepsis patients,
as these patients have exacerbated hyperglycemia due to sepsis.
For this analysis, insulin sensitivity profiles SI(t) of a patient are gener-
ated using the ICING model discussed in Chapter 2. The model is fitted to
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retrospective clinical data for blood glucose measurements, and insulin and
carbohydrate administration input data from the protocol used in ICU. With
this model, patient specific profiles can be generated for time varying SI and
its hour to hour variation as patient condition evolves.
This model-based SI has been observed to indicate the severity of ill-
ness and is therefore capable of capturing a patient’s metabolic status. In
particular, Blakemore et al [Blakemore et al., 2008] have shown that insulin
sensitivity of a patient decreased as the patient condition worsen. In addition,
it has been previously documented that SI decreases with worsening condi-
tion and increases with improvement in patient condition [Chase et al., 2008b;
Langouche et al., 2007].
Finally, sepsis induces a counter-regulatory hormone response causing
the reduction in SI [Agwunobi et al., 2000; Virkamaki and Yki-Jarvinen, 1994].
The use of glucocorticoids may exacerbate this situation [Dimitriadis et al.,
1997; Qi and Rodrigues, 2007; Pretty et al., 2011], and are commonly used
in the treatment of severe sepsis [Dellinger et al., 2004]. Sepsis induces a
strong pro-inflammatory acute immune response that worsens hyperglycemia
and reduces insulin sensitivity further [Weekers et al., 2003; Fernandez et al.,
2011]. Hence, the fact that insulin sensitivity and patient metabolic condition
are strongly linked, suggest that SI is capable of becoming a marker for real-
time diagnosis of sepsis.
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6.2 Insulin sensitivity of retrospective cohort
Clinical data of retrospective sepsis cohort was collected during their stay
in ICU. The data is then used with the model to identify insulin sensitivity
profiles, SI(t), for all 30 patients. These profiles provide an hour-to-hour tra-
jectory for each patient, before, during and after sepsis. Figure 6.1 illustrates
the cumulative distribution function (CDF) of 30 patients in the cohort, where
the shaded area indicates the 90% confidence interval range and dotted line
represents the median distribution. The interquartile range (IQR) is the area
between two continuous lines, which are closer to the median line.
Figure 6.1: Cumulative distribution function of insulin sensitivity for 30 pa-
tients in the sepsis cohort.
CDFs of SI on a per-patient basis are shown in Figure 6.2. Most of the
patients in the cohort had similar SI distribution. However, a few patients
had a slightly higher or lower SI distribution. Clearer distribution of SI on
each patient is illustrated in Figure 6.3. In this figure, the x and y-axes
6.2. INSULIN SENSITIVITY OF RETROSPECTIVE COHORT 135
represent patient number and insulin sensitivity, respectively. The plot shows
the median, IQR and 90% range plus out less for each patient. Overall, most
of the patients have the same range of SI and only 10% of the total patients
have significantly slightly higher or different ranges of SI .
Figure 6.2: Per patient cumulative distribution function of insulin sensitivity
for 30 patients in the sepsis cohort.
Table 6.1 represents the median SI , minimum and maximum SI , median
change in insulin sensitivity ( SI) and percentage of change in insulin sensi-
tivity (%  SI) across patients and the cohort. Maximum SI values are highly
variable across patients. The highest SI value in the cohort is 0.00927337
L/mU.min, seen in Patient 079.
Median SI of the cohort is 100 times larger compared to the median SI ,
where  SI describes an hour-to-hour change. Most of the patients had similar
ranges of  SI , as seen in Table 6.1. Higher median  SI has been observed on
Patients 063, 078 and 095. However, the median % SI is observed to be in
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Table 6.1: Insulin sensitivity and its variation among 30 patients in the sepsis
cohort.
Patient Median SI Minimum SI Maximum SI Median  SI Median  SI
ID (10 4) (10 4) (10 4) (10 6) (%)
002 4.5273 0.0010 32.1552 3.7108 1.084
010 4.4329 1.5402 6.8967 -7.0100 -1.261
012 12.8269 0.6251 31.6565 4.0684 0.471
013 1.6572 0.0010 4.8695 5.3074 3.349
017 4.7024 0.3252 7.9057 -1.0718 -1.021
022 4.9273 1.9004 19.2340 2.8245 0.562
027 8.0113 1.4104 24.1765 -1.6763 -0.255
030 3.6736 0.1142 16.2012 6.6803 1.531
031 3.4392 0.0010 23.2900 4.6365 1.255
032 4.0259 0.0010 19.6549 5.6550 1.597
033 5.0168 1.2815 58.9588 7.9494 1.819
035 3.2228 0.0010 17.8042 7.2160 1.967
038 8.5881 1.9173 42.5266 0.0720 0.012
039 4.3789 1.0615 35.3386 -0.0195 -0.004
044 4.0768 0.8462 13.8395 9.3274 2.705
047 4.1755 1.6226 25.7384 1.9691 0.573
051 3.1187 0.6704 9.6912 7.5956 3.226
052 4.1005 1.5885 66.0763 0.0972 0.003
055 1.7864 0.0010 4.1691 2.8621 1.118
056 1.1706 0.0010 5.7676 6.5147 4.243
063 3.3369 0.0010 9.8669 20.9228 4.554
069 3.3996 1.0894 10.2203 8.6194 2.053
078 9.0696 0.2302 32.5296 48. 2037 5.682
079 3.9202 0.0010 92.7337 17.9259 7.999
080 4.1192 1.1815 15.9559 3.8445 0.972
083 5.0928 0.8300 25.0050 2.8515 0.883
095 3.1732 2.2407 5.5890 -20.5320 -6.079
100 4.1031 0.2632 74.2105 7.5893 0.845
101 3.6671 0.2169 23.7300 2.1505 0.460
104 2.6532 0.0010 21.9804 3.3809 1.132
Cohort 4.1931 0.0010 92.7337 4.2534 1.114
6.2. INSULIN SENSITIVITY OF RETROSPECTIVE COHORT 137
Figure 6.3: Insulin sensitivity distribution for 30 patients in the sepsis cohort.
similar range for the whole cohort given that % SI for the cohort is 1.114%.
This latter result indicates similar variability across patients when normalized
by current SI value as a percentage.
Figure 6.4 shows the 5th - 95th percentile range, IQR and median proba-
bility bounds for the hour-to-hour stochastic model of 30 patients in the sepsis
study based on the models developed by Lin et al [Lin et al., 2006, 2008]. The
distribution indicates the hour to hour patient metabolic variability in SI .
The variation distributions are plotted as SI(n+1) on the y-axis against SIn on
the x-axis.
The dynamic change in SI from hour to hour also provides information
on metabolic dynamics and insulin resistance in this cohort. Importantly,
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the variability of SI over any given hour is dependent on its current value.
Therefore, the stochastic model represents the transition of SI from one hour
to the next and changes in variability may be indicative of changes in patient
condition, creating a further potential bio-marker.
Figure 6.4: Hourly insulin sensitivity distribution for sepsis cohort.
6.3 Insulin sensitivity in diagnosing sepsis
CDFs of SI on the SS2 score basis is shown in Figure 6.5. SS2 is determined
hourly as discussed in Chapter 5. SS2 = 0 has the highest SI distribution
followed by patients with SS2 = 1, SS2 = 2 and SS2 = 3. However, the SI
distribution for SS2 = 0, 1 and 2 are almost overlaid. SI reduces as the patient
condition worsens, as hypothesized. However, the discrimination while signif-
icant (p < 0.05), is not large. The p-values computed using Mann-Whitney
test are shown in Figure 6.5. The obvious separation between these three
groups at SS2 = 3 implies that, in the very worst condition for sepsis (SS2 =
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3), the SI profiles of a patient are much lower and much more distinguishable.
However, early diagnosis would rely on discrimination at lower scores of SS2.
Figure 6.5: Cumulative distribution function of insulin sensitivity grouped by
SS2. P -values are computed using Mann-Whitney test.
Figures 6.6 - 6.9 show the hourly distribution of insulin sensitivity, SI ,
changes in insulin sensitivity ( SI), percentage of changes in insulin sensitiv-
ity (% SI) and SS2 for four patients in the cohort. These four patients are
the same patients as selected in Chapter 5. These figures are used to describe
the issues schematically.
Referring to Figure 6.6, Patient 002 has an increasing value of SS2 at
the early stage of the stay to the maximum score of SS2. In contrast, SI is
slowly decreasing and marginally low at the beginning. At 15000 minutes, SI
changes dramatically. At this stage, SS2 decreases gradually from 2 to 0. The
 SI value at the early part of the patient’s stay is almost constant and more
fluctuations are seen in the second half of the stay. Similarly, constant % SI
has been observed mostly throughout the stay, showing no real response to
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Figure 6.6: Hourly plot of insulin sensitivity,  SI, % SI and SS2.
Figure 6.7: Hourly plot of insulin sensitivity,  SI, % SI and SS2.
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Figure 6.8: Hourly plot of insulin sensitivity,  SI, % SI and SS2.
Figure 6.9: Hourly plot of insulin sensitivity,  SI, % SI and SS2.
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SS2 value.
The hourly plot of Patient 012 is shown in Figure 6.7, where Patient 012
also has higher SS2 and low SI at the beginning of the stay. As time goes by,
it is observed that SI increases and SS2 keep reducing to a minimum level.
For the second half of the stay, SS2 maintains a minimum level. Even though
SI decreases for some time in the second half of the stay, the SI amount
is relatively higher compared to SI at the early stay. At minute 2500,  SI
starts to fluctuate until minute 3000. However, SS2 does not change during
this time. In the bottom plot, % SI varies at the beginning of the stay and
remains almost constant for the remainder of the stay.
Figure 6.8 shows the SI ,  SI , % SI and SS2 distribution during the
stay of Patient 063. Patient 063 has a maximum level of SS2 (SS2 = 3) when
admitted into the ICU and has very low SI . Later, the insulin sensitivity
improves as the patient reacts to treatment and therefore the SS2 level de-
creases, as well and as expected. In the early part of the stay,  SI changes
slightly and then slowly increases and follows the SI pattern. However, % SI
shows constant value throughout the stay with an obvious change only at the
beginning.
A similar pattern of SI and  SI is observed on Patient 079 shown in
Figure 6.9. SI is at minimum level at first, then increases gradually over time.
On the other hand, % SI is constant during the entire stay. Equally, % SI
changes slightly at the early stay and at minute 9500.
Overall, Figures 6.6 - 6.9 imply that SS2 decreases with increases in
insulin sensitivity, SI , given that SI is above a certain threshold. However,
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patients might have different patient-specific thresholds or baseline values to
indicate changes in their metabolic condition. Similarly, changes in SI may
also vary between patients. Some patients may have a huge change in SI
when shifting metabolic condition, while others may experience much smaller
changes for the same event. Nevertheless,  SI and % SI do not show a
significant correlation to the SS2, and thus may not serve as a bio-marker.
Equally, these results show that SI is an effective bio-marker, but patient-
specific thresholds make automated diagnosis difficult without external data.
In particular, the relation of insulin sensitivity, SI to SS2 may suggest
SI as a significant marker in determining sepsis level in critical illness. In
addition, the insulin sensitivity profile of a patient is able to be captured as
early as possible by computer. Therefore, the possibility of early treatment
and diagnosis of sepsis would be enabled conveniently. However, the change
in insulin sensitivity,  SI and % SI do not correlate well with SS2 profiles.
Thus, information on SI of a patient is potentially a good marker to diagnose
sepsis, but its variability is not.
Figure 6.10 shows the receiver operating characteristic (ROC) curves
where x-axis represents (1-specificity) and y-axis represents sensitivity. Plot-
ted lines lay in a sequence according to the SS2 value. As expected, higher SS2
values yield the best possible prediction and the plots show a similar trend
for all categories of SS2. There is a small gap between SS2   1 and SS2   2,
and large gap has been observed between SS2   3 to the rest.
Figure 6.10 also conveys that at low value of SS2, SI may be insignificant
in aiding sepsis diagnosis. However, at higher value of SS2 (SS2   3), which
represents the worst condition, such as septic shock, insulin sensitivity shows
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Figure 6.10: Receiver operating characteristic (ROC) plot showing the sensi-
tivity and specificity relation of SS2 and insulin sensitivity.
a significant response with increase in sensitivity. Hence, early diagnosis is
unclear, but positive predictive value with this marker alone is not significant
without further information. These results are largely due to the fact that SI
lags condition, resulting in SI values that do not match SS2 score when sepsis
state is changing. The end result is a loss of diagnostic power largely due to
the hourly nature of assessment and this lag.
6.4 Summary
Early identification of an inflammatory response to infection will enhance the
understanding of the cellular and immunologic mechanisms that can cause sep-
sis. Moreover, early detection and treatment of sepsis may increase chances
to recover and consequently decrease mortality rates. However, early detec-
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tion and treatment is a challenge due to the lack of physiological information
accessible in real-time that is relevant to infection, organ failure and sepsis.
Several studies clearly show that SI represents metabolic condition of a
patient. In addition, this chapter shows that information on SI can be highly
related to SS2, a modified sepsis scoring system indicating sepsis degree. SS2
increases with a decrease in SI and vice versa. However, other information
derived from SI do not show any direct relation to SS2, particularly in the
study of this cohort.
Even though SI shows a directly proportional relation to SS2, the change
in SI is highly variable and patient-specific especially at low value of SS2.
Patient-by-patient analysis shows clear trends and discrimination, but at
patient-specific levels that are not easily automated to diagnostic guidelines.
Thus, at low SI , it is almost impossible to differentiate the resulting sepsis
condition of a particular patient from other acute conditions. In particular,
different patients develop from different SI baseline values and at different
rates, confound the situation. Equally, lag between SS2 score and resulting
impact on metabolic bio-markers further confuses automation of diagnosis.
In a nutshell, the use of SI as a marker may potentially aid the process
of diagnosing sepsis. However, information on SI is insufficient to determine
the exact sepsis condition of a patient particularly at moderate sepsis levels
(eg SS2=1) which are important for early diagnosis as the condition develops.
Other physiological or clinical variables will have to be incorporated with SI
to provide better information for sepsis diagnosis in real-time. More con-
cisely, the impact of sepsis on metabolic markers, like SI , is clear. However,
patient-specific levels and thresholds confound this positive result in trying to
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automate its use as an effective diagnostic.
Chapter 7
Predicting Sepsis in Critical
Illness
This chapter investigates using one or a series of potential sepsis bio-markers
to detect (early) and thus effectively predict the existence of sepsis. Currently,
there are no reported studies that successfully predict the existence of sepsis in
a patient admitted in a hospital. Since there are many factors that may limit
the ability to diagnose emerging sepsis, clinicians focus on treating patients
according to their judgement and experience. Confirmative and definitive
diagnosis by blood culture results usually take about 1-3 days which is too long
a delay. More specifically, early treatment of sepsis has been shown to reduce
mortality and improve patient condition [Rivers et al., 2001]. However, the
lack of clear information and objective, accurate methods to diagnose sepsis
at an early stage makes this has become a significant challenge.
In this chapter, a series of data taken during a specific sepsis study from
the Intensive Care Unit (ICU) of Christchurch Hospital is used to analyze
and determine if there exists a potential viable bio-marker that is reliable
as a sepsis predictor. Several available clinical parameters were tested to
obtain a suitable parameter or parameter set that can be used as a marker.
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Insulin sensitivity, a patient metabolic parameter is also tested to analyze its
potential in assessing sepsis status based on its reflection of the metabolic
response to the inflammation and immune response actions concomitant with
sepsis [Blakemore et al., 2008]. The overall goal is to determine if a viable
hour-to-hour marker exists that is better than clinical experience. Currently,
no such metric exists and identifying one would be a major step forward.
7.1 Neural Network Time Series Analysis
Artificial neural networks (ANN) are flexible mathematical structures capable
of identifying complex, nonlinear relationships between one or more inputs
and outputs. It composed of interconnecting artificial neurons and processing
elements that can exhibit and capture complex global behavior, as determined
by the numerically weighted connections between the processing elements and
specific element parameters. The use of ANN models, particularly in a system
where the characteristics are unable to describe by physical equations, have
been found to be useful in many areas [Chiu et al., 2005; Hsu et al., 1995].
These black-box models are especially useful in cases, as with sepsis, where
the input-output relationships are not fully defined or known, or are highly
variable or non-linear.
A sequence of data points, known as a time series of data, is typically
measured at successive times spaced at a uniform time intervals. Time series
analysis comprises methods for analyzing time series data to extract meaning-
ful characteristics from the data. In time series analysis, forecasting is possible
by using a model to forecast future events based on known past events and
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patterns as a prediction before the point is measured. Ideally, an hourly pre-
diction of a diagnostic sepsis score can be generated using a model configured
by data from one or more previous hours.
Properly trained, ANNs thus can be used to find complex patterns with
predictive capability that are not necessarily obvious or clearly evident. Sep-
sis diagnosis is complex and based on a series of interacting and potentially
confounding variables. Hence, even clinical experience is far from perfect.
These features make ANNs potentially valuable approach to find patterns
and relations that are not clinically evident directly.
In this analysis, a flexible, non-linear auto-regressive technique is imple-
mented. Figure 7.1 illustrates the concept used in getting information about
Y, the predictive values. The equation used is shown in Equation 7.1, where
Y is the variable of interest. In this case, Y is the sepsis score and X is
the externally determined or measured variable(s). The information about
X is combined using several weights in predicting Y. Prior values of Y itself
can also be used, where L represents the lag of the network system in uti-
lizing prior values of Y. The use of time lags in neural networks in this way
can improve forecasting accuracy [Samarasinghe, 2007]. Figure 7.2 shows the
schematic decomposition of hidden layer functions represented as F in Figure
7.1.
The first layer of the hidden layer contains 10 neurons, where the second
layer has 1 neuron. The net product of the first layer, H1 is the summation
of weighted input, weighted output feedback and biases. The net product of
the first layer is then applied to a transfer function to obtain an output for
the first layer. The net product of the second layer, H2 is the summation
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Figure 7.1: Block diagram of nonlinear auto regressive technique.
Figure 7.2: Hidden layer parts used in neural network system, the block or
layer labelled "10" indicates a hidden layer of 10 neurons.
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of the weighted output from first layer and biases. This net product will go
through a second transfer function to determine the final output. This process
continues until a final value of the input parameter has been entered. The
equations used for hidden layer functions, H1 and H2 are shown in Equations
7.2 - 7.3.
Yt = F (Yt 1, Yt 2, Yt 3, ......, Xt, Xt 1, Xt 2, Xt 3...)+ 2t (7.1)
H1 = F (W1
T ·X1 +W2T ·X2 + b1) (7.2)
H2 = F (W3
T ·H1 + b2) (7.3)
The model in this analysis is a general complex structure since there is no
clear relationship between the input parameters used and desired output (Y =
SS2 values). The uncertainty of the relationship between SS2 and the input
parameters requires the used of a non-linear auto-regression model that is
suitable for a model with complex structure and unknown dynamics, exacting
matching the sepsis diagnosis case. ANNs are also considered superior to
conventional models in applicability in these cases where the system and its
relationship are not fully understood.
More specifically, in this analysis, the non-linear auto-regressive model
is used on time series data because of its advantages over other type of neural
network architectures. In particular, it has better computational properties,
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storage and learning processes and time-series forecasting properties. It thus
provides a better opportunity to develop a model describing the underlying
unknown relationship in a sequence of event outcomes [Samarasinghe, 2007].
Finally, 6 prior data points and 2 prior predicted values, also known as lags,
were selected as an input variables to encode knowledge of past events. There-
fore, the forecast value of SS2 in this architecture is also dependent on past
events.
The overall goal is to test several potential bio-markers and sets of com-
mon clinical data used in sepsis diagnosis. The ANN is used to determine
their predictive ability both individually and in groups. Successful outcomes
will provide useful diagnostics, and those sets that do not succeed indicate
data for which no clear pattern or diagnostic efficacy exists.
7.2 Data Collection
In this study, prospective data collection was undertaken for several patients
as part of a clinical trial. This data consists of sepsis-related clinical data, such
as body temperature, respiratory rate and urine output, blood glucose levels,
blood culture results, and further laboratory results including white blood cell
count. These metrics are related to immune response to infection (tempera-
ture, HR and RR) and organ failure (MABP and urine output); which are the
core aspects defining sepsis (see Chapter 5). It also includes the model-based
insulin sensitivity profiles, which are known to broadly correlate with some
aspects of sepsis in prior studies [Blakemore et al., 2008]. Ethics approval to
collect, audit and use this data under informed consent was obtained from the
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Upper South Regional Ethics Committee, New Zealand.
A total of 7505 data points were gathered from 30 patients in a selected
sepsis cohort. These 7505 data points represent a total of 7505 hours of
monitoring sepsis patients in the ICU. The data is then divided into 5 groups,
Group A, B, C, D and E. Therefore, the test set is independent of the training
set. The sampling method used is shown in Figure 7.3. These five groups are
then rearranged to obtain 5 sets of data that are used for neural network
training and testing processes. For example, in set 1, Groups B, C, D and
E were combined to form a training set, and Group A is used for testing the
resulting ANN. For every set of tests, there were 6004 of data points in the
training set, and 1501 data points used for testing, an 80:20 split.
In neural networks, the training set is used repeatedly to determine the
estimation of biases and weight for a candidate ANN design. The known
desired output (Y = SS2) is also used in the training process. It is then vali-
dated by estimating the performance error of the candidate ANN design. The
training process stops when the validation error stops decreasing. In contrast,
the testing set is used only once on the best ANN design to obtain an unbi-
ased estimate for the predicted error of unseen non-training data. Thus, data
in the test set is independent of the data in the training set [Masters, 1995].
More specifically, in the test set, no information on the output is available,
and this knowledge is only used to assess the accuracy of the resulting ANN
performance.
Figure 7.4 shows the sequence for developing the hourly prediction of
SS2 (see Chapter 5), where the input data is applied to the network system.
In Figure 7.4, SI is used as an input parameter, in this example. In this
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Figure 7.3: Group selection for training and testing.
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analysis, 10 neurons were used. These neurons receive one or more input
parameters depending on input selection and sum of the weighted inputs was
process with a sigmoid function to produce the output.
Figure 7.4: Development of desired output from available parameter.
7.3 Identifying Significant Parameters
There were several different clinical data available for the total of 7530 control
hours in ICU. These data include: temperature, heart rate, respiratory rate,
urine output and BG concentration. The full set is listed in Table 7.1. The
variables are tested either individually or combined with other variables to
determine the influence of each variable. Sensitivity and specificity for each
test set is presented for comparison. This analysis is divided into three cate-
gories, which are patient-specific profiles, clinical variables and incorporating
or adding the use of prior clinical feedback.
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Table 7.1: Clinical data set used for ANN training and testing.
Clinical variables Nomenclature
Heart rate HR
Temperature -
Urine output -
Blood glucose BG
Respiratory rate RR
Mean arterial blood pressure MABP
7.3.1 Insulin Sensitivity (SI)
SI , a patient-specific parameter is tested on the neural network system to in-
vestigate the ability of this parameter to predict SS2. In this test, the system
processes 6 prior data on SI and 2 prior SS2 outputs to predict SS2 for the
next hour. Table 7.2 shows the confusion plot for the testing process of sets A,
B, C, D and E. Blue cells indicate the matched cell between the output and the
target. Two different colors of percentage, red and green, represent the per-
centage of true predictions and percentage of wrongly identified predictions,
respectively.
Referring to Table 7.2(a), most of the true identified scores are at target
and output of SS2 = 1, where it covers 39.4% of overall data points in Set
A. However, most of the data points (49.3%) provide inaccurate results (1
instead of 0). Thus, 40% of data is correctly identified compared to 60%
that is wrongly identified. Similarly, in Table 7.2(b), 54% and 46% of data
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Table 7.2: Confusion plot for testing process of a) Set A, b) Set B, c) Set C, d)
Set D and e) Set E for the case where input and output are insulin sensitivity
and SS2, respectively.
a)
Target (SS2)
0 1 2 3
O
ut
pu
t(
SS
2)
0 0 0 0 0 -0.0% 0.0% 0.0% 0.0% -
1 740 591 65 28 42%49.3% 39.4% 4.3% 1.9% 58%
2 17 56 4 0 5%1.1% 3.7% 0.3% 0.0% 95%
3 0 0 0 0 -0.0% 0.0% 0.0% 0.0% -
0% 91% 6% 0% 40%
100% 9% 94% 100% 60%
b)
Target (SS2)
0 1 2 3
O
ut
pu
t(
SS
2)
0 8 20 9 0 22%0.5% 1.3% 0.6% 0.0% 78%
1 327 787 320 6 55%21.9% 52.4% 21.3% 0.4% 45%
2 0 11 13 0 54%0.0% 0.7% 0.9% 0.0% 46%
3 0 0 0 0 -0.0% 0.0% 0.0% 0.0% -
2% 96% 4% 0% 54%
98% 4% 96% 100% 46%
c)
Target (SS2)
0 1 2 3
O
ut
pu
t(
SS
2)
0 0 4 0 0 0%0.0% 0.3% 0.0% 0.0% 100%
1 701 617 135 44 41%46.7% 41.1% 9.0% 2.9% 59%
2 0 0 0 0 -0.0% 0.0% 0.0% 0.0% -
3 0 0 0 0 -0.0% 0.0% 0.0% 0.0% -
0% 99% 0% 0% 41%
100% 1% 100% 100% 59%
d)
Target (SS2)
0 1 2 3
O
ut
pu
t(
SS
2)
0 8 1 6 3 44%0.5% 0.1% 0.4% 0.2% 56%
1 333 706 127 65 57%22.2% 47.0% 8.5% 4.3% 43%
2 6 70 143 30 57%0.4% 4.7% 9.5% 2.0% 43%
3 3 0 0 0 0%0.2% 0.0% 0.0% 0.0% 100%
2% 91% 52% 0% 57%
98% 9% 48% 100% 43%
e)
Target (SS2)
0 1 2 3
O
ut
pu
t(
SS
2)
0 4 3 0 0 57%0.3% 0.2% 0.0% 0.0% 43%
1 315 1066 55 58 71%20.9% 71.0% 3.7% 3.9% 29%
2 0 0 0 0 -0.0% 0.0% 0.0% 0.0% -
3 0 0 0 0 -0.0% 0.0% 0.0% 0.0% -
1% 99% 0% 0% 71%
99% 1% 100% 100% 29%
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points in Set B are correctly and wrongly identified, respectively. The highest
percentage of matched output and target is 52.4% at input and target SS2 =
1. At target SS2 = 1, 96% of data is truly identified. Set C shows a slightly
different result in comparison to Sets A and B, given that majority (99.7%)
of data points lay on output SS2 = 1 as seen in Table 7.2(c). In addition,
more than half (59%) of data in Set C is wrongly identified and 41% is truly
predicted. Table 7.2(d) shows the confusion plot on Set D. 57% of data points
in Set D is correctly identified whereas 43% is wrongly predicted. In Set D,
the data is more scattered and a higher percentage are seen at target and
output SS2 = 2, where other data sets show smaller percentages at target and
output SS2 = 2. Finally, the confusion plot for Set E is shown in Table 7.2(e).
The percentage truly and wrongly predicted are 71% and 29%, respectively.
The highest percentage of correctly identified is at target and output SS2 =
1.
Overall, Table 7.2 indicates that most of the output of the network
system lay at output SS2 = 1 and SS2 = 2. The percentage of true prediction
is very low across all the testing sets. These results suggest that either the
network system could not account for the variability in the input applied or the
variability of the input itself, specifically in SI , are the cause of the inability
to correctly identify and forecast the value of SS2.
Table 7.3 summarizes the testing results using SI as an input parameter.
The hourly prediction of SS2 is based on 6 hours prior data on SI and 2
hours prior estimated output. As seen in Table 7.3, the MSE for Sets B
and E are marginally lower compared to other data sets. NPV values are
relatively small across all data sets. Interestingly, all sets have high sensitivity
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(> 90%) indicating a high proportion of actual positives that are correctly
identified. However, very low specificity across all data sets, which is less
than 10%, means this sensitivity comes from an inability to correctly identify
the proportion of actual negatives.
Table 7.3: Testing results on SS2 using SI as an input parameter. MSE, PPV
and NPV represent mean squared error, positive predictive value and negative
predictive value respectively.
Data set MSE PPV NPV Sensitivity Specificity
Set A 0.765 49.6 - 100.0 0.0
Set B 0.462 77.7 21.6 97.5 2.4
Set C 0.697 53.2 0.0 99.5 0.0
Set D 0.691 76.9 44.4 99.1 2.3
Set E 0.387 79.0 57.1 99.7 1.3
Note that these high sensitivity and low specificity results match a lot
of clinical practice. Typically, clinicians use experience and intuition, and,
importantly tend to err on the side of caution. They thus diagnose and treat,
with antibiotics, likely sepsis more often than confirmed by blood test. Typ-
ically, ⇠50% of all sepsis is culture negative [Martin et al., 2003], indicating
sensitivity of 80 - 100% but much lower specificity. Very similar to these
results, hence, what is seen is not a failure, but a failure to exceed current
clinical practice.
Variability among data sets can also be clearly seen in Table 7.3. PPV
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values are similar and more consistent across data sets. However, NPV is more
variable and inconsistent. Note that, the output obtained from simulation for
each data set is highly dependent on the input of the data set, the prior
output, and their weights.
From these results, it can be concluded that SI alone is not capable of
improving sepsis diagnosis and becoming an hourly sepsis predictor despite the
potential of representing patient metabolic condition in earlier, less in depth,
studies [Blakemore et al., 2008]. Therefore, other information is necessary to
predict sepsis status. Hence, several combinations of clinical inputs need to
be tested to see if a more ideal diagnostic system exists using typical clinical
data.
Figure 7.5 illustrates the distributions of BG across the SS2 values of
the cohort. The axes are left unmodified for a clearer picture of individual
distribution according to their SS2 values. Additionally, Figure 7.6 shows the
comparison of BG distribution for different SS2 value. At SS2 = 0 and SS2
= 1, where a high density of measurements has been observed compared to
SS2 = 2 and SS2 = 3. Surprisingly, the ranges of BG are almost similar
for all the different SS2 values, indicated by the overlapping of the normal
distributions in Figure 7.6. Thus, BG may not be a good discriminator on its
own, particularly where, as well with these patients on SPRINT [Chase et al.,
2008b], BG control is effective across all patients.
Similarly, Figure 7.7 presents the individual distributions of SOFA scores
according to SS2 value. Figure 7.8 shows the distributions of SOFA scores
across the SS2 values of the cohort. Referring to Figure 7.8, there is a clear
separation dividing the SS2 scores into two groups. SS2 = 0 and SS2 = 1 are
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Figure 7.5: Distribution of BG according to SS2 value.
Figure 7.6: Distribution of BG for different SS2 values.
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closer and less well separated. Whereas SS2 = 2 is closer to SS2 = 3. These
results separate severe sepsis from an early sepsis and no sepsis.
Figure 7.7: Distribution of SOFA score according to SS2 value.
Figure 7.8: Distribution of SOFA score for different SS2 values.
Table 7.4 summarizes the results of the testing process on SS2 using
several combinations of input parameters such as SI , blood glucose measured
(BG) and SOFA. Adding BG to SI as input parameter does not show sig-
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nificant improvement on sensitivity and specificity. However, combining SI
and SOFA shows some improvement on specificity and MSE as compared to
SI alone. In contrast, and as expected, adding BG to SI and SOFA does
not show any further improvement in discrimination. In particular, MSE,
PPV, and NPV decrease slightly. Similarly, slight changes have been seen in
sensitivity and specificity for most of the data sets.
Table 7.4: Testing results on SS2 using several combinations of input param-
eter. MSE, PPV and NPV represent mean squared error, positive predictive
value and negative predictive value respectively.
Input variables Data set MSE PPV NPV Sensitivity Specificity
SI , BG Set A 0.872 49.6 100.0 100.0 0.4
Set B 0.468 77.6 0.0 99.6 0.0
Set C 0.693 52.9 7.1 98.4 0.1
Set D 0.664 78.0 74.4 99.1 8.3
Set E 0.654 79.8 38.1 95.6 10.0
SI , SOFA Set A 0.582 62.4 86.5 92.9 45.0
Set B 0.351 83.0 82.1 98.1 30.1
Set C 0.560 60.0 67.2 85.3 34.5
Set D 0.664 81.2 74.8 97.3 26.2
Set E 0.448 82.5 28.3 68.9 45.8
SI , SOFA, BG Set A 0.606 61.1 70.6 78.5 50.9
Set B 0.512 82.8 69.9 96.2 30.4
Set C 0.562 59.6 68.0 86.4 33.1
Set D 0.600 82.3 56.9 91.8 35.3
Set E 0.478 82.7 29.4 71.1 44.8
Results in Table 7.4 indicate that BG is not suitable to be a meaningful
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part of a bio-marker for sepsis diagnosis and more potential can be seen for
SOFA as a bio-marker. This outcome occurs because SOFA gives more impact
by improving specificity values compared to BG and is more directly associated
with sepsis and its definition as infection plus organ failure. In addition,
BG is more a function of control than of condition and thus may not reflect
sepsis well. This latter point is particularly valid in this cohort, which was
on the SPRINT protocol [Chase et al., 2008b] and provided consistent control
regardless of condition. These outcomes are visible when noting that the BG
distribution for this cohort is very similar across all the different SS2 scores,
as shown in Figure 7.6.
7.3.2 Impact of Clinical Variables
Additional tests using ANNs are used to investigate if any of the other readily
available clinical parameters in Table 7.1 can potentially improve the results.
These variables are tested individually and in groups to identify their relation
with SS2 and their potential in creating and improved diagnostic marker.
Table 7.5 shows the results of the testing process using temperature,
urine, HR, RR, and MABP as input parameters. Significant improvement is
seen for the whole data set, particularly in specificity, as compared to using SI
alone in Table 7.3. However, NPV across the data sets are much smaller com-
pared to using SI and SOFA. Potentially, not all the clinical inputs used were
beneficial for predicting sepsis on an hourly basis. Therefore, each variable is
tested individually.
Table 7.6 presents the analysis results on the network system using dif-
7.3. IDENTIFYING SIGNIFICANT PARAMETERS 165
Table 7.5: Testing results on SS2 using all available clinical input parameters.
MSE, PPV and NPV represent mean squared error, positive predictive value
and negative predictive value respectively.
Data set MSE PPV NPV Sensitivity Specificity
Set A 0.647 60.6 75.9 85.3 45.4
Set B 1.201 81.2 65.2 96.6 22.4
Set C 0.837 58.4 55.8 70.1 43.1
Set D 0.867 80.7 45.5 88.9 30.5
Set E 0.510 85.4 33.1 69.9 55.5
ferent individual input parameters. PPV and sensitivity are a major challenge
to analyze since the values are mostly similar across the data sets and differ-
ent input variables. In contrast, NPV and specificity are much more variable,
and very low specificity has been observed for example using RR with zero
specificity for four data sets. Interestingly, Set D has the most promising re-
sult, even when using different input variables. In contrast, Set A has been
observed for having relatively worst result throughout the testing process.
These results reflect smaller differences in the specific patients in each set.
Table 7.7 summarizes the results of individual input tests by looking at
the mean average of the testing process across the data sets. As previously
mentioned, MSE, PPV, and sensitivity are almost similar across all the input
variables. Additionally, HR, temperature and urine show an acceptable NPV
value for individual testing of 60.3, 40.3 and 49.9, respectively. As noted
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Table 7.6: Testing results on SS2 using several clinical input parameter. MSE,
PPV and NPV represent mean squared error, positive predictive value and
negative predictive value respectively.
Input variables Data set MSE PPV NPV Sensitivity Specificity
Temperature Set A 0.833 48.2 17.2 93.5 1.3
Set B 0.472 77.9 39.1 98.8 2.7
Set C 0.792 50.9 39.1 87.6 3.7
Set D 0.661 79.4 71.1 97.9 16.8
Set E 0.447 81.3 35.1 87.5 25.1
RR Set A 0.625 49.6 - 100.0 0.0
Set B 0.469 77.7 0.0 99.9 0.0
Set C 0.682 53.2 0.0 99.8 0.0
Set D 0.676 76.9 83.3 99.9 1.4
Set E 0.403 78.8 - 100.0 0.0
HR Set A 0.990 54.1 90.7 98.1 18.1
Set B 0.448 84.5 57.9 91.3 41.8
Set C 0.612 57.3 89.2 98.3 16.5
Set D 0.772 76.3 12.5 96.3 1.7
Set E 0.402 80.8 51.1 96.1 15.0
Urine Set A 0.641 49.7 66.7 99.6 0.8
Set B 0.478 77.0 40.0 99.2 01.8
Set C 0.672 53.4 100.0 100.0 0.4
Set D 0.707 76.8 29.4 97.9 2.8
Set E 0.472 78.0 13.4 89.6 6.0
MABP Set A 0.619 49.6 50.0 99.9 0.1
Set B 0.595 77.6 0.0 99.7 0.0
Set C 0.730 53.3 - 100.0 0.0
Set D 0.998 76.3 22.5 73.4 25.4
Set E 0.580 76.1 7.7 80.8 6.0
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previously, these might be similar to clinical capability. However, RR has the
smallest specificity followed by urine, MABP, temperature and HR.
Table 7.7: Mean average testing results on SS2 using individual clinical in-
put parameter. MSE, PPV and NPV represent mean squared error, positive
predictive value and negative predictive value respectively.
Input variables MSE PPV NPV Sensitivity Specificity
Temperature 0.641 67.5 40.3 93.1 9.9
HR 0.645 70.6 60.3 96.0 18.6
RR 0.571 67.2 16.7 99.9 0.3
Urine 0.594 67.0 49.9 97.3 2.4
MABP 0.704 66.7 16.0 90.8 6.3
Figure 7.9 shows the cdfs for the clinical variables on different SS2 values.
Referring to Figure 7.9, the temperature, RR and HR distributions are almost
overlaid for different value of SS2. The separation between different SS2 values
can be seen in the urine output and MABP variables. The urine distributions
follow the sequence of SS2 values with highest urine output for SS2 = 0 and
lowest urine output for SS2 = 3. However, MABP distributions are separated
into two groups which are SS2 > 1 and SS2  1. A summary of the clinical
variable distributions are shown in Table 7.8.
Overall, the tests of clinical variables on predicting SS2 suggest that
clinical data, such as hourly urine output, MABP, temperature, RR and HR
add value, but cannot create a significantly improved bio-marker. In partic-
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ular, while PPV values were 66.7 - 70.6%, NPV values of 16.0 - 60.3% mean
that sensitivity and specificity do not exceed 99.9% and 18.6%. These values
are not much better than clinical experience.
It should be noted that the clinical variables recorded may change be-
cause of several factors. For example, changes in patient condition or patient
reaction towards treatment such as drugs and inotropes, unrelated to sepsis,
cleared the issue significantly. Moreover, clinical variables may not change at
the same rate for every patient, as their condition evolves. Therefore, and as
seen from the results, the recorded clinical variables are, at least sometimes,
potentially misaligned to the hourly sepsis score.
7.3.3 Clinical Feedback Factor
Despite all the results shown above, clinical feedback is another final parame-
ter, which may prove interesting to be analyzed. This parameter is of interest
because most of the decisions made in treating sepsis in the ICU are based
on clinical experience. Importantly, they are also not made in a vacuum, but
are, in fact, based on recent past observations and conclusions made by the
attending clinical staff, and not just a one-stop analysis. In this test, clinical
feedback of the true value was obtained for every 6 hours. Table 7.9 shows
the testing results on SS2 using clinical feedback and several other input pa-
rameters.
Referring to Table 7.9, using clinical feedback as an input parameter
improves the sensitivity and specificity. Sensitivity is slightly improved while
specificity is almost doubled compared to the best specificity obtained using
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clinical variables in Table 7.5. The mean average sensitivity and specificity are
0.918 and 0.840, respectively. SI and SOFA are also tested with clinical feed-
back and similarly, sensitivity and specificity improve dramatically compared
to previous tests discussed in Section 7.3.1. However, the improvements are
largely due to the influence of clinical feedback, which merely reflects current
practice, but does not significantly improve it.
From all the tests conducted, clinical feedback has the most promising
results with higher sensitivity and specificity observed compared to other sev-
eral tests. Moreover, adding SI , SOFA, and even both of these parameters
made no improvement.
7.3.4 Per-Patient Analysis
Additional analysis was done using the same network architecture on a per-
patient data input parameters such as SI and other clinical variables. How-
ever, overall results did not show additional improvement compared to whole
cohort data analysis. Generally, very few patients in the cohort have a promis-
ing results for different test sets and it is either the sensitivity or the specificity
and not for both simultaneously. Most of the sepsis patients (90%) have lower
sensitivity and specificity compared to sensitivity and specificity when using
clinical feedback input. In addition, 36% and 18% of test sets have higher sen-
sitivity and higher specificity, respectively compared to sensitivity of 86.3%
and specificity of 74.4%.
The lower results on sensitivity and specificity observed on per-patient
analysis indicate no significant difference when selecting per-patient data ver-
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Table 7.9: Testing results on SS2 using several combinations of input param-
eter. MSE, PPV and NPV represent mean squared error, positive predictive
value and negative predictive value respectively.
Input variables Data set MSE PPV NPV Sensitivity Specificity
CF Set A 0.204 88.2 86.8 86.3 88.6
Set B 0.143 94.8 86.4 96.3 81.5
Set C 0.187 92.9 88.7 89.7 92.2
Set D 0.307 92.2 76.8 93.1 74.4
Set E 0.164 95.4 78.4 93.8 83.1
CF, SI Set A 0.225 85.7 86.3 86.2 85.9
Set B 0.139 95.0 87.6 96.7 82.4
Set C 0.250 82.2 87.3 90.1 77.7
Set D 0.328 91.6 76.9 93.4 72.1
Set E 0.154 95.1 78.9 94.1 81.8
CF, SOFA Set A 0.211 85.3 87.5 87.6 85.2
Set B 0.198 91.0 79.8 95.1 67.2
Set C 0.172 91.7 89.0 90.1 91.0
Set D 0.285 91.8 80.6 94.7 72.4
Set E 3.822 77.1 20.1 39.8 56.1
CF, SOFA, SI Set A 0.233 84.1 86.5 86.7 83.9
Set B 0.157 92.2 86.0 96.7 71.6
Set C 0.193 91.6 88.9 90.1 90.6
Set D 0.311 91.1 77.6 93.8 70.1
Set E 0.329 93.6 82.0 95.5 75.5
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sus using the cohort data. Although the sensitivity and the specificity ob-
served were slightly better, most of the patients tend to have better predic-
tions only for one of the categories, either specificity or sensitivity and not for
both.
7.4 Factors in Defining a Successful Sepsis Bio-
Marker and Diagnostic
Insulin sensitivity, SI has shown a significant relation to metabolic condition
and therefore can be used to rule out the presence of sepsis (high NPV) in the
critically ill. Blakemore et al [Blakemore et al., 2008] showed that SI provides
a negative predictive diagnostic for sepsis with a sensitivity and specificity
of 78% and 82%, respectively. In addition, Lin et al [Lin et al., 2011a] on a
different cohort shows that SI is potentially a good sepsis bio-marker, par-
ticularly for diagnosis of only severe sepsis, achieving a 50% sensitivity and
76% specificity. However, in this study, SI does not correlate well with SS2,
particularly as an hourly predictor to SS2.
The use of clinical variables as a tool for hourly sepsis diagnosis is also
unsuccessful compared to current clinical capability, for this cohort, and may
be due to the fact that clinical symptoms frequently exist even if the patient is
free from infection or sepsis. It is thus a challenge to look at clinical variables,
such as temperature, MABP and RR, as these values may change due to
several factors changing in a particular patient and not just due to sepsis. In
addition, the change in variables may be different between patients for the
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same degree of sepsis, creating further difficulty in beating clinical practice.
To date, there is no specific bio-marker developed that can represent or
predict (early) the occurrence of sepsis with any better accuracy than found
here. Blood culture tests are still considered the gold standard for confirma-
tion of infection. However, even there, only 51% of sepsis cases are positively
identified [Martin et al., 2003]. Automated culturing systems are also used for
bacteria detection in sepsis diagnosis by determining the solution pH or the
the presence of CO2. However, this method requires 11-31 hours for detection
[Carrigan et al., 2004], and is thus neither earlier than clinical practice nor
real-time.
Other bio-markers that have been used for sepsis diagnosis are procal-
citonin (PCT), C-reactive protein (CRP), tumor necrosis factor-↵ (TNF↵),
interleukin 8 (IL-8) and interleukin 6 (IL-6) [Lavrentieva et al., 2011; Schuetz
et al., 2011; Tsalik et al., 2011; Ravishankaran et al., 2011; Povoa et al., 2011;
Salluh and Lisboa, 2011; Schrag et al., 2011; Uusitalo-Sepp L et al., 2011;
Suberviola et al., 2011]. Commonly, these methods require incubation and
consequently lead to a minimum of 2 - 3 hours delay for diagnosis. Moreover,
most of these markers struggle with the issue of accuracy level [Carrigan et al.,
2004]. Additionally, the outcome of a diagnostic marker is evaluated by ana-
lyzing the ROC curve, sensitivity and specificity at a specified cutoff value of
the marker. Current protein bio-marker research focuses on PCT and several
interleukins for detecting infection, since PCT achieves mean sensitivity and
mean specificity of 81% and 73%, respectively [Carrigan et al., 2004]. In addi-
tion, studies conducted by BalcI and colleagues [BalcI et al., 2003] shows that
PCT can discriminate between SIRS and sepsis, and therefore may become a
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diagnostic parameter. However, many lesser performances for PCT are also
reported [Tsalik et al., 2011; Bele et al., 2011; Kibe et al., 2011].
While more research is conducted to evaluate the use of protein bio-
markers for sepsis diagnosis, real-time diagnosis is still a major and important
interest. Delayed diagnosis has been shown to increase patient’s risk of infec-
tion and mortality [Rivers et al., 2001]. In addition, inappropriate antimicro-
bial treatments due to delayed diagnosis may create future patient resistance
to treatment [Carrigan et al., 2004] and consequently increase patient risk.
Importantly, criteria of a successful bio-marker of sepsis must be account-
able for diagnosis at a quick rate with a reasonable sensitivity and specificity
that exceeds the ⇠80% (each) of an experienced clinician [Holub and Zavada,
2011]. Additionally, capturing and analyzing typical ICU data for a diagnos-
tic is a second requirement for a real-time diagnosis, rather than relying on
laboratory testing that may take up to 48 hours. Moreover, additional crite-
ria for a bio-marker is to have a reasonable cost. Since the estimated annual
healthcare cost of sepsis is nearly US$17 billion in the US alone [Angus et al.,
2001], the test should be low cost but does not have to be negligible. Finally,
considering patient condition and the risk of mortality, an invasive diagnostic
procedure would also be suitable.
7.5 Summary
Limited diagnostic methods have prevented significant improvement in early
diagnosis and treatment. Thus, it limits the ability to reduce mortality and
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cost. Currently, an experienced clinician is the best diagnostic and best able
to consider, accurately, all the relevant data. Only a blood culture test is
considered a gold standard test in determining sepsis, but over ⇠50% of di-
agnosed sepsis is culture-negative [Lin et al., 2011a]. Equally, blood culture
tests require 1- 3 days to obtain the result, which is also far too slow.
In this chapter, several available model-based and clinical parameters
are tested using neural networks to investigate the influence level of each
parameter towards predicting SS2, a scoring system used to classify sepsis
state. From all the tests conducted, none could exceed current clinical prac-
tice. Thus, clinical feedback is the only parameter that resulted in higher
sensitivity and specificity in this format, hence, confirming this initial conclu-
sion. In this analysis, hourly input data are tested to evaluate their ability for
real-time diagnosis of sepsis. The main issue is that the data is not necessarily
perfectly correlated to SS2 or highly discrimination of sepsis.
In conclusion, this study analyzed the potentiality of several available
parameters captured in typical ICU settings as possible bio-markers for sep-
sis diagnosis. A flexible neural network framework showed that none, either
alone or in combination, provided an improvement over current conditions and
capability. Hence, it may be initially concluded that either a more powerful
framework is needed to detect and discriminate sepsis status, or that a more
optimal bio-marker is still needed.
Chapter 8
Sepsis, Microcirculation, and
Pulse Oximetry
The microcirculation is a critical physiological pathway through which oxygen
diffuses to tissues and waste products are returned to be processed by the cir-
culation. Microcirculation dysfunction is one of the most common conditions
suffered by critically ill patients with organ dysfunction. Clinically, micro-
circulatory dysfunction affects organs, such that tissues receive insufficient
amounts of oxygen or other substrates.
Sepsis is characterized as a disease of the microcirculation and thus in-
formation about microcirculation dysfunction could enable better and more
accurate tracking of patient state and sepsis status. This chapter presents
a non-invasive potential method to directly assess microcirculatory function
that might be used to monitor critically ill patients. In this study, a pulse
oximeter is used to assess microcirculation function via extraction. Extrac-
tion is the rate or level of exchange of oxygen and other products by the
microcirculation. In sepsis, extraction is very low.
Pulse oximeters measure the absorption of red and infrared light by
blood and tissues as the light passes through an individual’s finger. The raw
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red and infrared signals are processed to represent the relative absorption of
reduced hemoglobin and oxyhemoglobin. From this concept, oxygen satura-
tion and extraction can potentially be derived and thus can be used to assess
the status of the microcirculation. This use is a significant extension from the
use of pulse oximetry to measure oxygen saturation in tissues. In particular,
in this study, the changes in red and infrared signals are specifically being
investigated separately unlike the standard pulse oximeter that combines all
these signals into a single, calibrated oxygen saturation metric.
8.1 Sepsis is a Disease of the Microcirculation
The microcirculation consists of the smallest blood vessels, those with less
than 100 micrometers diameter, and consists of arterioles, capillaries, and
venules. A schematic illustration is shown in Figure 8.1. It connects the arte-
rial and venous systems taking arterial blood to the arterioles, to capillaries,
to venules, and back to the heart via the venous circulation.
Microcirculation transports oxygen and nutrients to tissue cells and also
helps ensure adequate immunological function. It also acts as a medium for
delivering therapeutic drugs to target cells [Ince, 2005]. The main cell types
constituting the microcirculation are the endothelial cells, smooth muscle cells,
red blood cells, leukocytes, and plasma components in blood. These differ-
ent types of cells each have individual roles in controlling the mechanisms of
microcirculatory perfusion. Specifically:
Endothelial cells are responsible for part of immune response, coagulation,
8.1. SEPSIS IS A DISEASE OF THE MICROCIRCULATION 179
Figure 8.1: Human microcirculation schematic indicating arterioles, capillar-
ies, and venules. Adapted from biology.about.com.
growth regulation, production of extracellular matrix components. It
functions as a modulator of blood flow and blood vessel tone [Sumpio
et al., 2002].
Smooth muscle cells line the arterioles and help regulate perfusion.
Red blood cells transport hemoglobin, which carries oxygen from the lungs
to the tissues. It also catalyzes the reaction between carbon dioxide
and water, and is responsible for most of the buffering power of blood
[Guyton and Hall, 1996].
Leukocytes provide a rapid defense against infection by localizing at infec-
tion sites. Leukocytes are formed partially in the bone marrow and
partially in the lymph tissue. The life span is normally 4-8 hours in the
blood when released from the bone and another 4-5 days in the tissues.
However, life spans are shortened to a few hours in the tissue in infection
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[Guyton and Hall, 1996], making leukocytes function a key element of
the microcirculation and its function in sepsis.
Plasma helps carry antibodies that are secreted into the lymph and carried
to the circulating blood.
The microcirculation plays an important role by providing oxygen to
the tissue cells and therefore ensures organ function. Sakr et al [Sakr et al.,
2004] found that microcirculatory distress is the only independent factor for
predicting patient outcome if it is not treated within 48 hours. In a worst case
scenario, microcirculatory dysfunction drives the pathogenic effects of sepsis
and results in organ failure [Ince, 2005] and increased risk of death [Spronk
et al., 2004].
Sepsis patients normally suffer microcirculatory dysfunction [Spronk
et al., 2004]. It is characterized by heterogenous abnormalities particularly
in blood flow and under-perfused capillaries. There are several aspects of sep-
sis that affect microcirculatory function, which thus affect coagulation and
immune function, which, in turn, increase the risk of a more severe infection.
The overall result can be a spiral of worsening infection and microcircula-
tion dysfunction. Hence, sepsis, organ failure, infection, and microcirculation
failure are all related.
In particular, microcirculatory units become hypoxic, a deficiency in the
amount of oxygen reaching the tissue, which is common in sepsis patients
[Lam et al., 1994; Goldman et al., 2004; Ince and Sinaasappel, 1999]. As a
result, the tissues and organs begin to fail. The end consequence is increased
risk of the organ failure that defines sepsis.
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In addition, signal transduction pathways and electrophysiological com-
munication are disturbed in sepsis rendering endothelial cells unable to func-
tion properly. This outcome decreases the efficacy of immune response to the
infection at the root of sepsis [Vallet, 2002]. Hence, the infection and resulting
microcirculation dysfunction are unchecked and grow worse.
Other severe conditions associated with sepsis patients are reduced
adrenergic sensitivity and reduced tone of smooth muscle cells [Price et al.,
1999], high rate of aggregation and less deformable red blood cells [Baskurt
et al., 1997; Piagnerelli et al., 2003; Reggiori et al., 2009], and the formation
of reactive oxygen species by leukocytes activated by septic inflammation or
oxidative stress. Oxidative stress and reactive oxygen, in particular, affect mi-
crocirculation function by destroying microcirculatory formation, cellular in-
teractions, and coagulatory function [Martins et al., 2003; Victor et al., 2004,
2009]. Furthermore, massive increases in reactive oxygen species consequently
damage mitochondrial respiratory dysfunction as indicated by reduced levels
of ATP and oxygen consumption [Victor et al., 2009]. The end result is a
further increased risk of organ failure and worsened infection.
Therefore microcirculation function plays a very important and central
role in the evolution of sepsis. Hence, it is well understood that sepsis directly
and broadly affects microcirculatory function by reducing microcirculatory
oxygen transport and tissue oxygen utilization. Therefore, analyzing oxygen
transport and utilization can potentially be done by using independent signals
from pulse oximetry to assess oxygen saturation and extraction.
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8.1.1 The Concept
The overall goal is to use this marker to assess microcirculation function,
and its changes over time. More specifically, the absorption of red and in-
frared light provides information on the amount of oxyhemoglobin and re-
duced hemoglobin concentrations, respectively. Variation over time can be
used to represent the time-varying absorption of oxygen into the tissue and
its rate of extraction. Thus, processed correctly, the signals commonly used
in pulse oximetry may contain significant additional information relevant to
sepsis via the assessment of oxygen transport and the microcirculation.
8.2 Pulse Oximeter: Principles and Operation
In general, a pulse oximeter is a device used to monitor heart rate and oxygen
saturation. Pulse oximeter operation is based on measuring the absorption
of red and infrared light passed through a patient’s finger or ear lobe. Back-
ground, such as fluid, tissue and bone, are factored out of the measurement by
monitoring the steady state of absorption from bone tissue, venous blood and
arterial blood. It measures periodic variations produced by arterial pulsation.
The periodic variations are an alternating current (AC) component, which is
very small relative to the steady state direct current (DC) component. In
normal use, the change in the AC signal relative to the DC signal measured
represents the absorption of oxygen into tissue. Specifically:
DC component represents the absorption of light by the tissue bed, includ-
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ing venous blood, capillary blood and nonpulsatile arterial blood.
AC component represents the absorption of light due to the pulsatile ex-
pansion of the arteriolar bed with arterial blood.
Figure 8.2 illustrates the different components of pulsatile and non-
pulsatile absorption when light passes through the finger. The principle of
pulse oximetry is based on the assumption that the only pulsatile absorption
between the light source and the photodetector is that of arterial blood. The
light source incorporated in the oximeter probe consists of two light-emitting
diodes (LEDs) that emit light at known wavelengths, specifically 660 nm (red,
R) and 940 nm (infrared, IR). These two wavelengths are used because oxyhe-
moglobin and reduced hemoglobin have different absorption spectra at these
particular wavelengths, as shown in Figure 8.3. In the red region, oxyhe-
moglobin absorbs less light than does reduced hemoglobin, while the reverse
is true in the infrared region. However, the difference in absorption in the
infrared region is much smaller compared to the red region. To measure
oxygen saturation, the pulse oximeter uses the ratio of red and infrared pul-
satile components as a percentage of the DC component. Specifically, it uses
(ACR/DCR)/(ACIR/DCIR) with a special calibration table to assess the level
of oxygen saturation in pulsatile blood.
8.3 Signal Acquisition and Processing
Generally, the red and infrared LED’s on the probe are alternately pulsed
in a controlled fashion. The output from the photodiode of the finger probe
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Figure 8.2: Light passing through the substances of a finger. Adapted from
cypress.com.
Figure 8.3: Transmitted light absorbance spectra of oxyhemoglobin and re-
duced hemoglobin.
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is passed through a current-to-voltage converter. The intensity of the IR
and R LED is controlled by the LED intensity control block to keep the
photo-receiver sensors within specification. The raw voltage converted signal
is amplified using a second stage amplifier. The signals from these two stages
are fed to two different channels of ADC. Figure 8.4 shows the example of AC
and DC components for red and infrared output signals, from the experimental
pulse oximeter built for this study because commercial devices do not permit
this specific data to be accessed.
The sampling rate used in this experiment is approximately 70 Hz. The
output data is captured from a serial port and stored in the PC. The DC
component at the top panel of Figure 8.4 is obtained by determining a 32
point moving average of the raw signal, while the AC on the bottom panel is
the remainder of the signal with the DC portion removed. The red signal is
represented by the red color, while the infrared signal is in blue color.
Figure 8.4: Sample of a signal indicate separation between R and IR output
with DC components on the top panel and AC components on the bottom
panel. The y-axis is in volts and the x-axis is in seconds.
186 CHAPTER 8. SEPSIS AND PULSE OXIMETRY
8.4 Data Processing
8.4.1 Intensity Adjustment
The raw signal measured from the finger probe is directly related to the
amount of the light received at the photodetector. The raw signal received
for the R wavelength is used to control the intensity control of R LED. Simi-
larly, the raw signal received for IR wavelength is used to control the intensity
control of IR LED. However, the absorption of R and IR light can vary depend-
ing on several factors, such as dyshemoglobins, ambient light, nail polish, skin
pigmentation, dyes, low-perfusion state and motion artifacts [Jubran, 2004,
1999].
Figure 8.5 shows an example of the raw DC and AC signals in volts
and light intensity in counts of R and IR. In this figure, higher values of the
DC and AC components indicate more light received at the photodetector
and vice versa. To eliminate the intensity change factor, the raw signal was
adjusted according to the average intensity during a baseline period. Baseline
is thus defined as the initial stabilization period during the tests.
Figure 8.6 shows the resulting DC and AC components and light inten-
sity after the process of standardizing the intensity for each LED’s intensity.
Adjusted DC and AC components in y-axes are in volts and adjusted inten-
sity is in counts. This adjustment is important as relative levels of R and IR
DC and AC signals are related to the extraction rate to be assessed. Thus,
comparable magnitudes must be used.
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8.4.2 Baseline Coordination
For each test, a baseline measurement was recorded for approximately 30 - 60
seconds. The baseline measurement was used to observe the initial condition
of the subjects before proceeding with any test and to indicate stability of the
test subjects. During this period, subjects were asked not to move their hand
or arm, and were in a resting position.
Figure 8.7 shows the comparison of the DC component of R and IR
before and after normalization using an average of 30 seconds during the
baseline. The average value computed is subtracted from the other recorded
values to find the respective measurements. The bottom panel represents the
resulting plot of R and IR AC components with respect to the x-axis as the
average baseline measured. Therefore, the change in wavelength can be seen
as a comparison to the baseline measurements.
8.4.3 Conversion of Intensity to Absorption
The raw signal measured is the processed output from the detector and repre-
sents the amount of light received by the photodetector. Therefore, a higher
amount of light detected at the receiver indicates less light being absorbed by
tissue and vice versa. To aid clinical interpretation, the plots are therefore
inverted, as shown in Figure 8.8, as an example. The inverted plot (bottom
panel) represents the inverse amount of light absorbed by a finger. Thus, a
higher value in this modified plot represents more light being absorbed for
the red or infrared signals and thus less light detected. More light absorbed
means greater number of cells or oxygen at that wavelength.
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More specifically, an increase in the R plot represents an increase in
amount of reduced hemoglobin (Hb), whereas increases in IR (blue) indicate
higher amounts of total oxyhemoglobin and reduced hemoglobin (HbO2 +
Hb). The bigger the gap in the DC plot, the greater amount of HbO2 in
blood. Thus, represents less oxygen being absorbed. Because of baseline
normalization, the changes are relative to the initial value. Hence, changes in
R and IR throughout a test represent higher or lower extraction with respect
to the initial condition during the test.
8.5 Measure of Microcirculation Efficacy
Oxygen is carried from the lungs to the rest of body by red blood cells. Blood
flows in the body and passes oxygen to the tissues. The amount of oxygen
uptake by a tissue is dependent on the oxygen transport factor. When oxygen
transport is decreased in healthy individuals, oxygen consumption is main-
tained by increasing tissue oxygen extraction. Therefore, oxygen extraction
is a function of blood flow and oxygen consumption, which indicates the mi-
crocirculation efficacy of an individual.
The pulse oximeter used in this study measures extraction by comparing
the DC components of R and IR signals. The IR signal is related to the
overall blood volume, (HbO2 + Hb) and the R signal is related to the amount
of reduced hemoglobin, (Hb). Differences between these two signals thus
represents the amount of oxygenated hemoglobin, HbO2. Therefore, a higher
value of IR signal relative to R signal indicates the amount of extraction. The
larger the gap between these two signals, the higher the extraction and vice
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versa, for a specific level of cardiac output.
8.6 Summary
Sepsis is a disease of microcirculation, and microcirculation dysfunction is a
critical element in sepsis and organ failure. In this chapter, the signals from a
pulse oximeter are presented as a means to extract additional information on
the absorption of oxygen and thus the efficacy of microcirculation function.
The processed signals capture reduced hemoglobin and blood volume (oxyhe-
moglobin plus reduced hemoglobin) at a particular time relative to its initial
condition. Therefore, changes in terms of amount or volume of oxyhemoglobin
and deoxyhemoglobin relative to its baseline can also be monitored as a marker
of extraction and microcirculation function. Therefore, blood flow and oxygen
extraction can be used to measure and assess microcirculation function.

Chapter 9
Pulse Oximeter Validation
In this chapter, several tests on healthy individuals are used to demonstrate
and validate pulse oximeter concept discussed in Chapter 8. In particular,
vascular occlusion tests (VOT) and physical exercise are used to artificially
create changes in extraction to test the concept. The goal is to determine if
changes in oxygen extraction, a key feature of sepsis, can be assessed with
good resolution under known and well understood perturbations.
In this context, the VOT has been used in research using near-infrared
spectroscopy to assess microvascular changes, particularly dynamic tissue oxy-
gen saturation [Bernet et al., 2011; Futier et al., 2011; Mayeur et al., 2011;
Bezemer et al., 2009; Gomez et al., 2008]. Results indicate that the VOT
permits the determination of tissue metabolic rate, particularly during is-
chemia [Mayeur et al., 2011; Colier et al., 1995]. Similarly indicative results
were found during exercise [Burton et al., 2004; Treacher and Leach, 1998;
Martin, 1999]. Additionally, the rate of desaturation determined immediately
during post-exercise ischemia have been used for the estimation of individual
metabolic rate and tissue oxygen consumption [Boushel et al., 2001].
The use of pulse oximeter data to assess changes in oxygen extraction
for an individual can therefore indicate changes in metabolic condition. Thus,
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the overall goal appears feasible with simple equipment that allows significant
and potentially clinically important additional information to be captured.
9.1 Test Design
In this analysis, several tests have been conducted to validate the pulse oxime-
ter concept discussed in Chapter 8. The tests were done on healthy indi-
viduals, and include a vascular occlusion test (VOT) and moderate physical
exercise to induce changes in extraction. This study and the use of this data
was approved by the University of Canterbury Human Ethics Committee,
Christchurch, New Zealand.
9.1.1 Vascular Occlusion Test (VOT)
In this test, subjects were comfortably seated with one arm rested on a table.
An initial manual blood pressure measurement was taken on the arm to de-
fine baseline perfusion pressure using a sphygmomanometer. A pulse oximeter
probe was attached to each subject’s finger and subjects were asked not to
move their hand or arm during measurements. The sphygmomanometer was
then placed on the forearm. A baseline measurement was recorded for 30-60
seconds. The sphygmomanometer was then rapidly inflated until the pressure
was 40 mmHg more than baseline systolic pressure to induce the occlusion.
Inflation took approximately 10-30 seconds. The sphygmomanometer was
then rapidly deflated after 3 minutes of vascular occlusion. The pulse oxime-
ter data was continuously recorded for at least another 3 minutes after the
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sphygmomanometer was released.
During the test, DC and AC signals for R and IR absorption were mea-
sured. The R signal measures reduced hemoglobin and the IR signal measures
the sum of reduced hemoglobin and oxyhemoglobin. During the inflation of
the sphygmomanometer, both the R and IR DC signals were expected to
decrease over time as less blood was flowing into the occluded area, before
reaching constant values indicating a constant blood volume in the occluded
area and no blood flow into it. Additionally, no pulsatile waveform should be
seen during this time since no pulsation of arterial blood should exist during
the occlusion. After the sphygmomanometer was released, the R and IR DC
signals should rise immediately above baseline as more blood flows initially
into the hand area, followed by blood redistribution and progressive desatu-
ration. This process occurs until the blood flowed has been normalized.
9.1.2 Physical Exercise
For physical exercise tests, subjects were required to run for at least 3 minutes
on a short, flat circuit. Pre-exercise measurement was recorded for at least
30 seconds. Post-exercise measurements were also recorded for at least 120
seconds. This process was repeated (exercise and record data) for up to five
laps.
In this test, AC R and IR signals are expected to increase during the
post-exercise compared to the baseline, due to increases in heart rate. In
addition, changes in oxygen extraction are expected during the post-exercise
period, as indicated by the difference between the IR signal relative to the R
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signal. In particular, the IR DC signal was expected to be higher than the R
signal. Depending on workout amount (laps) and intensity, changes in heart
rate and cardiac output were assessed by changes in period beat to beat,  t,
the amplitude of the AC signal, and the area under the curve of the DC signal.
9.2 Test Subject
There were 15 healthy volunteers who participated in the vascular occlusion
test, and 10 healthy individuals in the physical exercise test. Tables 9.1 and
9.2 show the demographic characteristics of the subjects for the VOT and
physical exercise test, respectively.
Table 9.1: Demographic characteristics of the test subjects for vascular occlu-
sion test (VOT).
Demographic characteristic Median [IQR]
Age (years) 26 [23 - 30]
Gender (%)
Female 40
Male 60
Dominant hand (%)
Right 93
Left 7
Weight (kg) 61 [46 - 72]
Height (cm) 166 [155 - 177]
Systolic blood pressure (mmHg) 110 [100 - 110]
Diastolic blood pressure (mmHg) 60 [60 - 64]
Heart rate (beats/minute) 65 [59 - 71]
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Table 9.2: Demographic characteristics of the test subjects for physical exer-
cise test.
Demographic characteristic Median [IQR]
Age (years) 27 [23 - 29]
Gender (%)
Female 30
Male 70
Weight (kg) 72 [50 - 76]
Height (cm) 178 [157 - 182]
Systolic blood pressure (mmHg) 108 [100 - 110]
Diastolic blood pressure (mmHg) 60 [55 - 70]
Heart rate (beats/minute) 51 [48 - 57]
9.3 Results
9.3.1 Vascular Occlusion Test (VOT)
Figure 9.1 shows the DC and AC components of the R and IR pulse oximeter
signals during a VOT on Subject 1. The VOT can be divided into three stages,
which are baseline, vascular occlusion, and recovery. Additionally, Figure 9.2
shows the scaled AC components of IR signals on Subject 1 for a 15 second
interval in each stage during the test.
In Figure 9.1, the huge drop of DC R and IR signals is observed during
vascular occlusion relative to baseline. As the vascular occlusion progressed,
the DC IR signal increases slightly, while the DC R signal was almost constant.
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Figure 9.1: DC components of R(red) and IR(blue) on the top panel and
AC components of R(red) and IR(blue) on the bottom panel during VOT on
Subject 1.
Figure 9.2: Infrared (IR) AC signals of Subject 1 for 15 seconds interval of
baseline (top panel), vascular occlusion (middle panel) and recovery (bottom
panel).
9.3. RESULTS 201
Both R and IR signals increased immediately after the sphygmomanometer
was deflated and there were greater changes in the IR signal compared to
the R signal. During the vascular occlusion presented in the middle panel of
Figure 9.2, no heart beat was detected, as expected, since blood flow ceased
and blood volume redistribution was limited.
Figure 9.3 shows the DC and AC components for R and IR signals
during a separate vascular occlusion test on Subject 2. Similarly, Figure 9.4
shows the AC components of IR signals on Subject 2 during the baseline,
vascular occlusion and recovery phases for an interval of 15 seconds in each
phase. No significant changes are observed in AC component on Subject 2
during baseline and recovery, as shown in top and bottom panels of Figure
9.4, where the heart beat is blocked in the occlusion phase.
Figure 9.3: DC components of R(red) and IR(blue) on the top panel and
AC components of R(red) and IR(blue) on the bottom panel during VOT on
Subject 2.
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Figure 9.4: Infrared AC signals of Subject 2 for 15 seconds interval of baseline
(top panel), vascular occlusion (middle panel) and recovery (bottom panel).
Similarly, Figures 9.5 and 9.6 show another example of the DC and AC
components of R and IR signals during a vascular occlusion test on Subject
14. Overall, the AC and DC patterns of all subjects are similar to the patterns
shown for Subjects 1, 2 and 14 . However, the changes varied across subjects
in terms of lower or higher signals observed during occlusion and recovery,
respectively. For example, the DC IR signal was sigificantly decreased during
occlusion for Subject 2 relative to its baseline compared to the profile for
Subject 1.
Table 9.3 summarizes the baseline and recovery characteristics for all 15
test subjects during the VOT. Overall, amplitude and beat-to-beat interval
of AC IR signal are almost the same during baseline and recovery, and no
significant changes are observed in heart rate for all test subjects. Median
amplitude of AC signals during baseline and recovery are 0.08 and 0.12 volts,
respectively. However, rise time, measured as time taken from the release of
the sphygmomanometer to the highest peak of recovery, were highly variable
across test subjects with a median [IQR] of 14.7 [5.8, 35.8] seconds.
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Figure 9.5: DC components of R(red) and IR(blue) on the top panel and
AC components of R(red) and IR(blue) on the bottom panel during VOT on
Subject 14.
Figure 9.6: Infrared AC signals of Subject 3 for 14 seconds interval of baseline
(top panel), vascular occlusion (middle panel) and recovery (bottom panel).
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Figure 9.7 shows the rise time profile for the 15 test subjects in the
VOT. The x-axis represents time in seconds and y-axis represents change
in amplitude (  Volts). In this context, rise time can be defined as the
time required to wash out the stagnant reduced hemoglobin with oxygenated
arterial blood during reperfusion.
Figure 9.7: Infrared AC signals for 15 subjects studied during the release of
sphygmomanometer to the highest peak indicating measure of rise time.
Table 9.4 shows the average value of oxygen extraction in volts and
percentage measured during baseline and recovery for all 15 subjects during
the VOT. Extraction is measured as the amount of oxygenated hemoglobin,
HbO2, that is the difference between IR and R DC signals. Most of the sub-
jects had increased oxygen extraction at recovery with respect to baseline, as
expected. However, the changes in oxygen extraction from baseline to recov-
ery were relatively small, and some individuals had lower oxygen extraction
at recovery than at baseline.
Changes in oxygen extraction shown in Table 9.4 are relatively small
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with a median [IQR] of 0.01 [0.00,0.03] volts. Additionally, the percentage of
absolute change is also small with a maximum of 42.6% and median [IQR] of
0.0 [-9.3,5.3] %. However, the relative change has a wider range with a median
[IQR] of 12.6 [5.6, 49.9] %.
9.3.2 Physical Exercise
Table 9.5 shows the average amplitude of IR AC signal for the pre-exercise
and five post-exercise phases (laps) for 10 test subjects in the physical exercise
activity. The IR AC signal also represents the relative amount of blood volume
(HbO2+ Hb). Due to health reasons, Subject 4 was unable to complete the
test until post-exercise 5. Overall, the amplitude during pre-exercise and
post exercise are highly varied across individuals. Additionally, median of the
average amplitude are largely increased from pre-exercise to post-exercise 1
and fluctuated from post-exercise 2 to post-exercise 5.
Table 9.6 summarizes the average value of the beat-to-beat interval in
seconds and heart rate in beats per minute during pre-exercise and post-
exercise phases for the same 10 subjects. Heart rate was significantly increased
during post-exercise 1 for all subjects compared to pre-exercise. However,
from post-exercise 1 to post-exercise 5, the heart rate continuously increased
for some individuals, while for others, the heart rate fluctuated from post-
exercise 1 to post-exercise 5. Median and IQR increased from pre-exercise
to post-exercise 2 and decreased during post-exercise 3, particularly for 25th
percentile. These differences are likely due to relative fitness and condition.
In contrast, the first test is a relative shock to the system for all subjects.
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Table 9.7 shows the average value of changes in oxygen extraction in volts
and changes in percentage of oxygen extraction for 10 subjects measured dur-
ing the physical exercise test. Average oxygen extraction was higher during
post-exercise 1 compared to pre-exercise for most subjects. Interestingly, only
Subjects 3, 7 and 10 had lower oxygen extraction during post-exercise 1 with
respect to their pre-exercise. Oxygen extractions were either decreased or
increased slightly from post-exercise 2 to post-exercise 5, and largely in a sim-
ilar range during post-exercise phases. Median and IQR of oxygen extraction
show a similar pattern to the median and IQR of heart rate shown in Table
9.6 Again, relative fitness plays a role, as not all volunteers were equally fit.
Figure 9.8 shows the change in cardiac output and change in cardiac
output over time throughout the pre-exercise, and post-exercise 1, 2, 3, 4, and
5 for Subject 5. During pre-exercise, very low cardiac output was recorded
compared to all post-exercise phases. Cardiac output increased significantly
during post-exercise 1 compared to pre-exercise and continue to increase dur-
ing post-exercise 2. The cardiac output began to drop during post-exercise 3
and continue to drop until post-exercise 5. In the bottom panel of Figure 9.8,
there is a clear separation between the change in cardiac output over time for
pre-exercise and all post-exercises.
Similarly, Figures 9.9-9.10 show another example of change in cardiac
output and change in cardiac output over time throughout the pre-exercise,
and post-exercise phases for Subjects 9 and 10. Overall, Subjects 9 and 10
have a similar cardiac output profile as Subject 5. However, Subject 10 has
a smaller gap between pre-exercise and other post-exercise phases compared
to Subjects 5 and 9 illustrating the variability between individuals and fitness
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Figure 9.8: Change in cardiac output (top panel) and change in cardiac output
over time (bottom panel) from pre-exercise to post-exercise phases 1 to 5 for
Subject 5.
Figure 9.9: Change in cardiac output (top panel) and change in cardiac output
over time (bottom panel) from pre-exercise to post-exercise phases 1 to 5 for
Subject 9.
9.4. DISCUSSION 213
levels.
Figure 9.10: Change in cardiac output (top panel) and change in cardiac
output over time (bottom panel) from pre-exercise to post-exercise phases 1
to 5 for Subject 10.
9.4 Discussion
9.4.1 Vascular Occlusion Test (VOT)
During vascular occlusion, DC components of both the R and IR signals
rapidly decreased as a result of less blood flow into the occluded area and
consequently reduced total blood volume. This process continues slowly un-
til total vascular occlusion is achieved. Additionally, small volumes of blood
may potentially shift within the vascular compartments as vasomotor tone de-
creases during this induced ischemia. However, these volume shifts are likely
very small in comparison to the total blood volume and highly variable across
individual responses.
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During this ischemic challenge, the DC IR signals that represent to-
tal blood volume, are almost constant for most test subjects. Nevertheless,
the blood compartment volumes will vary significantly amongst individuals as
capillary integrity, inflow vasomotor tone, and arterial pressure varies. This
variability will consequently lead to variability in the effect of the VOT among
individuals, as seen for example in Figures 9.1, 9.3 and 9.5. After the sphyg-
momanometer is deflated, both the R and IR signals immediately increased
as a result of the large amount of blood flow into the occluded area as normal-
ization of the blood and tissue occur. However, in general, this description is
largely similar for all test subjects, showing that the basic changes expected
were visible via these signals.
Generally, the VOT is used to evaluate the response of the system to
a pre-determined stress in terms of local metabolic demand and reperfusion
response in a healthy individual [Creteur et al., 2007; Pareznik et al., 2006;
Doerschug et al., 2007]. However, variation in metabolic rates may exist de-
pending on individual experience during ischemic challenge [Gomez et al.,
2008]. For example, in Figure 9.5, the DC R signals were slightly increased
after a period of time during vascular occlusion, which indicates that the
amount of reduced hemoglobin increased while the total blood remain con-
stant as might be expected as available oxygen is taken up. Interestingly, this
behavior was not clearly seen in Subjects 1 and 2. Potentially, this outcome
happened as Subject 3 had a longer period of vascular occlusion compared
to Subjects 1 and 2 because additional time was needed for proper inflation
at the beginning of vascular occlusion. Therefore, there is a potential for
greater oxygen uptake by tissue during the longer vascular occlusion process,
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as observed in this case.
After cuff pressure is released, total hemoglobin increased rapidly almost
to baseline level. In some cases, total hemoglobin increased above the baseline
level. This response was followed by a recovery process. The recovery process
represents the expected microvasculature response in which the determinants
of re-oxygenation includes capillary integrity, local blood volume, local vaso-
motor tone, perfusion pressure, tissue oxygen saturation and total hemoglobin
[Gomez et al., 2008].
Referring to Table 9.3, higher amplitudes of AC IR are observed during
recovery compared to baseline for all subjects. This outcome is due to the
higher total blood volume during the recovery compared to baseline as an ef-
fect of reperfusion after the vascular occlusion process. However, no significant
changes in heart rate were observed during these two activities across all sub-
jects. Therefore, where perfusion pressure is assumed to be adequate in this
test, the main criteria of microvasculature response is thus total hemoglobin
and tissue oxygen saturation, unaffected by changes in cardiac output.
Assessing recovery rates during VOT determines the microcirculatory
flow distribution, capillary recruitment and restoration. In addition, rise time
has been used to represent microvascular reperfusion in the assessment of
oxygen saturation [Bezemer et al., 2009]. In this test, 40% of all subjects had
a rise time less than 10 seconds. Another 20% of subject required more than
50 seconds. The remaining 40% were between 10-50 seconds. These results
illustrate the dynamic response due to the VOT and represents the patient-
specific tissue perfusion response. Therefore, longer response times indicate
that the specific subject required more time for microvascular reperfusion due
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to different microvasculature tone and response.
Oxygen extraction is expected to change slightly during the VOT due
to the greater blood flow during recovery compared to baseline, as seen in
Table 9.4. The change in extraction represents the amount of oxygen with
hemoglobin, HbO2. However, in some subjects, higher changes in extraction
can be observed. Variation of oxygen extraction are largely due to the effect
of the vascular occlusion process differing between individuals.
Overall, the vascular occlusion tests show very similar and expected
patterns for R and IR signals and both their AC and DC components across
different healthy individuals. Repeating the test in the same individual also
results in a similar pattern indicating repeatability across individuals, partic-
ularly using the pulse oximeter used in this study. Overall, the VOT results
show that the pulse oximeter concept can assess change in extraction due to
ischemia, but these change vary across individuals.
9.4.2 Physical Exercise
Generally, much more oxygen and carbon dioxide are exchanged during exer-
cise than at rest as exercise increases oxygen consumption and carbon dioxide
production [Martin, 1999]. The increase in oxygen is also due to the increase
in both arterial oxygen delivery and tissue oxygen extraction.
The average value of beat-to beat period and heart rate for pre-exercise
and different post-exercise phases shown in Table 9.6 clearly indicate that
heart rate increased largely from pre-exercise to post-exercise 1, which means
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from resting to doing physical activity. Heart rate continued to increase when
a person increased intensity of the exercise. For some subjects, heart rate
maintained at a certain level and started to decrease for the rest of the post-
exercise phases, likely due to fitness level and recovery from the initial start.
Throughout exercise, hemoglobin continues to be fully saturated with
oxygen particularly in people with normal respiratory function [Burton et al.,
2004]. Additionally, stroke volume, heart rate and cardiac output also increase
during activity. However, the increases of heart rate depend on metabolic
condition, workload, duration and intensity of the physical activity [Burton
et al., 2004]. At certain levels, stroke volume remained constant and further
increases of cardiac output are largely due to the increases in heart rate.
Hence, these two variables trade off.
The effect of exercise on oxygen extraction in healthy individuals can be
seen in Table 9.7. From the results presented, it shows that exercise increases
oxygen consumption, as expected. The increases in oxygen extraction are
represented by how the content of oxyhemoglobin increases over time during
exercise, particularly from pre-exercise to post-exercise 1. However, from post-
exercise 3 to post-exercise 5, the changes in oxygen extraction dropped and
remained at this range for most subjects. This latter outcome indicates more
oxygen combined with hemoglobin in blood cells initially and the amount of
oxyhemoglobin reached stability later on as oxygen has been transported into
the tissue. Additionally, the variation of exercise intensity and an individual
fitness become factors for the resulting changes in oxygen extraction.
In particular, fitter individuals will recover and require less oxygen after
the initial exercise shock. Less fit individuals will be unable to maintain effort
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and require less oxygen. In both cases, the pulse oximeter signals are able to
identify the changes in extraction, which is the main goal, regardless of cause.
In healthy individuals, exercise increases oxygen delivery and extraction
from the arterial blood. Furthermore, it also increases arterial-venous oxygen
content difference [Martin, 1999]. However, this may not happen to sepsis
patients due to microcirculatory dysfunction, such as insufficient amount of
oxygen reaching the tissue which affects the organ as well. Thus, in some
disease states, oxygen demand may exceed consumption. Overall, the pulse
oximeter measurements of extraction presented for the physical exercise test
show it is capable of capturing these dynamics.
The changes in cardiac output for activity shown in Figures 9.8-9.10
indicate that cardiac output increases during physical activity as a result
of increasing heart rate. However, cardiac output decreases slightly after
post-exercise 2 or 3 depending on the metabolic condition and intensity of
the physical activity done by individuals. Additionally, increases in cardiac
output indicate more oxygen delivers to the exercising muscles [Martin, 1999].
Interestingly, the change in cardiac output is directly related to the change in
oxygen extraction. Again, however, this sensor approach was able to assess
relative changes in cardiac output, yielding and additional possible use.
9.5 Summary
In this chapter, a pulse oximeter concept was used to assess metabolic condi-
tion in healthy individuals. Instead of measuring heart rate and oxygen sat-
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uration only, the pulse oximeter was used in this study to extract additional
information signals due to absorption of red and infrared light. These data
are processed to measure the change in extraction at or near the microvascula-
ture. Vascular occlusion tests and physical exercise are used to investigate and
validate the concept on changes in metabolic condition in heathy individuals.
In VOT, pulsatile signal is eliminated during occlusion due to limited
blood flows into the occluded area. In addition, recovery process significantly
indicate metabolic and microcirculatory condition of an individual by com-
paring amplitude, period and rise time. No significant changes in oxygen
extraction has been observed when comparing baseline and recovery during
the VOT.
In addition, heart rate and cardiac output were clearly seen to be in-
creased during physical activity indicating higher oxygen extraction changes
particularly from rest to exercise. Both parameters were generally increased
when exercise was continuously performed. However, the increased rate varies
across studied subjects since it depends on the metabolic change and metabolic
requirement of an individual.
In conclusion, the pulse oximeter sensor concept used in this study is ca-
pable of extracting valuable information to assess metabolic condition. More
importantly, the tests used in this study validated the concept of this pulse
oximeter based sensor approach to assess underlying changes in microvascu-
lature response and oxygen extraction. Thus, implementing this concept and
method on ICU patients has the potential to aid sepsis diagnosis. Moreover,
since pulse oximeters are very widely used in ICU settings, they represent a
simple, non-invasive, low-cost means to monitor these patients.

Chapter 10
Conclusions
Hyperglycemia, organ failure and sepsis are common clinical conditions faced
in ICU and highly associated with mortality. These conditions are highly cor-
related since the physiological effects of hyperglycemia lead to organ dysfunc-
tion and potentiates the pro-inflammatory response typical in sepsis. Thus,
tight glycemic control (TGC) in critical illness has been documented to reduce
mortality and sepsis.
Despite positive emerging evidence in favor of TGC in reducing organ
failure, sepsis and mortality, reproducing the beneficial results is challenging
since most glycemic control protocols are based on clinician experience. This
situation is exacerbated by the fact that metabolic condition, nutritional sup-
port, and insulin regiments are highly variable across and between patients.
Therefore, a physiological model that captures the glucose-insulin system dy-
namics is a basis for optimal, patient-specific glycemic control.
The physiological model presented in this thesis is robust, adaptable
to patient-specific condition, and, most importantly, clinically validated and
applicable. This model was validated using independent critical care patient
data, is robust to different clinical interventions, and accurately predicts clin-
ical intervention outcomes. Overall, it represents a balanced tradeoff of com-
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plexity and non-linearity versus simplicity with respect to other models, which
span a range of these tradeoffs. In essence, it is the interaction between model-
based insulin sensitivity, SI , the insulin and nutrition administered, and the
patients variability over time that determines glycemic outcome in TGC. The
glucose-insulin system model and model-based metric, SI are fully validated
in Chapter 4, for both fitting and prediction error.
The model achieves median fitting error <1% in data from 173 patients
(N = 42,941 hours in total) who received insulin while in the ICU and stayed
for more than 72 hours. More importantly, the median per-patient one-hour
ahead prediction error is a very low 2.80%. A sensitivity study, as part of
an internal model validation to assess the reliability of the model, confirms
the validity of limiting time-varying parameters to SI only. It is significant
that the 75th percentile prediction error is now within the lower bound of
typical glucometer measurement errors of 7-12%, which is better than any
other reported model. The result confirms that the model used is suitable
for developing model-based insulin therapies, and capable of delivering tight
blood glucose control, in a real-time model based control framework with a
tight prediction error range.
To date, diagnosing sepsis in critical care has been a great challenge. In
particular, ad-hoc protocols have been implemented which are largely based
on clinical experience. A wider range of scoring systems have also been widely
used to represent sepsis condition for diagnosis across different centers. In this
thesis, a new scoring system has been developed which is more realistic and
clinically and physiologically sensible. Incorporating the new scoring system
together with other model-based metric and patients data is expected to aid
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sepsis diagnosis, particularly for real-time basis.
However, information on SI was found to be insufficient to determine
the exact sepsis condition of a patient, particularly at moderate sepsis levels
(eg SS2=1) which are important for early diagnosis as the condition develops.
The result is unfortunate given that the physiological impact of sepsis on
metabolic markers, such as SI , is clear. Several other relevant physiological
and clinical variables were also tested. Neural network and statistical analysis
conclude that clinical feedback is the only parameter that resulted in higher
sensitivity and specificity than is currently obtained.
Sepsis is a disease of the microcirculation. Since information on SI
and other clinical variables are insufficient for sepsis diagnosis on their own,
particularly on the cohort used in this study, a pulse oximeter is used in a
further study to assess microcirculation function. The pulse oximeter used
is able to capture the amount of reduced hemoglobin and oxyhemoglobin.
Therefore, the absorption of oxygen and extraction at the microcirculation
can be estimated. The pulse oximeter concept has been validated using a
vascular occlusion test and physical exercise on several healthy individuals to
show it an measure the range and type of changes that might be expected.
In summary, the model presented in this thesis is physiologically relevant
for clinical control and has been validated using independent data. Model-
based metric and several clinical and physiological variables have been inves-
tigated to identify their possibility in becoming sepsis bio-marker. However,
the concepts and methods used on pulse oximeter to assess microcirculation
and metabolic condition have more promising results. Therefore, relative oxy-
gen extraction can be used as a marker to aid sepsis diagnosis. The overall
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work presents a novel, knowledgeable contribution to solving the critical care
glycemic control problem, particularly for sepsis diagnosis. Furthermore, im-
plementing the introduced concept and methods can aid sepsis diagnosis in
critical care.
Chapter 11
Future Avenues
The models and control methods presented in this thesis provide a framework
and background for automating glucose control and sepsis diagnosis in critical
care. Insulin sensitivity, SI , a patient-specific parameter, has accurately rep-
resented the severity of illness as discussed in Chapter 3 and and 4. However,
the challenges in defining a sepsis specific bio-marker with this metric and
other data open the doors for a wider view on diagnosing sepsis as a disease.
11.1 Further Clinical Validation
Timely diagnosis and treatment of sepsis in critical illness requires signifi-
cant clinical effort, experience and resources. Insulin sensitivity is known to
decrease with worsening condition and could thus be used to aid diagnosis.
Initial studies in adults have shown insulin sensitivity provides a negative
predictive diagnostic for sepsis [Blakemore et al., 2008]. Accurate and timely
diagnosis of early onset sepsis remains challenging to the clinician and the lab-
oratory. Thus, real-time, model-fitted insulin sensitivity may provide a novel
marker of sepsis in this cohort.
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The data from the sepsis study presented in this thesis covers only 30
patients selected based on clinician experience. They were confirmed as having
sepsis based on blood culture results taken from blood tests later in the study.
Therefore, there is a possibility of mismatch on time recorded for the blood
culture results to the computer generated profile of insulin sensitivity that
would skew results. More results from a more rigorous clinical trial may
increase the sample data and potentially provide better cohort for testing and
diagnosis.
11.2 Clinical Implementation
The proposed proof-of-concept study using the pulse oximeter will be a first
clinical step towards developing a comprehensive and non-invasive method
to detect sepsis at an early stage by assessing microcirculation function. By
implementing the concept discussed in Chapter 8 in the ICU, on ongoing
project, different responses between non-septic and septic patients can be
analyzed to prove the concept clinically.
Long-term implementation of a standard test procedure using a pulse
oximeter in intensive care would require developing robust, verified software
and hardware. Additionally, critical care nursing is a highly technical profes-
sion, and staff are typically proficient with computerised technology. However,
any system needs to operate using terminology and workflow patterns familiar
to clinical staff to reduce training time and ease implementation.
In addition, the procedure must be standardized and require minimum
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clinical effort. Therefore, protocol violations and insufficient staff will not be
an issue. The software for monitoring the test may be stored on dedicated
bedside computers. Any further embodiment of the software would include
its incorporation into standard hospital and laboratory information systems.

Appendix A
Pulse Oximeter Validation
Figure A.1: Change in cardiac output (top panel) and change in cardiac
output over time (bottom panel) from pre-exercise to post-exercise phases 1
to 5 for Subject 1.
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Figure A.2: Change in cardiac output (top panel) and change in cardiac
output over time (bottom panel) from pre-exercise to post-exercise phases 1
to 5 for Subject 2.
Figure A.3: Change in cardiac output (top panel) and change in cardiac
output over time (bottom panel) from pre-exercise to post-exercise phases 1
to 5 for Subject 3.
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Figure A.4: Change in cardiac output (top panel) and change in cardiac
output over time (bottom panel) from pre-exercise to post-exercise phases 1
to 3 for Subject 4.
Figure A.5: Change in cardiac output (top panel) and change in cardiac
output over time (bottom panel) from pre-exercise to post-exercise phases 1
to 5 for Subject 6.
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Figure A.6: Change in cardiac output (top panel) and change in cardiac
output over time (bottom panel) from pre-exercise to post-exercise phases 1
to 5 for Subject 7.
Figure A.7: Change in cardiac output (top panel) and change in cardiac
output over time (bottom panel) from pre-exercise to post-exercise phases 1
to 5 for Subject 8.
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